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Tuberculosis (TB) is one of the world’s deadliest infectious diseases. Caused by the 
pathogen Mycobacterium tuberculosis (Mtb), the standard regimen for treating TB 
consists of treatment with multiple antibiotics for at least six months. There are a 
number of complicating factors that contribute to the need for this long treatment 
duration and increase the risk of treatment failure. Person-to-person variability in 
antibiotic absorption and metabolism leads to varying levels of antibiotic plasma 
concentrations, and consequently lower concentrations at the site of infection. The 
structure of granulomas, lesions forming in lungs in response to Mtb infection, creates 
heterogeneous antibiotic distributions that limit antibiotic exposure to Mtb. 
Microenvironments in the granuloma can shift Mtb to phenotypic states that have higher 
tolerances to antibiotics. We can use computational modeling to represent and predict 
how each of these factors impacts antibiotic regimen efficacy and granuloma 
sterilization.  
 
In this thesis, we utilize an agent-based, computational model called GranSim that 
simulates granuloma formation, function and treatment. We present a method of 
incorporating sources of heterogeneity and variability in antibiotic pharmacokinetics to 
simulate treatment. Using GranSim to simulate treatment while accounting for these 
sources of heterogeneity and variability, we discover that individuals that naturally have 
low plasma antibiotic concentrations and granulomas with high bacterial burden are at 
greater risk of failing to sterilize granulomas during antibiotic treatment. Importantly, we 
find that changes to regimens provide greater improvements in granuloma sterilization 
times for these individuals. We also present a new pharmacodynamic model that 
incorporates the synergistic and antagonistic interactions associated with combinations 
of antibiotics. Using this model, we show that in vivo antibiotic concentrations impact the 
strength of these interactions, and that accounting for the actual concentrations within 
 xii 
granulomas provides greater predictive power to determine the efficacy of a given 
antibiotic combination.  
 
A goal in improving antibiotic treatment for TB is to find regimens that can shorten the 
time it takes to sterilize granulomas while minimizing the amount of antibiotic required. 
With the number of potential combinations of antibiotics and dosages, it is prohibitively 
expensive to exhaustively simulate all combinations to achieve these goals. We present 
a method of utilizing a surrogate-assisted optimization framework to search for optimal 
regimens using GranSim and show that this framework is accurate and efficient. 
Comparing optimal regimens at the granuloma scale shows that there are alternative 
regimens using the antibiotic combination of isoniazid, rifampin, ethambutol and 
pyrazinamide that could improve sterilization times for some granulomas in TB 
treatment. In virtual clinical trials, these alternative regimens do not outperform the 
regimen of standard doses but could be acceptable alternatives. Focusing on identifying 
alternative regimens that can improve treatment for high risk patients could help to 
significantly decrease the global burden for TB. Overall, this thesis presents a 
computational tool to evaluate antibiotic regimen efficacy while accounting for the 
complicating factors in TB treatment and improves our ability to predict new regimens 




Chapter 1 Introduction 
 Motivation 
Tuberculosis is one of the world’s deadliest infectious diseases and has plagued 
humanity for thousands of years. Caused by the pathogen Mycobacterium tuberculosis 
(Mtb), it has waged a war of attrition against humanity, evading immune responses and 
drug therapies, while simultaneously surviving in human lungs for years. The current 
treatment for TB involves months of antibiotics, and while it is >95% effective against 
drug-susceptible Mtb when the regimen is properly adhered to, there is still a need to 
find ways to lessen the global disease burden [1]. TB treatment is further complicated 
by drug-resistant strains of Mtb, which require the use of alternative antibiotics and are 
becoming increasingly difficult to treat. Individuals have varying pharmacokinetics (PK) 
and complex lung lesions in TB disease that both generate variability and heterogeneity 
in antibiotic exposure at the site of infection. Combinations of antibiotics can lead to 
synergistic or antagonistic effects on the pharmacodynamic (PD) effect. Investigating all 
possible drug regimens to find an optimal therapy is difficult considering the number of 
drug candidates available for TB. Given the variability of disease, it is also difficult to 
know whether that optimal therapy will be optimal for all patients. In this thesis, I will 
present a multi-scale computational model that serves as a tool to integrate the PK and 
disease variability, PD drug interactions, and optimization algorithms to predict optimal 
antibiotic regimens. Using this model, I demonstrate how sources of heterogeneity in TB 
disease and treatment impact granuloma sterilization during antibiotic therapy, and how 
spatial gradients within the granuloma can impact antibiotic interactions and PD effect. 
Using surrogate-assisted optimization algorithms, I predict potential optimal antibiotic 
regimens and compare those regimens in a virtual clinical trial setting. 
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 Global tuberculosis disease burden 
TB is one of the world’s most common infectious diseases and is the leading cause of 
death from a single infectious pathogen. According to the 2019 WHO Global 
Tuberculosis Report, an estimated 10 million new TB cases were reported in 2018, and 
approximately 1.5 million TB-related deaths [2]. The ‘End TB’ strategy is an initiative 
launched by the WHO that aims to reduce the number of TB-related deaths by 90% and 
the TB incidence rate by 80% by 2030 when compared to the 2015 statistics. Co-
infection with TB and HIV is common, and approximately 250,000 of the 2018 TB-
related deaths were HIV-positive people [2]. Risk factors associated with developing 
active TB disease include HIV, undernutrition, immunosuppressive therapies, as well as 
socioeconomic factors including overcrowding and poverty [3]. The majority of TB cases 
occurred in South-East Asia, Africa, and Western Pacific regions, with 86% of 2018 
cases in those three regions [2].  
 
 Tuberculosis treatment 
As a bacterial infection, the standard of care for TB treatment involves a regimen of 
antibiotics. The current recommended regimen for treating active TB disease involves 
treatment with four first-line antibiotics for up to six months: isoniazid (INH, H), rifampin 
(RIF, R), ethambutol (EMB, E) and pyrazinamide (PZA, Z) [4]. Multi-drug resistant TB 
(MDR-TB) has been an emerging problem, and there were a total of approximately 
186,000 MDR-TB and rifampin-resistant TB in 2018 [2]. MDR-TB is classified as 
resistant to both INH and RIF. The introduction of fluoroquinolones, including 
moxifloxacin (MXF, M), levofloxacin (LVX, L) and gatifloxacin (GFX, G), have led to new 
regimens used to treat MDR-TB. While a fluoroquinolone is strongly recommended for 
use in MDR-TB treatment, extensively drug-resistant TB (XDR-TB) is additionally 
resistant to a fluoroquinolone and an injectable antibiotic and presents an even greater 
challenge to treatment. Depending on the specific antibiotics a strain of Mtb is resistant 
to, guidelines recommend building a regimen containing five or more drugs that contain 
either moxifloxacin or levofloxacin, bedaquiline, linezolid, clofazimine and cycloserine, 
with an extensive list of secondary antibiotics consisting of oral and injectable antibiotics 
if a regimen is unable to be built from those prioritized drugs [5]. Recently, the Nix-TB 
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regimen, consisting of bedaquiline, linezolid, and pretomanid, has shown success in 
leading to high percentages of favorable outcomes after 6 months of therapy in patients 
with XDR-TB or nonresponsive MDR-TB [6]. 
 
 Tuberculosis disease pathology 
1.4.1 Clinical description of tuberculosis 
Individuals are infected with Mtb when they inhale aerosolized droplets that contain the 
pathogen, expelled from contagious individuals when they cough or breathe [7]. When 
someone is infected with the pathogen, they may not progress to active disease and 
instead harbor a latent infection [8]. Developing active disease is associated with 
symptoms such as fever, cough, night sweats and chest pains. While pulmonary TB is 
most common, extrapulmonary TB can occur, involving infection of other organs [9]. 
Extrapulmonary TB in also more common in children, who are more susceptible to 
progressive disease[10]. Individuals with latent infection are at risk of progressing to 
active disease, as latent infection can persist for years. Circumstances that lead to 
immune suppression, such as age, co-infection with HIV, or immune suppressive 
medication, can result in reactivation of latent disease [3]. While the clinical definition of 
latent versus active disease is traditionally binary, it is widely thought that individuals 
infected with Mtb lie on a spectrum from latent to active disease [11].  
 
1.4.2 Immune response to infection and granuloma formation 
The immune response in TB occurs over multiple organs and involves numerous cell 
types (Figure 1.1). Initially, Mtb in the lung are phagocytized by macrophages, initiating 
the immune response leading to granuloma formation. Antigen presenting cells, such as 
dendritic cells, will bring antigen to lymph nodes, and present to naïve T cells. 
Meanwhile, at the site of infection, cytokine secretion and signaling pathways recruit 
macrophages and neutrophils to fight the infection. The adaptive immune response 
recruits T cells from the lymph node to the granuloma site. T cells are then transported 
to the granuloma to aid in immune activation and cytotoxic function.  
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Figure 1.1 Multiscale immune response in TB.  
The immune response in TB is complex and occurs over multiple length and time scales and involves multiple 
organs. The response is initiated when Mtb is inhaled into the lungs. Mtb infect macrophages in the lung, initiating the 
innate immune response and recruitment of other macrophages, neutrophils and dendritic cells to the cite of infection. 
Meanwhile, dendritic cells traffic antigen to the lymph nodes, where they prime a T cell response. T cells eventually 
travel to the lung, initiating the adaptive immune response at the infection site, and completing the formation of a 
granuloma. Figure adapted from reference [12]. 
 
One aspect of TB disease that allows for the latent infection is the granuloma. The 
granuloma is a collection of immune cells, bacteria, and necrotic tissue. It forms in 
response to the infection, in an attempt to both kill the pathogen and prevent the spread 
of infection [13]. In TB disease, multiple granulomas can form in the lungs, arising from 
multiple infection sites or developing due to the dissemination of existing infection [14]. 
The arrangement of a granuloma is classically viewed as containing macrophages and 
other leukocytic cells, surrounded by a lymphocyte cuff containing T cells [15,16]. As 
cells die in the granuloma, caseum, consisting of dead cell debris, can develop in the 
center of the granuloma [12]. These caseous regions are typically hypoxic, slowing the 
metabolism and increasing antibiotic tolerance of Mtb in these areas [17,18]. Fibrosis 
can also occur in granulomas, often associated with healing granulomas [16,19]. 
Pulmonary cavitation is another common pathological feature of TB that arises due to 
the liquification and degradation of the granuloma structure, and is associated with 
treatment failure [20,21]. 
 
 Pharmacokinetics of TB antibiotics 
The purpose of pharmacokinetic (PK) studies on TB drugs is to determine how the drug 
is absorbed and metabolized in the body, and how well the drug is able to reach the 
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granulomas where Mtb reside. These studies provide evidence to determine appropriate 
dosing, and other factors that influence plasma exposure for different antibiotics. 
Population PK studies seek to identify covariates that exist in populations to determine 
what doses are both safe and effective for individuals in a population [22]. These 
studies can help to identify conditions or patients that may be at risk for sub-therapeutic 
levels of antibiotic and thus at increased risk for resistance or treatment failure. The PK 
of the first-line antibiotics (INH, RIF, EMB and PZA) have been extensively studied [23–
27]. Population PK studies have also been used to determine effective doses in 
populations for newer anti-TB drugs, such as fluoroquinolones [28], linezolid [29], 
bedaquiline [30] and pretomanid [31].  
 
Sources of population variability come from numerous factors, such as genetic 
differences in the population, co-administration with other drugs (especially HIV 
medication), and even nutrition [25,32–34]. Understanding the population-level 
variability and the factors that influence drug concentrations in plasma has important 
implications on treatment outcome [35]. Techniques such as the hollow-fiber model 
have provided a way to study how varying levels of drug concentration in vitro impact 
the pharmacodynamic effect and emergence of resistance for numerous antibiotics [36–
40].  
 
Understanding the sources and impact of variability in plasma concentrations is 
important because it is a potential cause of sub-therapeutic antibiotic concentrations in 
granulomas [41]. As Mtb reside inside granulomas in TB disease, the ultimate target for 
antibiotics are these lesions, and antibiotics must travel from blood into the lung 
environment, and ultimately distribute throughout the granuloma in sufficient 
concentrations to be effective [42]. The granuloma itself, and in particular caseous and 
necrotic portions of the granuloma, can present a physiological barrier to antibiotic 
diffusion, which can impact an antibiotic’s ability to sterilize a granuloma [43]. While in 
vitro and physiochemical properties can influence distribution in tissue, attempts to find 
strong correlations between these measurements and effective in vivo concentrations 
have failed [44]. Studies looking at distribution of INH, RIF, EMB and fluroquinolones in 
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rabbit granulomas have uncovered important trends and patterns in how these 
antibiotics distribute in lesions, and potential relationships to sterilizing ability [45–47]. 
Another important aspect in determining drug distribution in granulomas is binding to 
macromolecules, in particular those present in caseum. Advances in assays that can 
measure binding to this material have greatly increased our understanding and ability to 
predict drug distribution in a granuloma [48]. 
 
 Pharmacodynamics of TB antibiotics 
Pharmacodynamics (PD) describes the relationship between drug concentration and its 
therapeutic effect. With regards to antibacterial effect on Mtb, this refers to either the 
growth inhibition or bactericidal effect of anti-TB drugs. PD parameters, such as the 
minimum inhibitory concentration and minimum bactericidal concentration, measure the 
concentration at which a certain level of inhibition or killing is achieved [44]. Other types 
of assays also measure effective concentrations in hypoxic or nutrient starved 
conditions, such as the Wayne cidal concentration [49] and Loebel cidal concentration 
[50,51]. These measures are of particular importance to determine the PD effect a given 
antibiotic has on Mtb, as Mtb harvested from caseum have been shown to exhibit 
tolerance to high concentration to certain antibiotics [18]. Given the complex nature of 
the granuloma, and the hypoxic and nutrient starved environments it can present to Mtb, 
translating in vitro measurements directly to in vivo efficacy is difficult, as the necessary 
concentration for killing Mtb can vary greatly depending on the specific environment 
[43]. 
 
Another important aspect of determining PD effect is that antibiotic therapy for TB 
consists of multiple antibiotics. The presence of multiple drugs to achieve some 
therapeutic activity can lead to non-linear effects in their action, resulting in synergistic 
or antagonistic effects [52,53]. With regards to TB antibiotics, there is growing evidence 
that these drug-drug interactions could be predictive of clinical efficacy for TB regimens 
[54]. These drug-drug interactions can be measured in checkerboard assays that 
combine varying concentrations of antibiotics together and measure the resulting PD 
effect. The combinatorics involved with screening high-order (3 or more drugs) 
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interactions requires a prohibitively large number of experiments, even with recent 
advancements that limit the number of concentration combinations needed to measure 
the drug interactions [55,56]. To more efficiently predict drug interactions for any drug 
combination, machine-learning algorithms have been used to identify drug-gene 
expression patterns from transcriptomics data to predict synergy or antagonism for 
novel combinations of antibiotics [54,57–59]. 
 
 Animal Models of TB 
Numerous animal models have been used to contribute to the understanding of 
tuberculosis pathology, immunological response and treatment, using species such as 
mice, guinea pigs, rabbits, non-human primates and zebrafish [60].These models have 
varying utility depending on the specific scientific study in question, as they can vary 




Mice are useful models in studying immune responses in infectious diseases. With 
regards to TB research, they typically fail to develop necrotic lesions and fail to develop 
the same latent infection present in humans [61]. More recently, the C3HeB/FeJ mouse 
model for TB was developed that can form necrotic lesions and potentially be used to 
study antibiotic treatment [62]. The C3HeB/FeJ mouse was used to show that 
clofazimine as a single-drug treatment lacked efficacy if granulomas progressed to 
hypoxic and necrotic granulomas [63]. The mouse model has also shown that PZA can 
contribute to a sterilizing effect in combination with first-line TB antibiotics, but is likely 
inactive in neutral pH caseum [64,65]. The ability of the C3HeB/FeJ mouse to develop 
necrotic lesions allows for the ability to study the dependence of drug distribution in 
granulomas on efficacy. 
 
1.7.2 Rabbits 
Rabbits are relatively resistant to infection with Mtb, but they do produce granuloma 
heterogeneity and structure that is very similar to human lesions in TB [66–68]. 
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Although rabbits are resistant to chronic infection and therefore fail to provide a model 
to study disease progression and reactivation, rabbits are frequently used to study 
tissue specific distribution. PK models built and calibrated to concentration data for 
isoniazid, rifampin, pyrazinamide and moxifloxacin helped to describe the differences in 
lesion concentrations for those different agents, and identified lesion-specific indices to 
apply PK studies [45]. Studies with rabbits analyzed ethambutol cellular accumulation in 
granulomas, and partially explained the disconnect between observed ethambutol 
clinical efficacy and lack of in vitro efficacy [46]. Using matrix-assisted laser 
desorption/ionization mass spectrometric (MALDI-MS) imaging in rabbit studies has 
provided a powerful tool to visualize the qualitative distribution of antibiotics, and identify 
the critical PK properties of antibiotics and physiological granuloma characteristics that 
influence antibiotic distribution [43,69]. MALDI-MS imaging, together with computational 
modeling of antibiotic distribution, characterized the differences in distribution between 
the fluoroquinolones moxifloxacin, levofloxacin, and gatifloxacin and their relative 
efficacies [47]. 
 
1.7.3 Non-human primates 
Non-human primate models have provided an excellent model in studying the spectrum 
of disease and immune response in TB. Macaques, which are outbred, are a popular 
primate used in the study of TB disease, and studies show that there are variable 
outcomes in disease trajectory similar to humans [70]. Cynomolgus macaques infected 
with a low-dose of Mtb have been extensively characterized and shown to produce of 
spectrum of TB disease and granuloma types, providing a valuable model to study 
disease progression, reactivation and treatment [71], and mechanisms or markers that 
could predict disease progression or sterilization [72–74]. Macaque models have been 
used PET-CT imaging to monitor treatment progression and the efficacy of antibiotic 
regimens to protect against TB reactivation [75,76]. Recently, they have been useful to 
study new antibiotics, including linezolid [77,78].  
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 Multi-scale modeling in TB 
The entire immune response in TB disease relies on the integration of events occurring 
at the molecular, cellular and organ scales. As immune cells encounter Mtb, molecular 
signals recruit more immune cells to the site of infection, and T cells travel from lymph 
nodes through the blood and into the lung. As a way to address complexities of 
biological systems, and better understand the role different aspects of the immune 
response have on granuloma formation, maintenance, and function, systems biology 
and multi-scale modeling approaches have helped to connect these multiple 
phenomena. Multi-scale modeling is modeling that involves more than one level of 
resolution in the time, space or function [79]. Multi-scale modeling is used widely in the 
computational biology field, with applications in cancer [80,81], inflammatory responses 
[82], muscle regeneration [83], cellular and signaling trafficking [84,85] and more [79]. 
 
1.8.1 Granuloma simulation: GranSim 
Multi-scale computational modeling in TB has been used to study many aspects of 
granuloma formation and disease progression [86]. GranSim is an agent-based model 
that captures the emergent behavior of granuloma formation and function to study the 
heterogeneity of TB lesions and the importance of various immune responses [87–91]. 
Briefly, GranSim simulates the immunology-inspired rules of interaction between 
immune cells and bacteria on a computational grid. Immune cells, including 
macrophages and T cells, can move, secrete cytokines and chemokines, and change 
states through interactions with their environment and other immune cells. Mtb exist as 
agents in the model and exist in subpopulations of intracellular (inside macrophages), 
replicating extracellular, or non-replicating extracellular. Cytokines, chemokines, and 
antibiotics can diffuse through the computational grid. Studies uncovered critical 
cytokines and signaling pathways that can lead to different TB outcomes, and how the 
balance between pro- and anti-inflammatory signals can control the disease response 
[89,92–94]. Inclusion of lymph node recruitment also helped to inform how and when 
immune cells are recruited to the site of infection, including recruitment to multiple 
granulomas, and provides a way to track potential biomarkers for infection outcome 
[73,95]. ODE models representing multiple granuloma formation in a single lung 
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environment, connected by blood and lymph node recruitment, have predicted how 
granuloma progression is linked to disease dissemination [96].  
 
While TB computational modeling is used to study many of the aspects of the immune 
response, ranging from signaling pathways to cellular recruitment through the blood, 
multi-scale modeling has also been critical in studying aspects of Mtb and its role in the 
granuloma. Simulating Mtb as individual agents in an agent-based model gave the 
ability to show how mutations at the bacterial level leading to antibiotic resistance 
influence in treatment outcome and granuloma sterilization [97]. Additionally, metabolic 
pathways in Mtb influence growth rate, and the availability of nutrients and oxygen 
inside a granuloma influence the phenotypic state of Mtb [17]. 
 
1.8.2 Simulating antibiotic treatment in GranSim 
Antibiotic distribution and concentration in granulomas involve events that occur over 
multiple organ, length and time scales, similar to the immune response in TB. Oral 
antibiotics are absorbed into the blood, where they can partition into peripheral tissues 
and are eliminated through hepatic or renal function. In the lung, antibiotics permeate 
through blood vessels into the lung tissue, where they can diffuse, bind to extracellular 
material, and partition into cells such as macrophages. Modeling PK at multi-scale 
resolutions is also beneficial and is required to capture the observed heterogeneity in 
antibiotic distribution in granulomas [41,42], and provides a tool to design new 
therapeutic approaches, including oral and inhaled regimens [12,98]. Using agent-
based models to simulate the cellular-level interactions and organizational structure of 
the granuloma provides an environment to simulate antibiotic distribution, and has led to 
uncovering immune system mechanisms that impact sterilization during antibiotic 
treatment [91]. Linking the PK occurring in the blood with tissue-level PK/PD models 
provides a tool to explore how different regimens influence sterilization in vivo at a 
granuloma scale [99]. Adding another layer of complexity by simulating the dynamic 
binding of fluoroquinolones to extracellular material and partitioning into macrophages in 
granulomas has provided a model that accurately describes the unique distribution 
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characteristics of fluoroquinolones in granulomas and a tool to compare their efficacies 
[47]. 
 
1.8.3 Optimization in TB treatment 
Research involving efforts to optimize TB treatment to find the appropriate combination 
of antibiotics and doses is an important step in improving TB treatment [55,100,101]. 
Based on the number of antibiotics available to treat TB, and the numerous possible 
combinations of antibiotics, is too large to test experimentally. Formalizing locating 
better antibiotic treatment regimens as an optimization problem and using 
computational modeling to compare regimen efficacies can provide a method to 
efficiently predict optimal regimens through a rational design approach. A variety of 
optimization algorithms are applied in science, math and engineering [102,103]. Of 
these algorithms, population-based algorithms, such as genetic algorithms, and 
surrogate-assisted optimization algorithms have been widely used across many fields of 
science and technology [104–106]. Because options for optimization algorithms are as 
variable as the types of problems they can solve, selecting the appropriate algorithm is 
essential. For the purpose of optimizing antibiotic regimens for TB, we must use an 
algorithm that can efficiently and accurately predict relevant regimens with good 
efficacy.  
1.8.4 Virtual clinical trials 
Previous studies using GranSim to simulate antibiotic treatment focus on treatment at 
the granuloma scale. However, treatment of a patient with TB requires treating and 
sterilizing multiple granulomas. Choosing the best regimen for TB treatment should 
ensure that it can sterilize all granulomas in an individual and perform well in a diverse 
population. When using computational models to predict regimen efficacies, simulating 
a virtual clinical trial can provide a way to compare different regimens or interventions in 
a way that mimics actual clinical trials [107–109]. Virtual clinical trials can be used to 
generate a virtual population of individuals that have the same characteristics and 
variability in disease and responses that exist in the real population. For the purpose of 
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TB treatment, individuals have variable PK and heterogeneous granulomas that both 
can impact treatment [110].  
 
 Thesis summary 
In this thesis, I utilize a multi-scale computational model to simulate antibiotic treatment 
in TB granulomas. Using this model, I address how PK variability and granuloma 
heterogeneity impact granuloma sterilization with antibiotic treatment in Chapter 2. In 
Chapter 3, I present a PD model that adjusts antibiotic killing rates based on drug-drug 
interactions and discuss how these interactions are dependent on concentration 
distributions and how they impact regimen efficacy. In Chapter 4, I present a way of 
optimizing antibiotic regimens using computational simulations and compare the 
efficiency and accuracy of different optimization algorithms. In Chapter 5, I utilize a 
surrogate-assisted optimization algorithm to optimize the doses of isoniazid, rifampin, 
ethambutol, and pyrazinamide for treatment of primary TB, and compare optimal 
regimens at the granuloma and virtual population scale using virtual clinical trials. This 
thesis shows that incorporating multi-scale phenomena and appropriately representing 
the heterogeneity and variability in TB disease and treatment is critical in evaluating 
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Chapter 2 Both Pharmacokinetic Variability and Granuloma 
Heterogeneity Impact the Ability of the First-Line 
Antibiotics to Sterilize Tuberculosis Granulomas 
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 Abstract 
Tuberculosis (TB) remains as one of the world’s deadliest infectious diseases despite 
the use of standardized antibiotic therapies. Recommended therapy for drug-
susceptible TB is up to six months of antibiotics. Factors that contribute to lengthy 
regimens include antibiotic underexposure in lesions due to poor pharmacokinetics (PK) 
and complex granuloma compositions, but it is difficult to quantify how individual 
antibiotics are affected by these factors and to what extent these impact treatments. We 
use our next-generation multi-scale computational model to simulate granuloma 
formation and function together with antibiotic pharmacokinetics and 
pharmacodynamics, allowing us to predict conditions leading to granuloma sterilization. 
In this work, we focus on how PK variability, determined from human PK data, and 
granuloma heterogeneity each quantitatively impact granuloma sterilization. We focus 
on treatment with the standard regimen for TB of four first-line antibiotics: isoniazid, 
rifampin, ethambutol and pyrazinamide. We find that low levels of antibiotic 
concentration due to naturally occurring PK variability and complex granulomas leads to 
longer granuloma sterilization times. Additionally, the ability of antibiotics to distribute in 
granulomas and kill different subpopulations of bacteria contributes to their 
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specialization in the more efficacious combination therapy. These results can inform 
strategies to improve antibiotic therapy for TB. 
 
 Introduction 
Tuberculosis (TB) continues to be one of the world’s deadliest infectious diseases, 
leading to the death of 1.3 million people in 2017, about 2-3 people per minute [1]. 
Caused by infection with the pathogen Mycobacterium tuberculosis (Mtb), TB most 
commonly presents as a pulmonary disease in adults when individuals inhale 
aerosolized Mtb transmitted by other infected individuals. The immune response in the 
lungs leads to the formation of multiple lesions called granulomas, collections of 
immune cells that act to contain the infection both immunologically and physically but 
also present a barrier to antibiotic diffusion and delivery [2–4]. Understanding 
penetration and distribution of antibiotics in granulomas is critical to understanding how 
best to treat TB. 
The current recommended regimen to treat active, drug-susceptible TB disease 
requires up to six months of multiple antibiotics [5]. For the first two months, patients 
take daily doses of isoniazid (INH, H), rifampin (RIF, R), ethambutol (EMB, E), and 
pyrazinamide (PZA, Z), referred to as HRZE. Each of these antibiotics has side effects 
associated with their use that, together with the lengthy treatment duration, make it 
difficult for patients to properly adhere to the regimen [6,7]. Efforts such as directly 
observed therapy (DOT) attempt to increase patient adherence but are not tractable on 
a global scale [8,9]. Emergence of multidrug-resistant (defined as resistant to INH and 
RIF) and extensively drug-resistant TB (resistant to INH, RIF and a second-line 
injectable) further complicates treatment [1]. There is a need for improved antibiotic 
therapy for TB and to understand what causes treatment failure. 
There are two key factors outside of drug resistance that have been identified as 
contributing to drug failure in TB: pharmacokinetic (PK) variability (acting at population 
scale) and granuloma heterogeneity (acting at the host scale). How these factors 
interact to affect both the rate and extent of sterilization during treatment is not well-
understood. PK variability is defined as differences in plasma antibiotic exposure, 
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typically measured as variability in plasma area under the curve (AUC) measurements. 
Population PK models can help determine appropriate dosing of TB antibiotics and 
represent this variability based on distributions of PK model parameters [10–13]. These 
distributions can be related to natural differences in populations through covariates such 
as weight, age or overall health. Additionally, PK variability can be due to differences at 
the genetic scale, such as in N-acetyltransferase 2 involved in the metabolism of INH 
[14,15]. This PK variability can lead to poor exposure in granuloma lesions, reducing the 
amount of time antibiotic concentrations are above therapeutic thresholds during 
therapy [16]. 
Host-scale heterogeneity encompasses host-level variations in granuloma number, size, 
and composition. Granuloma size and composition can lead to slower diffusion of 
antibiotics, spatial gradients of concentration and underexposure at the host tissue 
scale [3,4,17,18]. Granuloma composition can affect how antibiotics accumulate or fail 
to accumulate within lesions [3]. For example, EMB’s clinical efficacy may partially be 
explained by its ability to accumulate in cellular regions of the granuloma [19]. Structural 
differences in lesions affect the sterilizing ability of PZA, as shown in different strains of 
mice [20]. Caseous regions of the granuloma may also harbor bacteria that are 
phenotypically more tolerant, and may be less accessible, to many TB antibiotics [21]. 
Capturing both PK variability at the population scale and granuloma heterogeneity at the 
host scale in a computational model can help predict granuloma sterilization and design 
antibiotic regimens. Our group previously developed a computational model that 
incorporates the host formation of granulomas and antibiotic PK to predict the 
sterilization of granulomas using different regimens with INH and RIF [4,22]. Using this 
multi-scale, systems pharmacology model, we have also highlighted major differences 
between members of the fluoroquinolone drug class and simulated TB therapy with 
development of antibiotic resistance [23,24]. Using this computational framework 
provides a way to include both PK variability and granuloma heterogeneity to predict 
whether a treatment can achieve granuloma sterilization in primary, pulmonary TB in 
adults.  
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Here we use our hybrid, multi-scale agent-based model to capture PK variability and 
granuloma heterogeneity and to simulate antibiotic treatment of primary, lung 
granulomas. For the first time with this model, we simulate treatment based on human 
PK and with the combination of the four first-line antibiotics used to treat TB: INH, RIF, 
EMB and PZA. We also present a sequential calibration scheme that captures spatial 
distributions of antibiotics within granulomas and known PK variability that exists across 
the population scale and at the host scale within granulomas. Using this highly detailed 
model, we discuss the role of first-line antibiotics (HRZE) in sterilizing granulomas and 




2.3.1 Computational model of granuloma formation and function 
GranSim is a well-established hybrid, multi-scale computational model that produces 
the emergent behavior of granuloma formation in Mtb infection [25–28]. Briefly, this 
agent-based model simulates immune cell movement and interactions, and bacterial 
growth on a spatial grid representing an area of lung tissue. The immune cell agents, 
such as different classes of macrophages and T cells, move in response to chemokine 
gradients and interact with each other according to immunology-derived rules to activate 
or deactivate immune cells/responses. Bacteria in the model are simulated as individual 
agents, and they exist in three distinct subpopulations: extracellular replicating, 
extracellular non-replicating, or intracellular (inside macrophages). The effective growth 
rate of bacteria in these three subpopulations is influenced by extracellular or 
intracellular location and availability of nutrients and oxygen [29]. Non-replicating Mtb 
represent bacteria trapped within caseum, which presents hypoxic conditions with 
limited nutrient resources [21,30]. A more detailed explanation of GranSim and the 
simulation rules and assumptions can be found online 
(http://malthus.micro.med.umich.edu/GranSim/). GranSim simulates lung granulomas 
that form due to primary, pulmonary infection in adults and captures a wide diversity of 
granulomas through variations in host immune system parameters and stochastic 
events in the agent-based model. The boundary of the granuloma is defined by regions 
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of high cell density, and outlines of the granuloma are drawn to enclose these regions. 
Parameters that were varied to generate our library of heterogeneous granulomas are 
listed in Table 2.1. 
2.3.2 In silico granuloma library  
We generate two distinct libraries of granulomas that are heterogeneous in bacterial 
load and cellular composition: one categorized as low-CFU (colony-forming unit, equal 
to the number of bacteria in the simulation) granulomas and the other as high-CFU 
granulomas. The low-CFU granulomas are smaller in size and have CFU/granuloma 
that are more stable over time, whereas the high-CFU granulomas are larger in size, 
have increasing CFU over time, and have higher levels of caseum. To generate the low-
CFU granulomas, we sampled 500 parameter sets based on ranges for host immune 
system parameters listed in Table 2.1 using Latin Hypercube Sampling (LHS) [4]. Using 
the simulation outputs at day 300 for granuloma size and CFU, we performed sensitivity 
analysis using partial rank correlation coefficients to determine parameters that have the 
most significant impact on those two outcomes [31]. A total of 400 high-CFU 
granulomas were generated by increasing or decreasing the upper and lower bounds of 
the parameter ranges that have the strongest correlation with granuloma size and CFU, 
as well as initializing simulations with multiple infection locations to generate larger 
granulomas. Parameter ranges for all granulomas are shown in Table 2.1. Low-CFU 
granulomas are simulated on a 200 by 200 compartment square grid representing a 4 
by 4 mm section of lung tissue (each grid compartment has a side-length of 20 
microns), whereas the high-CFU are run on 300 by 300 compartment grid representing 
6 by 6 mm. Note that we simulate the small granulomas on a smaller grid for 
computational efficiency, as the larger is not required. At day 300, a total of 354 low-
CFU granulomas and 352 high-CFU granulomas still had bacteria and were selected for 
treatment simulations. Figure 2.1 shows CFU per granuloma of these two groups. 
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Figure 2.1 Heterogeneous granulomas generated using the computational model GranSim.  
There are two groups of in silico granulomas at day 300 post infection: low CFU granulomas (black/gray, n=354) and 
high CFU granulomas (red, n=352). High CFU granulomas have increasing CFU over time relative to the more stable 
lower CFU granulomas (A). (C) shows the distribution of CFU per granuloma in the low CFU group (black) and the 
high CFU group (red) at day 300. (B) shows an example of a low CFU in silico granuloma and (D) shows an example 
of a high CFU granuloma. In both simulations the colors represent: macrophages green; resting; blue, active; orange, 
infected; red, chronically infected), T cells (IFN-gamma producing; pink, cytotoxic, purple; regulatory, light blue), and 
caseated regions (tan). 
 
2.3.3 Plasma pharmacokinetic model 
The plasma PK model is comprised of a two-compartmental model with one or two 
transit compartments that simulate oral absorption. INH and RIF follow a two-absorption 
compartment model based on previously developed PK models, whereas EMB and PZA 
are simulated with one absorption compartment based on best fits and other PK models 
[4,11,12,19,32]. The two-compartment model simulates distribution between plasma 
and peripheral tissue, and antibiotics are eliminated with a first-order clearance rate 
constant (Figure 2.2). Pharmacokinetic variability can be introduced by varying the 




Figure 2.2 Pharmacokinetic/pharmacodynamic dynamics in GranSim.  
Plasma concentration is simulated with a two-compartment PK model with one (EMB and PZA) or two (INH and RIF) 
transit compartments to capture oral absorption. The amount of drug added or subtracted through the vascular 
sources in the agent-based spatial grid depends on local gradients of antibiotics. Antibiotics on the grid can diffuse, 
degrade, bind to extracellular material (such as caseum) and partition into macrophages. Based on intra- or 
extracellular concentrations in each grid compartment, a killing rate constant based on a Hill curve determines the 
probability per time step that a given bacterium will die due to exposure to antibiotics. 
 
2.3.4 Tissue pharmacokinetic model 
The plasma PK model is linked to the agent-based environment through blood vessels 
placed on the simulation grid (Figure 2.2). Based on the difference between the plasma 
concentration and local tissue concentration in the compartments surrounding a blood 
vessel and the permeability of the antibiotic through blood vessel walls, a flux of 
antibiotic through the vessel wall is calculated as in previous work [4]. Antibiotics in the 
tissue (on the simulation grid) undergo a series of distribution events: diffusion, binding 
to extracellular material such as caseum, partitioning into macrophages, and 
degradation. Implementation of vascular permeation, diffusion, binding and degradation 
is as previously published [4,33]. Antibiotics on the simulation grid can be tracked as 
free molecules, bound to extracellular material, or partitioned into macrophages. When 
calibrating and fitting to data, we use total drug concentration in a grid compartment, but 
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only free or intracellular antibiotic is used to determine antimicrobial activity, depending 
on the location of bacteria. Calibrated tissue PK parameters are given in Table 2.3 (see 
below for calibration datasets). 
2.3.5 Sequential pharmacokinetic model calibration scheme  
Gradients between plasma and tissue concentrations drive the amount of antibiotic 
delivered into the agent-based model simulation through blood vessels, so fitting tissue 
PK parameters to match the experimentally observed spatial distribution and average 
antibiotic concentrations in granuloma lesions requires incorporating both plasma PK 
variability and granuloma heterogeneity. We have devised a pipeline for incorporating 
these factors into GranSim (Figure 2.3). Using our in silico granuloma library, each 
granuloma is assigned a different plasma PK set sampled using LHS from parameter 
ranges that capture biological variability (Table 2.2). Next, changes in antibiotic tissue 
concentrations over time are simulated for each granuloma with 200 tissue PK 
parameter sets sampled using LHS. For each tissue PK parameter set, the results from 
each granuloma are averaged at each time point, and then compared to experimental 
data. The tissue PK parameter set that both minimizes the sum of the squared error 
between average granuloma concentration and the experimental lesion concentrations, 
as well as provides a good visual fit to the data is chosen as the calibrated tissue PK 




Figure 2.3 Capturing pharmacokinetic variability and granuloma heterogeneity in PK calibration and 
treatment simulations.  
(A) shows our strategy. Based on population variability and ranges in plasma PK parameters, sets of plasma PK 
parameters are sampled and assigned to a set of in silico granulomas. Based on experimentally guided ranges for 
tissue PK parameters, a set of tissue PK parameters is obtained using LHS.  Simulations then predict antibiotic 
concentrations in the tissue. The average concentration over all granulomas for a given tissue PK parameter set is 
calculated and compared to experimental lesion concentrations. (B) shows the four types of treatment simulations 
that capture biologically relevant PK variability and granuloma heterogeneity: average PK exposure with low or high 
CFU granulomas and low PK exposure with low or high CFU granulomas.  
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2.3.6 Pharmacokinetic Data 
Plasma and tissue PK parameters for INH, RIF and PZA are calibrated using plasma 
and lesion antibiotic concentrations measured in resected lung samples from patients 
with drug-refractory TB [18]. EMB concentrations in rabbit TB granulomas are used to 
calibrate tissue PK parameters, based on rabbit plasma PK parameters [19]. Since 
tissue PK parameters are based on physical properties and interactions between drug 
molecules and tissue, we assume that tissue PK parameters in rabbits and humans are 
similar. To simulate human treatment with EMB, we replace the rabbit plasma PK 
parameters with human parameters fit to population PK measurements [12]. 
2.3.7 Pharmacodynamic model 
The pharmacodynamic model involves evaluating a concentration-dependent killing rate 





The killing rate constant k (units of 1/timestep or 1/10 min) is dependent on the variable 
concentration (C), the maximum killing rate constant (Emax), the concentration at half 
maximal killing (C50) and the Hill curve constant (h). The concentration used to 
determine the antibiotic killing rate constant is based only on free drug concentration. 
Parameters Emax, C50, and h need to be determined for each antibiotic and for each 
bacterial subpopulation (replicating extracellular, non-replicating extracellular, and 
intracellular). To fit these parameters, we use in vitro dose-response assays from 
individual experiments from the literature of Mtb growth/death under varying antibiotic 
concentrations (see Table 2.4 for parameters and references for data and refer to 
Figure A.1 (Appendix A) for calibrated fits to dose-response curves). In the present 
model, we do not include drug-drug interactions, so the highest single antibiotic killing 
rate constant for each antibiotic within a specific grid compartment in the simulation is 
used as the effective antibiotic killing rate constant for that location [22,34]. This 
assumption isolates the impact of PK variability and granuloma heterogeneity on 
granuloma sterilization within this study. 
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2.3.8 In silico antibiotic treatment of granulomas 
Treatment simulations are executed by choosing the non-sterile set of low and high 
CFU in silico granulomas that have formed 300 days post infection (in the absence of 
antibiotics). The doses for the standard regimen are based on CDC recommended adult 
doses for each of the four antibiotics: INH, 5 mg/kg; RIF, 10 mg/kg; EMB, 17 mg/kg; 
PZA 21 mg/kg [5]. Simulated treatments use daily doses of each antibiotic. Treatment 
simulations are administered for a maximum of 180 days, which are based on standard 
regimen length [5]; simulations are stopped once granulomas sterilize to reduce 
computational resource use. After treatment, we calculate a simulated early bactericidal 
activity (EBA), which is defined as the rate of decrease of log10(CFU) per day. For 
example, the EBA for 0-2 days is calculated as (log10(CFU	day	0)- log10 (CFU	day	2))/2. 
We simulate four groups of granulomas to incorporate PK variability and granuloma 
heterogeneity (Figure 2.3). Group 1 has population average plasma PK exposure (AUC) 
with low-CFU granulomas and Group 2 has average PK exposure with high-CFU 
granulomas. Groups 3 and 4 both have low plasma PK exposure, with low and high-
CFU granulomas respectively. Plasma PK parameter values for the low and average PK 
exposure are listed in Table 2.2.  
 
 Results 
2.4.1 Pharmacokinetic model captures plasma and lesion variability in antibiotic 
concentrations 
Heterogeneity in antibiotic exposure within granulomas is the result of two factors. 
Differences in plasma drug concentrations among individuals can be due to differences 
in drug absorption and elimination rates, and these are reflected in distributions of 
plasma PK parameters across a population. Additionally, granuloma structural 
heterogeneity (including differences in size and composition) can lead to differences in 
antibiotic exposure at the lesion level. To capture both sources of heterogeneity, which 
occur at different length scales, we devised a sequential calibration scheme to calibrate 
the PK model from data (Figure 2.3; parameters in Table 2.2 and Table 2.3).  
Figure 2.4 shows antibiotic total concentrations (sum of free and bound) within both 
plasma and granulomas for all four first-line antibiotics (INH, RIF, EMB and PZA). 
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Results are shown for 24 hours following an oral dose and compared to experimental 
data. Using our sequential calibration scheme, we capture a large proportion of the 
experimentally observed antibiotic concentration data in both plasma and granulomas. 
The C50 values for each bacterial subpopulation, obtained by fitting the data referenced 
in Table 2.3, indicate the free-drug concentration when a given antibiotic is at half its 
maximum bacterial killing rate. INH, RIF and EMB achieve sufficient concentrations to 
kill extracellular replicating Mtb for a majority of the dosing period. Both INH and EMB 
can achieve concentrations above the C50 for intracellular Mtb. Only RIF approaches 
concentrations necessary to achieve bactericidal activity against non-replicating Mtb. 
Based on average granuloma concentrations, PZA appears to have little sterilizing 
activity in granulomas. 
Figure 2.4 also shows antibiotic total concentrations as a function of position throughout 
the grid, at the time of maximal average granuloma drug concentration following a 
single oral dose of each antibiotic in the same in silico granuloma, shown in grayscale to 
allow for the illustration of gradual concentration changes. INH shows a relatively 
homogenous distribution in the lesion that rapidly clears as INH is eliminated in the 
plasma. RIF accumulates poorly in granulomas at early time points but can slowly 
accumulate in the caseum following multiple doses (Figure A.2, Appendix A). EMB 
tends to accumulate in regions with a high density of macrophages but fails to diffuse 
into caseum significantly. PZA shows a slight accumulation in caseum relative to the 
macrophage-rich regions of the granuloma. To further validate our model, Figure 2.5 
shows PZA distribution identified experimentally using matrix-assisted laser 
desorption/ionization mass spectrometry imaging (MALDI-MSI) as we have done 
previously [18] and compares the PZA signal intensity distribution to two simulated 
granulomas. Overall, our simulated distributions for other antibiotics agree with 
observations made through MALDI-MSI in TB granulomas [18,19]. These qualitative 
features observed in the simulations for each antibiotic were not used in calibrating the 
tissue PK parameters, but rather resulted from estimating and fitting the tissue PK 
parameters to average granulomas concentrations (Table 2.1). 
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Figure 2.4 Simulations capture both the experimentally observed temporal and spatial antibiotic 
concentrations.  
Simulations and data for each antibiotic (INH, RIF, EMB and PZA), dosed singly, are shown in different columns, 
respectively. The top row shows plasma concentrations and the middle row shows average lesion concentrations with 
varying plasma PK parameters (median, solid blue line; range between minimum and maximum of simulations, blue 
shade) and experimentally measured antibiotic concentrations (black points). Concentrations in granulomas are in 
mg/kg (assuming tissue density is approximately 1 kg/L), and reflect the sum of concentrations of free, bound and 
intracellular drug.  Horizontal lines represent the C50 values for intracellular (green), extracellular replicating 
(magenta) and non-replicating (red) subpopulations of Mtb (C50 values not shown are above the range of lesion 
concentrations displayed on the plot). Data in the middle row are measurements from human granulomas (INH, RIF 
and PZA (Prideaux et al. 2015) [18]) and rabbit granulomas (EMB (Zimmerman et al. 2017) [19]). The bottom row 
shows spatial distribution of antibiotics in GranSim at the time of the maximal average lesion concentration. Red 
outlines indicate edge of granuloma (outer line) and caseated locations (inner lines). 
 
Figure 2.5 Comparison of spatial distribution of PZA in GranSim  
(A) and in experimental images of granulomas using MALDI-MSI (B). The simulation images show heat maps of the 
spatial distribution of PZA at 5 hours after a single-PZA dose. In the simulated concentration heat maps, shown in 
color to mimic the images from MALDI-MSI (A), the red area corresponds to lung tissue outside of the granuloma, the 
darker blue regions indicates regions inside the granuloma with higher densities of macrophages, and the lighter blue 
to green sections show correspond to caseated regions. Both simulation images are on a 200 by 200 grid, 
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representing a 4 mm by 4 mm section of lung tissue. Experimental images (B) show PZA distribution in granulomas 
imaged with MALDI-MSI, with granuloma boundary outlined in black, and caseated regions outlined in white. Both 
simulation and experiments show some accumulation of PZA inside caseous regions, relative to the cellular portions 
of the granuloma. 
 
2.4.2 Single-drug treatments sterilize granulomas at different rates and to different 
extents 
We next tested the abilities of each first-line antibiotic, when dosed alone, to sterilize 
granulomas with average plasma PK exposure and low or high-CFU (Groups 1 and 2 of 
Figure 2.3). The rates and extents of sterilization differ for each antibiotic in low-CFU 
granulomas, as shown in Figure 2.6, due to differences in sterilizing activity against 
various subpopulations of bacteria as well as the antibiotic distribution within 
granulomas. After 180 days of treatment, single-drug therapy with RIF sterilizes all low-
CFU granulomas. INH sterilized 93% low-CFU granulomas. EMB and PZA each 
sterilize just 32% and 1.7% of low-CFU granulomas, respectively. INH and EMB all 
have early sterilizing ability and were able to sterilize 29% and 31% of granulomas after 
two weeks, respectively. RIF alone only sterilized 5% by two weeks, and PZA failed to 
sterilize any granulomas by two weeks.  
Our simulations show that INH can quickly distribute within granulomas, and in sufficient 
concentrations to kill both intracellular and extracellular replicating bacteria, and 
therefore provides rapid sterilization for some granulomas, as shown in Figure 2.4 and 
Figure 2.5. However, with poor sterilizing ability against non-replicating Mtb found in 
caseum [21], INH usually requires many months to sterilize granulomas that have a high 
number of non-replicating Mtb and leads to the drawn-out sterilization of non-replicating 
Mtb in INH-treated granulomas. EMB, similar to INH, has poor ability to kill non-
replicating Mtb, so our simulations show it is only able to sterilize a subset of 
granulomas, even though it distributes throughout cellular regions of the granuloma. 
However, it does rapidly kill both extracellular replicating and intracellular Mtb, indicated 
by the percentage of granulomas sterilized by two weeks, which is consistent with 
favorable early bactericidal activity (EBA) for EMB [35]. Because INH and EMB are 
bacteriostatic and have low ability to kill non-replicating Mtb, sterilization time (for INH) 
and total Mtb remaining in the granuloma (for EMB) are highly correlated with the initial 
number of non-replicating bacteria present in the granuloma (Figure A.3, Appendix A). 
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RIF shows more complete sterilization of low-CFU granulomas than any other individual 
antibiotic as it has some sterilizing ability against each subpopulation of bacteria. 
We observe similar trends with single-drug treatments in high-CFU granulomas (Figure 
2.6). Overall, the sterilization times are longer when compared to low-CFU granulomas. 
INH and RIF both sterilize lower percentages of the high-CFU granulomas than they do 
low-CFU granulomas. High-CFU granulomas are also more likely to have higher total 
numbers of non-replicating Mtb, decreasing the ability of INH to completely sterilize 
these granulomas. RIF, with weakened ability to kill intracellular Mtb due to low 
granuloma concentrations, fails to kill all intracellular Mtb in some granulomas. This 
weakness is amplified in larger granulomas, slowing diffusion of antibiotics into the 
granulomas. 
 
Figure 2.6 Single-antibiotic treatments and combination therapy of low-CFU  
(A, C) and high-CFU (B, D) granulomas show different sterilizing rates and extents for each of the first-line antibiotics 
and all four antibiotics together (HRZE). (A) and (B) show the percentage of granulomas sterilized over the course of 
treatment for both groups of granulomas. (C) and (D) show the distribution of sterilization times for only the 
 37 
granulomas that sterilized for each treatment, with the time when 90% of granulomas were sterilized indicated by a 
red line. Percentage below each treatment indicates the total percentage of granulomas that sterilized. For example, 
EMB sterilized 32% of low-CFU granulomas (C), and of those sterilized granulomas, a majority of them sterilized in 
the first few days (indicated by the box plot collapsing to a line). 
 
2.4.3 Specialization of individual antibiotics contributes to success of combination 
therapy 
Combination therapy – all four first-line antibiotics – sterilizes low-CFU granulomas at 
nearly the same rate as the best single-antibiotic treatment (RIF) (Figure 2.6). All 
granulomas are sterilized after 147 days of combination therapy, with 33% sterilized 
after 2 weeks. The difference in early versus late sterilizing ability for the single-drug 
treatments is one reason why the combination therapy shows faster and more complete 
sterilization than any one drug on its own. Early in treatment, INH and EMB do much of 
the killing, and the presence of RIF completes the sterilization.  
The benefit of combination therapy is more dramatic for high-CFU granulomas (Group 2 
of Figure 2.3). Here, treatment with INH or RIF show only 33% and 39% sterilization 
after 180 days of therapy, respectively, compared to 97% of granulomas sterilized with 
HRZE (Figure 2.6). Although RIF is able to sterilize granulomas as well as HRZE in low-
CFU granulomas, the same behavior is not observed in high-CFU granulomas. RIF is 
relatively slow at killing intracellular bacteria. In the low-CFU granulomas, the number of 
intracellular Mtb is low enough where RIF can kill these bacteria eventually. In high-CFU 
granulomas, RIF is not always able to kill intracellular Mtb fast enough to keep up with 
its replication, and therefore fails to sterilize all high-CFU granulomas. The presence of 
INH and EMB provide assistance in killing the intracellular Mtb, so the combination of 
antibiotics allows for more complete sterilization. Our model predicts that the different 
abilities to kill each of the subpopulations of bacteria and the different distributions 
within granulomas complement each other in combination therapy. 
During combination therapy (HRZE), a majority of bacterial death is due to antibiotics; 
antibiotics are responsible for roughly an order of magnitude more bacterial death than 
the immune response, and two orders more than bacterial death in caseum 
representing a lack of oxygen and nutrients (Figure A.4, Appendix A). This trend is 
consistent across the single-drug treatments with the exception of PZA, which shows 
the poorest efficacy and thus allows for continued bacteria growth and continued slow 
killing via the immune response.  
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2.4.4 High-CFU and low PK exposure lengthen sterilization times during combination 
therapy 
We next tested how sterilization time and thus the necessary length of treatment is 
affected by plasma PK variability between individuals and granuloma heterogeneity. We 
compared the sterilization times of all four granuloma groups (Figure 2.3) when treated 
with daily doses of HRZE. Figure 2.7 shows the distribution of sterilization times for 
each of these treatment scenarios. Simulating the low-CFU granulomas with low PK 
exposure (Group 2) results in a shift in the distribution towards longer sterilization times 
relative to average PK exposure (Group 1), with the 90% sterilization time increasing 
from 97 to 133 days. In contrast, 165 days of HRZE are required to sterilize 90% of the 
high-CFU granulomas with average PK exposure, and 90% sterilization cannot be 
reached within 6 months of treatment when those same granulomas have low PK 
exposure.  
With some granulomas failing to sterilize after 180 days of treatment, we sought to 
analyze the characteristics of those granulomas. We grouped our granulomas into four 
different ‘risk’ categories: low (sterilize in under 90 days of HRZE), medium (sterilize 
between 90 and 150 days), high (sterilize after 150 days), and unsterilized. For each of 
these groups, we compared characteristics of the granulomas before treatment to see 
what types of granulomas have different levels of risk. Unsterilized and high-risk 
granulomas tend to be higher in CFU, size, and amount of caseation (Figure A.5, 
Appendix A), with median CFU/granuloma levels before treatment of 1.1x105, 6.0x104, 
2.1x104, and 1x103 for the unsterilized, high, medium and low risk categories. However, 
these pretreatment characteristics are not sufficient in predicting whether a specific 
granuloma will fail to sterilize during treatment, as there are some granulomas with high 
CFU, diameter and caseation that sterilize within 90 days. Although these low risk 
granulomas look like high risk or unsterilized granulomas, they have higher percentages 
of intracellular Mtb. At the beginning of treatment with HRZE, these intracellular bacteria 
can be quickly killed, making the granulomas easier to sterilize. 
Variation in plasma PK exposure may impact treatment with some antibiotics more 
profoundly than others. To test this, we sampled a set of 200 plasma PK parameters 
from the ranges used in calibrating the PK model (Table 2.2). With each of these 
 39 
plasma PK parameter sets that generate different levels of exposure in plasma, we 
treated the same granuloma with each single-drug treatment (Figure 2.8). Overall, RIF 
is most impacted by natural variability in plasma exposure, and varying plasma PK 
parameters for RIF results in a wider spread of treatment outcomes than other 
antibiotics, ranging from a minimum sterilization time of 38 days to unsterilized 
granulomas by the end of treatment (Figure 2.8). This indicates that optimizing dose for 
RIF and other antibiotics that are particularly sensitive to variations in PK existing in 
human populations may be critical in designing better regimens. 
 
Figure 2.7 Distributions of sterilization times for different granuloma treatment groups, 
Distributions of sterilization times for different granuloma treatment groups referenced in Figure 2.3, treated with 
HRZE indicate factors that negatively impact sterilization. (A) shows simulations of the standard regimen (HRZE). (B) 
shows the simulations of high RIF dose treatments (20 mg/kg). Each dot is the sterilization time of a specific 
granuloma simulation, with the red line indicating the time of 99% sterilization. Low CFU granulomas with average PK 
exposure sterilize the fastest. Low CFU granulomas with low PK exposure show a shift to longer sterilization times 
compared with average exposure. Similarly, high CFU granulomas with average exposure sterilize faster than high 
CFU granulomas with low exposure. Results for low CFU and high CFU with average PK are shown in Figure 2.6 and 
are plotted again here for comparison. 
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Figure 2.8 Simulation treatment outcomes of single-drug treatments of the same in silico granuloma vary 
with different plasma PK parameter sets.  
A single granuloma was treated with each of the single-drug treatments with 200 different plasma PK parameter sets. 
Above shows the CFU for each granuloma simulation over time during treatment for INH (A), RIF (B), EMB (C) and 
PZA (D). The standard deviation of sterilization times for different plasma PK parameter sets for RIF normalized to 
mean sterilization time is 0.40. This indicates greater variability in sterilization times due to changes in plasma PK for 
RIF compared to INH, for which the value is 0.19. EMB and PZA have standard deviations of log-transformed CFU 
normalized to the mean at the end of treatment standard deviations of 0.033 and 0.034, respectively. 
 
2.4.5 Treatment time can be shortened for some granulomas by increasing the dose of 
RIF 
There have been numerous efforts to shorten TB treatment regimens and clinical trials 
that involve replacing one or more antibiotics in the standard regimen or increasing 
doses of the first-line antibiotics [36,37]. Increasing RIF dosage to 20 mg/kg is a 
strategy applied in several clinical trials [38–40], and is rational because it could lessen 
the impact PK variability has on RIF given our results (Figure 2.7). We investigated how 
increasing the RIF dose impacts granuloma sterilization time while accounting for 
granuloma heterogeneity and PK variability. To simulate high RIF dose treatments, we 
simulated each treatment group of granulomas with the same combination regimen as 
before but increased the RIF dose to 20 mg/kg. 
Increasing the RIF dose in combination therapy results in shorter average sterilization 
times as compared to the standard combination therapy (Figure 2.7). The 90% 
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sterilization times for low-CFU granulomas decrease by 25 days for average PK and 41 
days for low PK exposure. High-CFU granulomas with average PK exposure showed a 
decrease in 90% sterilization times by 33 days when treated with a high RIF dose, and 
the low PK exposure simulations increased the percent of sterilized granulomas from 
62% to 91% (the latter giving a 90% sterilization time of 179 days). Overall, the 
improvement observed is greater in the low PK exposure simulations than in average 
PK simulations.  
 Discussion 
Treatment of drug-susceptible TB requires multiple months of antibiotics, after which 
treatment may still fail due to unsterilized granulomas. A better understanding of the 
first-line combination therapy, HRZE, will help to develop rational approaches to reduce 
treatment duration and improve cure rates. To analyze the use of first-line antibiotics 
and the factors that impact granuloma sterilization and conditions of treatment failure, 
we developed a computational framework that captures both granuloma heterogeneity 
and PK variability observed in human studies to determine the rate and extent of 
sterilization during treatment with first-line TB antibiotics at the granuloma scale.  
To place the findings of our work into better context with clinical evidence that has been 
gathered on first-line TB antibiotics, we compared our simulations for single-drug 
treatments and combination treatments to early bactericidal activities (EBA) measured 
in multiple studies (Table 2.5). The EBA estimates based on the simulations are shown 
as the decrease in log10(CFU)/day for each treatment. Many of our simulated estimates 
are near the clinically measured EBA values (given as reported ranges or confidence 
intervals). For simulated EBA estimates that do not match clinical results, our 
simulations tend to predict lower EBA values than those observed clinically. Our EBA 
estimates account for the entire granuloma’s CFU count, and it is possible that we 
predict lower EBAs as our simulations detect more remaining bacteria than those that 
would be detected clinically in sputum due to limitations of detection in assays used. 
We found that typical PK variability and granuloma heterogeneity can create scenarios 
that profoundly impact sterilization rates and treatment success. The level of antibiotic 
concentration in plasma leads to commensurate concentrations within granulomas, 
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creating differences in sterilization rates. Individuals with lower plasma PK exposure are 
at higher risk of antibiotic underexposure in selected granulomas. When coupled with 
complex and caseous granuloma structure with impaired vascular supply, this can lead 
to longer sterilization times using standard HRZE TB therapy (Figure 2.7). Other models 
using various experimental data, including hollow fiber experiments, show that low drug 
exposure can lead to decreased rates in bacterial killing [41], and have used variability 
in PK to predict variability in required treatment durations [42].  The model we present 
builds on these findings by providing the ability to simulate sterilization in a granuloma, 
while accounting for human-based PK variability and granuloma structure. The benefit 
of simulating treatment in the context of the whole granuloma is that it includes the 
spatial microenvironments that can influence both antibiotic distribution and bacterial 
susceptibility or tolerance to antibiotics. Treating each Mtb as an individual agent also 
provides the ability to simulate treatment while accounting specifically for antibiotic 
resistance [24]. Our model is a tool that can provide quantitative predictions and 
sterilization times for a given regimen at a granuloma level, the possibility to predict 
entire host treatment through linking of plasma pharmacokinetics, and the potential to 
search for optimal treatment regimens [43].  
We show that treatment with any of the current first-line TB antibiotics alone is not 
sufficient to sterilize all granulomas, and that combinations of antibiotics result in more 
rapid and complete sterilization. Although RIF shows the best sterilizing ability on its 
own and is about as effective as HRZE in low-CFU granulomas, RIF alone fails to 
sterilize many of the high-CFU granulomas, where it only sterilizes 39% of granulomas 
compared to 97% with HRZE. Although our simulations predict that PZA sterilizes very 
few granulomas on its own, evidence suggests that PZA does show sterilizing ability 
when administered on its own, and suggests that our simulations underestimate its 
activity and that there is discrepancy between the in vitro activity of PZA and in vivo 
efficacy that our model does not capture [20,44,45].  
Granulomas with increased CFU and lower antibiotic exposure can dramatically 
increase sterilization time and increase the risk of granulomas that do not completely 
sterilize. Granulomas with high risk of not sterilizing tend to be larger and have more 
CFU; however, the type of bacteria present in those granulomas may affect the risk of 
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treatment failure as well. Granulomas with high CFU may still have a low risk of 
treatment failure if they have high percentages of intracellular Mtb. Because some of the 
antibiotics in HRZE are good at quickly killing this subpopulation, these granulomas that 
look like high risk granulomas pretreatment, quickly become low risk granulomas as 
treatment begins. 
RIF is the antibiotic that provides the best sterilizing ability on its own, but also is the 
antibiotic that shows the highest inter-individual PK variability [46] and is most impacted 
by PK variability. To reduce the impact the sensitivity RIF has to PK variability, we 
simulated HRZE treatment while doubling the RIF dose. Indeed, we did observe faster 
granuloma sterilization and more complete sterilization in high-CFU, low PK 
granulomas, yet some granulomas in that group still failed to sterilize. Additionally, there 
was only a slight improvement in sterilization times for granulomas that were already 
easy to treat, indicating there might only be a modest improvement in treatment for a 
subset of those granulomas. Understanding an individual’s PK profile for different drugs 
would be an important step in developing a personalized medicine approach to 
treatment. 
While our model can recapitulate key experimental observations and also predict TB 
treatment outcomes, there are several limitations to our findings. Clinical results 
measure outcomes at the host level, and GranSim fundamentally simulates treatment 
and sterilization at the granuloma scale. The relevance of our results relies on the 
assumption that treatment at the granuloma scale is indicative of treatment at a host 
scale. Our model simulates primary granulomas and does not fully capture the full 
complexity of multiple pulmonary lesions as is observed during TB disease. It is 
appreciated that non-replicating and persisting Mtb are critical targets to achieve full 
sterilization of lesions, and while we observe this in our model, their importance could 
be amplified in cavitary disease or fibrotic lesions that are not captured in our model. 
Further, directly relating in vitro antimicrobial activity to in vivo efficacy does not 
necessarily capture the full range of antimicrobial activity that occurs within granulomas 
and may partially account for any discrepancies between our simulation results and 
clinical observations. An additional limitation of our model is that it currently assumes 
there are no interactions occurring between antibiotics, and synergistic or antagonistic 
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combinations may be relevant in determining regimen efficacy [47,48]. Going forward, 
we are currently introducing synergistic and antagonistic antibiotic interactions to 
improve the PD model and further refine our estimates and predictions of granuloma 
sterilization [49–51]. The current model also does not include the development of 
antibacterial resistance, which may profoundly impact granuloma sterilization; see [24] 
for a previously published model examining development of resistance and a discussion 
of modeling resistance development. Finally, this work drew on data sets from a variety 
of human and animal studies, and predictions of treatment efficacy for other and newer 
drugs is dependent on the acquisition of similar data sets. 
The significant impact that population PK variability and granuloma heterogeneity have 
on granuloma sterilization highlights the continued need for new approaches and drugs 
for treatment, and optimization of new regimens. Close collaboration between wet lab 
and computational scientists will help facilitate the evaluation of these new approaches 
and provide a more efficient and comprehensive development of new ways to treat TB. 
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Table 2.1. Host immune parameters for in silico granulomas.  
Timestep units represent 10-minute time steps in the agent-based simulation. Parameter values based on previously 
published work [4]. 
  Low CFU Granulomas High CFU Granulomas 
Parameter definition Units Min Max Min Max 
# immune cell deaths causing 
compartment caseation 
 6 10 6 10 
Time to heal caseated 
compartment 
Timesteps 909 1365 901 1398 
TNF threshold for causing 
immune cell apoptosis 
Molecules 690 1035 690 1200 
Rate constant for TNF-induced 
apoptosis 
1/s 1.36e-6 2.04e-6 1.00e-6 2.00e-6 
Minimum chemokine 
concentration to induce 
chemotaxis 
Molecules 0.27 0.41 0.27 0.41 
Maximum chemokine 
concentration to induce 
chemotaxis 
Molecules 392 588 392 588 
Initial density of macrophages Fraction of grid 
compartments 
0.019 0.029 0.019 0.029 
Time between resting 
macrophage movements 
Timesteps 4 6 4 6 
Time between active 
macrophage movements 
Timesteps 15 23 15 23 
 
Time between infected 
macrophage movements 
Timesteps 169 255 169 255 
TNF threshold to induce NFkB 
activation 
Molecules 42.8 64.1 35.1 65.0 
Rate constant for NFkB 
activation 
1/s 6.77e-6 1.01e-5 6.00e-6 1.00e-5 
Probability resting 
macrophage kills extracellular 
Mtb 
 0.0738 0.111 0.0738 0.111 
Killing probability adjustment 
for resting macrophages with 
NFkB activation 
 0.129 0.194 0.129 0.194 
# bacteria to cause NFkB 
activation 
 236 354 236 354 
# bacteria for macrophage to 
become chronically infected 
 12 18 12 18 
# bacteria to cause 
macrophage to burst 
 19 29 19 29 
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# bacteria activated 
macrophage can phagocytose 
 3 5 3 5 
Probability activated 
macrophage will will heal a 
caseated compartment 
 0.00459 0.00687 0.00459 0.00687 
Probability a T-cell will move 
to same compartment as a 
macrophage 
 0.0367 0.0550 0.0251 0.0550 
Probability IFNγ producing T-
cell induces Fas/FasL 
apoptosis 
 0.0293 0.0439 0.0290 0.0440 
Probability IFNγ producing T-
cell also produces TNF 
 0.0514 0.0770 0.0510 0.0779 
Probability cytotoxic T-cell kills 
macrophage 
 0.00505 0.0121 0.00806 0.0121 
Probability cytotoxic T-cell kills 
a macrophage and all its 
intracellular bacteria 
 0.619 0.928 0.611 0.920 
Probability regulatory T-cell 
deactivates macrophage 
 0.00584 0.00876 0.00580 0.00880 
Time when T-cell recruitment 
begins 
Timesteps 3225 4722 3225 4397 
Time delay after T-cell 
recruitment begins until 
maximal recruitment rate 
Timesteps 650 976 650 849 
Macrophage maximal 
recruitment probability 
 0.0241 0.0361 0.0240 0.0500 
Macrophage threshold for 
recruitment by chemokines 
Molecules 0.641 0.960 0.640 0.960 
Macrophage threshold for 
recruitment by TNF 
Molecules 0.00859 0.0129 0.00851 0.0130 
Macrophage half sat for 
recruitment by TNF 
Molecules 1.22 1.82 1.21 1.83 
Macrophage half sat for 
recruitment by chemokine 
Molecules 1.68 2.52 1.68 2.52 
IFNγ producing T-cell maximal 
recruitment probability 
 0.0484 0.0726 0.0300 0.0620 
IFNγ producing T-cell 
threshold for recruitment by 
chemokine 
Molecules 0.0535 0.0802 0.0530 0.0800 
IFNγ producing T-cell 
threshold for recruitment by 
TNF 
Molecules 1.01 1.51 1.00 1.51 
IFNγ producing T-cell half sat 
for recruitment by TNF 
Molecules 1.22 1.82 1.21 1.82 
 47 
IFNγ producing T-cell half sat 
for recruitment by chemokine 
Molecules 1.64 2.46 1.63 2.45 
Probability a IFNγ producing 
T-cell is cognate 
 0.0437 0.0655 0.0201 0.0650 
Cytotoxic T-cell maximal 
recruitment probability 
 0.0370 0.0554 0.0370 0.0550 
Cytotoxic T-cell threshold for 
recruitment by chemokine 
Molecules 3.55 5.32 3.54 5.32 
Cytotoxic T-cell threshold for 
recruitment by TNF 
Molecules 0.920 1.38 0.922 1.38 
Cytotoxic T-cell half sat for 
recruitment by TNF 
Molecules 0.715 1.07 0.711 1.07 
Cytotoxic T-cell half sat for 
recruitment by chemokine 
Molecules 5.24 7.86 5.25 7.85 
Probability a cytotoxic T-cell is 
cognate 
 0.0414 0.0620 0.0410 0.0619 
Regulatory T-cell maximal 
recruitment probability 
 0.0246 0.0369 0.0242 0.0618 
Regulatory T-cell threshold for 
recruitment by chemokine 
Molecules 2.03 3.04 2.02 3.04 
Regulatory T-cell threshold for 
recruitment by TNF 
Molecules 1.65 2.47 1.65 2.47 
Regulatory T-cell half sat for 
recruitment by TNF 
Molecules 2.00 3.00 2.00 3.00 
Regulatory T-cell half sat for 
recruitment by chemokine 
Molecules 1.23 1.84 1.22 1.84 
Probability a regulatory T-cell 
is cognate 




Table 2.2 Plasma pharmacokinetic parameters  
Plasma pharmacokinetic parameters listed with the ranges used to calibrate the tissue pharmacokinetic parameters, 
as well as the parameter values for the average and low PK exposure treatment groups. 





INH Absorption rate 
constant 
1/h 0.50 6.0 3.25 0.57 Fit to data from 
[18] 
INH Intercompartmental 
clearance rate constant 
L/(h*kg) 0.20 0.70 0.45 0.67 Fit to data from 
[18] 
INH Central 
compartment volume of 
distribution 




compartment volume of 
distribution 
L/kg 25 40 32.5 37 Fit to data from 
[18] 
INH Plasma clearance 
rate constant 
L/(h*kg) 0.0080 0.070 0.039 0.061 Fit to data from 
[18] 
RIF Absorption rate 
constant 
1/h 0.40 2.5 1.5 0.41 Fit to data from 
[18] 
RIF Intercompartmental 
clearance rate constant 
L/(h*kg) 2.0 5.9 3.9 3.95 Fit to data from 
[18] 
RIF Central 
compartment volume of 
distribution 
L/kg 0.18 0.57 0.38 0.48 Fit to data from 
[18] 
RIF Peripheral 
compartment volume of 
distribution 
L/kg 0.32 0.97 0.64 0.9 Fit to data from 
[18] 
RIF Plasma clearance 
rate constant 
L/(h*kg) 0.050 0.30 0.175 0.3 Fit to data from 
[18] 
EMB Absorption rate 
constant 




clearance rate constant 
L/(h*kg) 0.45 0.70 0.57 0.56 Fit to data from 
[12] 
EMB Central 
compartment volume of 
distribution 
L/kg 0.80 1.95 1.37 1.7 Fit to data from 
[12] 
EMB Peripheral 
compartment volume of 
distribution 
L/kg 8.1 12.7 10.4 12.6 Fit to data from 
[12] 
EMB Plasma clearance 
rate constant 
L/(h*kg) 0.3 1.0 0.65 0.99 Fit to data from 
[12] 
PZA Absorption rate 
constant 




clearance rate constant 
L/(h*kg) 0.10 0.70 0.40 0.35 Fit to data from 
[18] 
PZA Central 
compartment volume of 
distribution 
L/kg 0.25 0.75 0.50 0.74 Fit to data from 
[18] 
PZA Peripheral 
compartment volume of 
distribution 
L/kg 0.010 0.050 0.030 0.050 Fit to data from 
[18] 
PZA Plasma clearance 
rate constant 






Table 2.3 Calibrated tissue PK parameters for each antibiotic. 
Parameter INH RIF EMB PZA Source 
degRateConst 
Extracellular degradation 
rate constant (1/s) 
6.94e-8 3.90e-8 1.73e-8 1.34e-8 Fit to data from [18,19] 
degRateConstInt 
Intraceullar degradation rate 
constant (1/s) 
2.84e-6 2.59e-4 8.75e-6 2.26e-3 Fit to data from [18,19] 
Diffusivity 
Effective diffusivity* (cm2/s) 
6.58e-7 5.08e-8 5.20e-7 3.24e-6 Fit to data from [18,19] 
cellUptake 
Cellular accumulation ratio 
1.13 24 5.95 0.593 Fit to data from [18,19] 
vascularPermeability 
Vascular permeability (cm/s) 
1.34e-6 2.65e-7 1.33e-7 8.62e-6 Fit to data from [18,19] 
permCoeff 
Permeability coefficient 
0.25 3.3 7.4 1 Fit to data from [18,19] 
caseumUnboudFraction 
Fraction unbound to caseum 
1 0.052 0.35 1 Fit to data from [17–
19] 




Table 2.4 Pharmacodynamic parameters  
Pharmacodynamic parameters and sources for data used for parameter fitting/estimation. Units of 1/timestep 
represent per model timestep of 10 minutes. 
Parameter INH RIF EMB PZA Sources 
Intracellular C50 (mg/L) 0.070 20 5.22 70 [21,53–55] 
Extracellular, replicating C50 
(mg/L) 
0.015 1.23 0.05 370 [21,53–55] 
Extracellular, 
Non-replicating C50 (mg/L) 
17.7 81 1000 370 [21,56] 
Intracellular Emax 
(1/timestep) 
0.0056 0.014 0.026 0.0006 [21,53–55] 
Extracellular Emax 
(1/timestep) 
0.0056 0.019 0.025 0.007 [21,53–55] 
Intracellular hill constant, h 1 0.5 2.5 3.2 [21,53–55] 




Table 2.5 Comparison of antibiotic treatment simulations to clinical early bactericidal activity (EBA) data.  
Table shows the simulation EBA, calculated as the decrease in log10(CFU) per day over the day intervals indicted. Values reported are the mean daily decrease in 
CFU over all granulomas simulated with the standard regimen doses and average PK. Standard deviation is indicated in parenthesis. The clinical EBA values 
reported are taken from a number of studies and reviews. The simulation EBA for (0-!) days is calculated as (log10(CFU day 0)- log10 (CFU day x))/x. 
 Simulation, Mean (SD) Clinical 
















Ranges from 0.37-0.77 
involving 13 studies 
summarized in [35] 
0.25 (range of 0.19-0.40) as 
summarized in [35] 
Ranges from 0.189-0.192 involving 2 







Ranges 0.174-0.631 involving 
8 studies summarized in [35] 
0.226 (SD 0.144) reported in 
[57] 
b0.11 (SD 0.096) reported in [35] from 







0.25 (95% CI: 0.06-0.45) 
pooled in [58] 







0.01 (95% CI: -0.07-0.09) 
pooled in [58] 







0.3 (95% CI: 0.09 – 0.50) 
pooled in [58] 
a0.16 (95% CI: 0.09 – 0.24) 
pooled in [58] 
0.16 (95% CI: 0.11-0.21) pooled in 
[58] 
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Chapter 3 A multi-scale pipeline linking drug transcriptomics 
with pharmacokinetics predicts in vivo interactions of 
tuberculosis drugs 
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Tuberculosis (TB) is the deadliest infectious disease worldwide. The design of new 
treatments for TB is hindered by the large number of candidate drugs, drug 
combinations, dosing choices, and complex pharmaco-kinetics/dynamics (PK/PD). Here 
we study the interplay of these factors in designing combination therapies by linking a 
machine-learning model, INDIGO-MTB, which predicts in vitro drug interactions using 
drug transcriptomics, with a multi-scale model of drug PK/PD and pathogen-immune 
interactions called GranSim. We calculate an in vivo drug interaction score (iDIS) from 
dynamics of drug diffusion, spatial distribution, and activity within lesions against various 
pathogen sub-populations. The iDIS of drug regimens evaluated against non-replicating 
bacteria significantly correlates with efficacy metrics from clinical trials. Our approach 
identifies mechanisms that can amplify synergistic or mitigate antagonistic drug 
interactions in vivo by modulating the relative distribution of drugs. Our mechanistic 
framework enables efficient evaluation of in vivo drug interactions and optimization of 
combination therapies. 
 
 Introduction  
Tuberculosis (TB), caused by inhalation of Mycobacterium tuberculosis (Mtb), remains 
the world’s deadliest infectious disease, infecting 30% of all people world-wide and 
leading to ~1.3 million deaths annually [1,2]. The emergence of multidrug resistance 
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coupled with slow progress in developing new drugs has created a pressing need to 
identify new approaches to treat TB. The current standard TB treatment regimen is a 
combination of 4 first-line anti-TB drugs – the antibiotics isoniazid (H), rifampicin (R), 
pyrazinamide (Z), and ethambutol (E). This treatment has remained unchanged over 50 
years [3–5]. Typical combination therapy for TB is administered for at least six months, 
while treating drug-resistant strains may take up to two years. New drugs, such as 
bedaquiline, linezolid, and pretomanid, are being tested in new regimens to potentially 
shorten TB treatment [6,7] The WHO has called for entirely new strategies to meet the 
goals for ‘End TB’, which aims to reduce TB deaths by 95% by 2035.   
 
The large number of potential drug combinations greatly complicates TB treatment 
design [8]. Therapy involving drug combinations can lead to surprising non-linear 
effects; some drugs can enhance each other’s action leading to higher potency 
(synergy), or drugs can interfere with their action leading to reduced potency 
(antagonism) [9,10]. These drug interactions can impact treatment efficacy and 
emergence of drug resistance [11]. Such synergistic or antagonistic drug interactions 
can be determined using checkerboard assays by screening a panel of drug 
combinations in multiple doses against Mtb [12]. However, such experimental screening 
of drug interactions has limited throughput despite recent developments in reducing the 
number of doses required for measurement [13–15]. Designing an optimal 4-drug 
combination from a set of just 50 candidate drugs at a single dose requires ~200,000 
drug interaction experiments. The dosage and dosing frequency further increase the 
space of possible regimens exponentially [16].  
 
Measuring in vivo drug interactions is even more challenging as it requires mice, 
primates, or other model organisms infected with Mtb [17]. Consequently, the number of 
drug candidates that can be screened through these model organisms is very limited. 
Further, current drug screening strategies for TB do not consider a patient’s immune 
system. Once Mtb is inhaled, it triggers a cascade of immune responses that result in 
the accumulation of an immune cell-rich mass around infected cells and bacteria known 
as a granuloma. Mtb can persist for decades within granulomas, and there are multiple 
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granulomas within lungs of infected patients [18]. Granulomas also create a physical 
barrier altering the penetration of drugs, which can greatly impact relative drug 
concentrations at the site of infection and lead to effective mono-therapies in 
granulomas [19–22]. Granulomas also produce nutrient-starved and hypoxic 
environments that contain Mtb that are phenotypically tolerant to antibiotics, further 
complicating treatment [23,24]. 
 
This study addresses these challenges by creating a multi-scale pipeline combining two 
cutting-edge computational approaches, operating at different biological scales, to 
evaluate combination therapies using drug transcriptomics and pharmacokinetics 
/pharmacodynamics (PK/PD) (Figure 3.1). First, to rapidly predict drug-drug interactions 
(synergy/antagonism) among combinations of two or more drugs, we utilize the existing 
in silico tool —inferring drug interactions using chemogenomics and orthology (INDIGO) 
optimized for Mtb (INDIGO-MTB) [8,12]. INDIGO-MTB uses a training data of known 
drug interactions along with drug transcriptomics data as inputs. INDIGO-MTB then 
utilizes a machine-learning algorithm to identify gene expression patterns that are 
predictive of specific drug-drug interactions. Once trained, INDIGO-MTB can determine 
if new drugs in combination have synergistic or antagonistic interactions using 
transcriptomics data. We previously used INDIGO-MTB to identify synergistic drug 
regimens for treating TB from over a million possible drug combinations using the 
pathogen response transcriptome elicited by individual drugs. The INDIGO-MTB model 
contains 164 drugs with anti-TB activity and it accurately predicted novel interactions of 
two-drug and three-drug combinations in vitro [8]. 
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Figure 3.1 Overview of our multiscale pipeline to predict in vivo drug interactions.  
a) INDIGO-MTB uses Mtb transcriptomic responses to drugs and experimentally measured drug-drug interactions as 
inputs for training a machine-learning model, inferring synergistic and antagonistic interactions between new drug 
combinations as output [8,25]. b) Components of the model integrating GranSim and INDIGO-MTB. From right to left, 
the plasma PK model determines the time-dependent concentration of all antibiotics following oral doses, which in 
turn determines the amount of antibiotic delivered onto the agent-based model grid. The computational grid is 
200x200 square grid spaces, representing 4mm by 4mm of lung. Within the agent-based model, the tissue PK model 
describes antibiotic diffusion and binding as well as immune cell accumulation. Based on the local concentration of 
antibiotics, the PD model evaluates an antibiotic killing rate constant based on an effective concentration that is 
calculated from each individual antibiotic concentration. The corresponding FIC predicted from INDIGO-MTB either 
increases or decreases this effective concentration, depending on whether the combination is synergistic or 
antagonistic. c) Different predictions and outcomes, with the gradient above corresponding to the relevant length 
scale for the model/prediction. From left to right, predictions made by integration of GranSim and INDIGO-MTB are 
shown, including FIC predictions from INDIGO-MTB, Mtb-specific killing rate and interactions, number of cells/Mtb 
overtime used to evaluate simulated EBA, spatial analysis of antibiotic concentration and interactions, and 
sterilization time distributions from a collection of granulomas. 
 
Next, to predict in vivo interactions and efficacy, here we integrate INDIGO-MTB 
predicted drug interactions within an existing multi-scale model of pathogen-immune 
dynamics leading to granuloma formation, known as GranSim [22,26–29]. GranSim 
integrates spatio-temporal host immunity, pathogen growth and drug PK/PD into a 
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single computational framework. GranSim uses a hybrid agent-based model to describe 
interactions between immune cells and cytokines with bacteria and antibiotic delivery to 
granulomas, and provides a dynamic picture of pathogen clearance leading to 
granuloma sterilization [22]. Previously, we modeled PK/PD in GranSim and explored 
regimens with isoniazid and rifampin, three fluoroquinolones, and more recently HRZE 
[30–32]. However, in these studies we assumed no interaction between antibiotics. 
Hence, we now integrate INDIGO-MTB predictions of drug interactions within the 
GranSim framework, allowing the full characterization of drug interaction dynamics at 
the molecular and cellular scales, and verify our results against patient-level data. This 
allows us to evaluate how drug interactions and PK/PD at the molecular scale influence 
in vivo efficacy at the granuloma scale.   
 
Our study herein represents the first pipeline that incorporates both in vitro drug 
interactions and in vivo PK/PD to simulate treatment dynamics of numerous drug 
regimens. Our study overcomes the limitation of prior studies that have focused on 
variation in PK/PD parameters alone to predict treatment outcome [33–35]. Combining 
INDIGO-MTB with GranSim allows us to compare different regimens based on the 
impact of their interactions on various simulated metrics such as rate of pathogen load 
decline in granulomas and granuloma sterilization rates. Our approach provides a 
measurement of drug interactions within lung granulomas based on concentrations that 




3.3.1 INDIGO-MTB model for predicting drug interactions 
INDIGO-MTB identifies interactions between drugs in a combination regimen by utilizing 
pathogen transcriptomics in response to individual drugs. INDIGO-MTB was built using 
drug response transcriptome data for 164 drugs, including well known drugs rifampicin, 
isoniazid, streptomycin, and several fluoroquinolones [8]. The model first generates a 
drug-gene association network using the transcriptomics data, and the machine-
learning algorithm, Random Forest. The algorithm identifies genes that are predictive of 
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drug interaction outcomes using a training data set of known interactions [25]. This 
trained network model is used to predict interactions for novel drug combinations and 
provides the Fractional Inhibitory Concentration (FIC) as an output (Figure 3.1). The 
model can identify all possible 2-way, 3-way, 4-way and 5-way synergistic, additive and 
antagonistic drug interactions after in silico screening of more than 1 million potential 
drug combinations. INDIGO-MTB predicted FIC scores to be integrated within GranSim 
were generated for all possible combinations of the first line drugs and two 
fluoroquinolones (H, R, Z, E, Levofloxacin (L) and Moxifloxacin (M)), as listed in Table 
B.1 (Appendix B). 
 
3.3.2 GranSim model of granuloma formation and function 
GranSim is a well-established agent-based model of granuloma formation and function 
[22,26–29]. It simulates the spatial heterogeneity and bacterial burden of primary TB 
lesions by simulating the immune response to infection with Mtb in a computational grid 
representing a small section of lung tissue, with formation of a granuloma as an 
emergent behavior (Figure 3.1). The simulation begins with a single infected 
macrophage at the center of the grid, and macrophages and T cells are recruited to the 
site of infection and interact with each other according to immunology-based rules that 
describe cell movement, activation, cytokine secretion, and killing of bacteria (for a full 
list of rules see referenced webpage [36]). Bacteria are tracked individually and 
modeled as individual agents in the simulation, existing in three distinct subpopulations: 
intracellular (inside macrophages), extracellular replicating and extracellular non-
replicating. The effective growth rates of extracellular bacteria are modulated by the 
number of bacteria in a given grid compartment. The growth rate becomes zero when 
the carrying capacity for that compartment is reached to reflect the relative availability of 
nutrients and physical space limitations [28]. Growth rates of extracellular Mtb are also 
slowed by the presence of caseum (dead cell debris), as a way to estimate the effect of 
lack of oxygen [37]. The parameter values describing rules and interactions are based 
on previous GranSim studies and evidence from experimental literature and datasets on 
non-human primates [22,32,38]. 
 
 63 
3.3.3 Simulation of antibiotic delivery and concentrations within granuloma 
We simulate antibiotic delivery within the GranSim computational framework as 
previously described [22,30,32]. Briefly, a plasma PK model simulates absorption into 
plasma following an oral dose, exchange with peripheral tissue, and first-order 
elimination from plasma. Flux of antibiotics into the simulation grid is based on the local 
gradient between the average drug concentration surrounding vascular sources on the 
agent-based grid and the plasma concentration. Here we use a 200x200 grid 
representing a 4 mm x 4 mm lung section. The flux is calculated over time as plasma 
concentrations change within and around each vascular source and allows for delivery 
or subtraction from the computational lung environment, depending on the direction of 
the concentration gradient. Once on the grid, antibiotics diffuse, bind to extracellular 
material (epithelial tissue and caseum), partition within macrophages and degrade 
(Figure 3.1). Based on relative binding and partitioning rates into macrophages, 
concentrations of intracellular and bound antibiotic are modeled at pseudo-steady state 
for isoniazid, rifampin, ethambutol and pyrazinamide. The drugs moxifloxacin and 
levofloxacin exhibit slower rates of binding and partitioning relative to diffusion. Hence 
the dynamic binding and partitioning of these drugs are modeled using ordinary 
differential equations [30]. We determined plasma PK parameters by calibration to 
human data as previously described [20,32,39]. We calibrated tissue PK parameters 
based on concentrations in rabbit or human lesions [20,30,32,40]. 
 
3.3.4 Calculation of antibiotic killing rate and in vivo drug interaction 
We calculate the antibiotic killing rate constant using an Emax model (Hill equation) as 
we have done previously [22]. This antibiotic killing rate constant is evaluated at each 
time step for every Mtb in the simulation based on the local grid concentrations as they 
change over time. The antibiotic killing rate constant (") is evaluated as 
 
 
 "($) = '!"#
($%%($)&
($%%($)& + ('(&




where '!"# is the maximal killing rate constant, ('( is the concentration at which half 
maximal killing is achieved, h is the Hill coefficient, and ($%% is the effective 
concentration of the antibiotic (or combination of antibiotics). To reflect each antibiotic’s 
unique levels of activity against different sub-populations of bacteria, the PD parameters 
('(, '!"# and h vary depending on the location of the bacteria  within the granuloma 
(intracellular, extracellular replicating, or extracellular non-replicating).The relationship 
between a combination of drug concentrations and pharmacodynamic effect (such as 
killing and inhibition) is described using the Loewe Additivity model [14,41]. In the 
Loewe additivity model, a simply additive interaction between two antibiotics is 





= 1 Eq. 3.2 
 
where +(#,) and +(#,+ are the inhibitory concentrations of drugs 1 and 2 that achieve x% 
inhibition on their own, and () and (+ are the concentrations that achieve the same level 
of inhibition in combination. We can convert the concentration of drug 2 to an equipotent 
concentration of drug 1, shown in Figure 3.2 and denoted (+,",-. This gives the 
concentration of drug 1 that results in the same antibiotic killing rate constant as the 
given concentration of drug 2 ((+), which we define as the adjusted concentration for 
















The corresponding inhibitory concentrations for a given x% inhibition for drugs 1 and 2 
are now both equivalent to +(#,), because both () and (+,",- are expressed in terms of 
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concentration of drug 1. Substituting (+,",- for (+ and +(#,+ for +(#,), Eq. 3.2 can be 
rewritten as 
 
 () + (+,",- =	 +(#,) Eq. 3.4 
 
If there are 3 or more drugs under consideration, we define this sum of concentrations 











We define synergy or antagonism between two or more drugs based on deviations from 
simple additivity, as assumed above. This deviation is represented using the Fractional 
Inhibitory Concentration (FIC) [42]: 
 
 





where (2 represents the observed combined drug concentration to yield a given level of 
inhibition, and ($ is the expected combined drug concentration to yield the same level of 
inhibition if the two drugs or more drugs were simply additive [14]. The FIC measures 
changes in potency, i.e. how much drug is needed to produce a certain 
pharmacodynamic effect. Based on the value of FIC, synergistic or antagonistic 
combinations result in a lower or higher effective drug concentration to achieve the 
same level of killing. To incorporate drug interactions into our model, we assume the 
effective concentration for a combination of 5 drugs is adjusted from Eq.3.5 based on 















Eq. 3.7 adjusts effective concentration so that synergistic combinations (FIC < 1) result 
in a higher effective concentration, and antagonistic combinations (FIC > 1) result in a 
lower effective concentration. Using our defined effective concentration, we substitute 
Eq. 3.7 into Eq. 3.1 to evaluate the antibiotic killing rate constant for combinations of 
antibiotics while also accounting for drug interactions. Our drug interaction model and 
effective concentration formulae accurately recreate in vitro drug interaction behavior 
observed in checkerboard assays (Figure 3.2) [14]. 
 
To evaluate the impact that each drug interaction has on the calculated killing rate 
constant (Eq. 3.1) for a given combination of antibiotics in our in vivo simulation, we 
define an in vivo Drug Interaction Score (iDIS). The iDIS is the ratio of the bacterial 
killing rate constant with a predicted FIC to the killing rate constant if FIC was equal to 
1, i.e. no or additive drug interactions. This allows us to quantify the impact that drug 
interactions have on bacterial killing for each individual Mtb at each time step during 
simulated treatment.  
 
Figure 3.2 Graphical representation of computing the adjusted concentration and killing rate constant (Eq. 
3.1 and 3.3).  
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The adjusted concentration of a drug is found by computing the equipotent concentration for another drug. The plot of 
two Hill curves for three different drugs (drug 1, orange; drug 2, blue) shows the relationship between concentrations 
of the two antibiotics and their adjusted concentration (A). The effective concentration, evaluated as the sum of the 
adjusted concentrations, determines the antibiotic killing rate constant. Antibiotic killing rate constant contours show 
the behavior of the drug interaction model for a combination of two theoretical drugs. Drug 1 has a c50 of 1 mg/L, 
Emax of 0.02 1/s, and a hill coefficient of 1. Drug 2 has a c50 of 2 mg/L, Emax of 0.01 1/s, and a hill coefficient of 1. 
When the two drugs have an FIC of 1.0 (B), 1.5 (C), or 0.6 (D), the contours show the characteristic straight line or 
curved contours characteristic of checkerboard assays for additive, antagonistic, or synergistic combinations. A sham 
combination of Drug 1 (E) results in a simply additive case. 
 
3.3.5 Antibiotic treatment simulations and calculation of regimen efficacy  
To simulate treatment with different antibiotic combinations, we first created an in silico 
granuloma library to generate a set of granulomas. Each library consists of 500 
granulomas simulations, generated from 100 parameter sets sampled with Latin 
Hypercube Sampling (LHS), and each parameter set was replicated five times [43,44]. 
Table B.2 (Appendix B) lists the parameters varied and their ranges, which have been 
established in previous work [22,32]. Parameter ranges capture natural variability in the 
immune response and lung environment, such as differences in cellular recruitment and 
immune cell activation. In addition, replicating simulations with the same parameter set 
incorporates variability due to stochasticity in the simulations. Granulomas are 
simulated for 300 days in the absence of antibiotics. At day 300, a random sample of 
100 unsterilized granulomas is selected from the relevant library for treatment. The 
prescribed regimens are simulated for 180 days or until the granuloma is sterilized. See 
Table B.1 (Appendix B) for the full list of regimens tested.  
 
We evaluate three metrics from our simulations to assess the efficacy of each regimen 
tested: log decrease in CFU per day, percent of simulated granulomas that are sterilized 
after eight weeks of treatment (sterilization percent), and average time at which those 
granulomas become sterile (sterilization time). For each regimen, 100 granulomas are 
simulated and results from those simulations are used to calculate 3 outcomes 
measures: simulated log decrease in CFU per day, sterilization percent, and sterilization 
time.  
 
3.3.6 Comparison to clinical trials 
To validate our model results, we compared our treatment simulation outcomes to 
Phase IIb clinical trial data [45]. We compared the clinical datasets outcomes for each 
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regimen with our simulated granuloma sterilizations after 8 weeks of treatment. We 
used the percent of granulomas that are completely sterilized at 8 weeks as a lower 
bound estimate. Our upper bound estimate is the percentage of granulomas with fewer 
than 10 CFU after 8 weeks. We chose this value as these granulomas with low bacterial 
load would not be detectable in sputum. Additionally, we compared the rank of clinically 
tested regimens, ranked by sputum conversion, to the rank of regimens based on 
simulation results. Simulated regimen rankings were ranked by average sterilization 
time, FIC, and average iDIS for non-replicating Mtb. Further, we compared our 
predicted treatment sterilization times for fluoroquinolone-containing regimens with 
clinical endpoints (up to 6 months) from recent phase III clinical trials that include 
fluoroquinolones for treating drug-susceptible TB [46–48]. 
 
3.3.7 Plasma PK sensitivity analysis on interaction strength 
We performed a sensitivity analysis to evaluate how PK parameters impact the 
predicted iDIS for regimens with different levels of synergy. For four regimens (HRZE, 
RE, HE, RM), we selected a single granuloma to simulate treatment for one day to 
measure an iDIS. For each regimen, we simulated the granuloma 500 times with 
different plasma PK parameters sampled using LHS. For each plasma PK parameter 
set, we calculated the average iDIS over the first day of dosing over all non-replicating 
Mtb. Finally, we evaluated the partial ranked correlation coefficient (PRCC) between 
each plasma PK parameter and the predicted iDIS to determine the impact each 
parameter has on the drug interactions [44,49].  
 
 Results 
3.4.1 Drug interactions significantly impact in vivo treatment dynamics in GranSim 
We focus on combinations of 2, 3 or 4 drugs involving the first-line antibiotics and two 
fluoroquinolones (Table B.1, Appendix B). These drugs include isoniazid (H), rifampin 
(R), ethambutol (E), pyrazinamide (Z), moxifloxacin (M), and levofloxacin (L). We chose 
these drugs as they are part of the current standard-of-care for treating TB. Further, 
transcriptomics and PK/PD parameters are available for these drugs for simulation 
using both INDIGO-MTB and GranSim. 
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Using INDIGO-MTB, we first predicted all possible in vitro interaction outcomes for 
these combinations. The combinations are predicted to have FIC values that range from 
synergistic (e.g. HRZ – FIC of 0.74) to antagonistic (e.g. RM – FIC of 2.31). The 
standard regimen (HRZE) is predicted to be synergistic (FIC – 0.82) while moxifloxacin-
containing regimens were mostly antagonistic (Table B.2, Appendix B).  
 
Given the various factors that can impact antibiotic efficacy in vivo that are captured in 
GranSim, the relative impact of drug interactions on treatment outcomes is unclear. We 
hypothesized that analysis of various drug regimens with different drug interaction 
scores (FIC) can help tease out the impact on treatment outcome. Our previous studies 
of antibiotic treatment using GranSim did not consider drug interactions. Here we 
explore how either antagonistic or synergistic affects overall efficacy. We tested the 
impact of incorporating drug interactions on treatment dynamics using GranSim.  
 
We input FIC values into GranSim and simulated the immune response and antibiotic 
delivery to granulomas (Methods). The plasma and tissue PK parameters for these 
drugs within the GranSim computational framework were derived from previous studies 
calibrating PK parameters to experimental plasma and lesion drug concentrations 
(Methods). For each regimen tested, 100 simulated granulomas were treated for up to 
180 days with daily doses of each antibiotic in the specified regimen. To compare the 
efficacy of each of these regimens, we evaluate three measures: the log decrease in 
CFU per day, percent sterilization of granulomas, and average sterilization time. 
 
The in vitro FIC value of each combination is correlated with each of the three simulated 
efficacy outcomes that we calculated (Figure 3.3). For our simulated log decrease in 
CFU per day from 0-14 days and the sterilization percent, we observe that both 
outcomes tend to decrease as FIC values go from synergistic to antagonistic 
(correlation R = -0.52 and -0.59 respectively, Figure 3.3). The average sterilization time 
is positively correlated with FIC value (correlation R = 0.59, Figure 3.3). Overall, this 
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indicates that synergistic regimens are more likely to sterilize a greater percentage of 
granulomas in a shorter time at both early and later time points.  
 
Although these relationships show moderate levels of correlation, there are a few 
notable deviations. Interestingly, the regimen RM (FIC = 2.31) performs better than the 
less antagonistic regimen HE (FIC = 1.46). The best regimen in terms of average 
sterilization time is HRZE (FIC = 0.82); however, the regimen RE (FIC = 0.74) has a 
lower FIC but does not perform as well as HRZE. These results suggest that FIC values 
are not the only factor impacting granuloma sterilization. Because these results are 
based on sterilization in granulomas, the concentrations of each antibiotic in the 
granuloma compartment (based on dosage and PK) also impact the ability of each 
regimen to sterilize. 
 
Figure 3.3 Regimen efficacy is correlated with FIC for 64 simulated drug regimens.  
Mean decrease in log CFU (0-14 days) averaged over 100 granulomas simulated for each drug regimen (A) and 
percentage of sterilized (negative) granulomas after eight weeks of treatment (B) are negatively correlated with FIC 
values, with correlation coefficients of -0.52 and -0.59, respectively. Mean sterilization time for each regimen over 100 
granulomas (C) is positively correlated with FIC with a correlation coefficient of 0.59. Each point represents the 
regimen outcome measurement for a given regimen and error bars indicate +/- standard deviation from the sample of 
100 granulomas simulated. The 64 drug regimens simulated are listed in Table B.1 (Appendix B). The colored points 
correspond to the regimens HRZE (light blue), RE (dark blue), RM (red) and HE (orange) for emphasis. 
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3.4.2 The in vivo drug interaction score is predictive of treatment dynamics 
The antibiotic killing rate is dependent not only on the FIC value, but also on local drug 
concentrations within a granuloma, the subpopulation of bacteria (intracellular, 
extracellular replicating, extracellular non-replicating), and the specific PD parameters of 
antibiotics involved. Based on the definition of the FIC, synergistic or antagonistic drug 
combinations result in a lower or higher effective concentration to achieve the same 
level of bacterial killing. To evaluate the overall impact of drug interactions on the 
calculated killing rate constant, we evaluate an in vivo Drug Interaction Score (iDIS) for 
the three subpopulations of bacteria. The iDIS measures the relative increase or 
decrease of the antibiotic killing rate constant due to the specific drug interaction. We 
calculate iDIS as the ratio of the antibiotic killing rate constant evaluated in the 
simulation to the rate constant if the interaction is simply additive (FIC equal to 1.0). 
This ratio provides a measure of how much the drug interaction impacts the killing rate 
constant and is unique for each individual mycobacterium within GranSim as drug 
concentrations change over time. At each time step during treatment, the average iDIS 
over all Mtb by subpopulation is evaluated as a model output.  
 
Figure 3.4 shows the average iDIS for non-replicating Mtb over the first dose interval for 
each regimen, and its relationship to regimen outcomes. A value of 1 indicates the 
interaction has no impact on the killing rate constant; values greater than 1 or less than 
1 indicate synergistic or antagonistic combinations, respectively. 
 
The iDIS for each regimen is strongly correlated with the outcomes from our GranSim 
simulations: log decrease in CFU per day (R = 0.86), percentage of negative 
granulomas at eight weeks (R = 0.73), and the average sterilization time (R = -0.73) 
(Figure 3.4). The correlations are much stronger than those observed for FIC (Figure 
3.3), indicating that measuring the iDIS, which is calculated for specific granuloma 
environments, provides more information on regimen efficacy than examining FIC 
values, which are calculated based on in vitro environments.  
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Figure 3.4 Regimen efficacy is correlated with the in vivo Drug Interaction Score (iDIS). 
iDIS associated with non-replicating Mtb killing is evaluated for 3 measures over 64 simulated drug combination 
regimens. The decrease in log CFU (0-14) averaged over 100 granulomas simulated for each regimen (A) and 
percentage of sterilized (negative) granulomas after eight weeks of treatment (B) are positively correlated with iDIS of 
non-replicating Mtb during the first 24 hours of treatment (correlation coefficients of 0.86 and 0.73, respectively). 
Mean sterilization time for each regimen over 100 granulomas (C) is negatively correlated with iDIS of non-replicating 
Mtb (correlation coefficient of -0.73). Each point represents the regimen outcome measurement for a given regimen 
and error bars indicate +/- standard deviation from the sample of 100 granulomas simulated. The 64 drug regimens 
simulated are listed in Table B.1 (Appendix B). The colored points correspond to the regimens HRZE (light blue), RE 
(dark blue), RM (red) and HE (orange) for emphasis. 
 
Each combination of antibiotics has a different absolute killing rate constant based on 
the specific combination of PD parameters associated with that combination together 
with the distribution of antibiotics within a granuloma. These results suggest that iDIS 
provides a more accurate representation of how well a given combination of antibiotics 
achieves sterilization as it accounts for the unique killing rate constant that each 
individual Mtb experiences and measures the impact that an FIC value has on that 
killing rate constant. 
 
Antibiotics work stronger on replicating Mtb than against non-replicating Mtb. Antibiotic 
killing rate constants that are higher and closer to their overall Emax value are less 
impacted by drug interactions. We found that correlations between regimen outcomes 
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and the average iDIS associated with replicating extracellular and intracellular Mtb are 
weaker than when comparing regimen outcomes to the iDIS from non-replicating Mtb 
(Figures B.1 and B.2, Appendix B). The average iDIS measurements for replicating Mtb 
are closer to 1.0 and weaken the correlation with regimen outcomes. Hence, the strong 
correlation between drug interactions and clinical outcomes are primarily driven by drug 
action against non-replicating bacteria. 
 
Figure 3.5 shows a heat map of the mean sterilization time, iDIS and FIC for each 
regimen, ordered by decreasing iDIS. In general, the regimens with the fastest 
sterilization times also have high iDIS. The top 17 regimens, as measured by shortest 
average sterilization time, all contain RIF, indicating that RIF is a very important addition 
to regimens. Another general trend is that two-drug combinations typically perform 
worse than 3- or 4-drug combinations. Fluoroquinolones tend to participate in more 
antagonistic combinations, as measured by the iDIS. For example, 22 of the 31 MXF or 
LVX containing regimens are above the median iDIS of all 64 regimens. Two regimens 
(R23.5E45dpw2 and R23.5E90dpw1) with synergistic iDIS measurements showed slow 
sterilization times, as they were dosed less frequently than a day. 
 
Figure 3.5 Heat map capturing three metrics for 64 different regimens. 
The list of regimens is ordered by decreasing predicted iDIS (middle row). For each regimen, the log2(FIC) value 
(bottom row) and the average predicted granuloma sterilization time (top row) are also represented. For predicted 
iDIS and FIC, blue represents synergy, white represents additivity, and red represents antagonism. For sterilization 
time, blue represents shorter sterilization times and red represents longer. 
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3.4.3 INDIGO-MTB - GranSim regimen rankings are correlated with clinical rankings 
To explore how our predictions of regimen efficacy compare to clinical results, we 
compare our INDIGO-MTB - GranSim treatment simulations to results from TB drug 
clinical trials. Drawing from the meta-analysis of phase II trials presented in Bonnet et al 
(2017), we selected all regimens that reported sputum culture conversion in solid media 
[45]. The efficacy metric presented for Phase IIb trials is the percent of patients with 
negative sputum culture after 8 weeks of therapy. Since our simulations predict 
treatment outcomes at the granuloma scale, we estimated how sterilization at the 
granuloma level relates to host-level culture conversion. Figure B.3 (Appendix B) shows 
the comparison of the upper and lower bound estimates for percent sputum conversion 
from our simulation to clinical trial results for 26 regimens (Methods). For most 
regimens, estimates of sterilization percentage compare closely to clinically measured 
culture conversion. In general, INDIGO-MTB - GranSim simulations appear to 
overpredict the rates of sterilization and most incorrect predictions fall into this category 
(Figure B.3, Appendix B). This observed overprediction is likely due to the simplification 
of predicting sterilization at the granuloma scale that does not include the full spectrum 
of complex granuloma lesions, failed adherence to regimens, and other factors that 
complicate TB treatment.  
 
We next validate our simulation results by comparing the ranking of the efficacy of each 
of the regimens with the corresponding ranking of the efficacy from clinical trials (Figure 
3.6). The clinical rank is determined by ranking each regimen by the pooled culture 
conversion after 8 weeks, so that a ranking of 1 is the regimen with the lowest culture 
conversion. The simulation rank is determined by percentage of granulomas sterilized 
after 8 weeks. We used the Spearman ranked correlation coefficient, weighted by the 
number of patients in each pooled regimen result, and found a significantly strong 
correlation between simulations and clinical trials (R = 0.72).  
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Figure 3.6 INDIGO-MTB-GranSim compared with clinical data.  
Comparison and validation of treatment simulations with clinical trial results for 26 different regimens compiled in 
Bonnet et al. (2017) [45]. Predictions from GranSim simulations for 26 drug regimens correlate with clinical outcomes. 
The simulation rank, ranked by percentage of sterilized granulomas after 8 weeks, and clinical rank, ranked by 
clinically reported culture conversion, have a weighted correlation of 0.72, weighted by the number of patients treated 
with each regimen. 
 
Recent phase III clinical trials have investigated the impact of introducing 
fluoroquinolones into treatment regimens to treat drug-susceptible TB, some with the 
additional intent of shortening treatment time from six months to four. Many of these 
trials have failed to show improvement in TB treatment, and often led to higher rates of 
unfavorable outcomes at the trial’s endpoints [46–48]. These trends are reflected in our 
analysis of the drug interactions for various drug combinations. The control regimen, 
HRZE, is strongly synergistic as measured by iDIS, and we predict short average 
sterilization times (14 days, Figure 3.4). In contrast, fluoroquinolone containing 
regimens, such as HRMZ and RMZE, are closer to additive, and are predicted to have 
longer sterilization times of 41 and 21 days respectively. These trends indicate that our 
simulation predictions are consistent with phase III clinical trial observations. Thus 
INDIGO-MTB - GranSim simulations provide strong predictive measures of clinical 
outcome for different regimens. 
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Both iDIS and INDIGO-MTB FIC predictions for these regimens are also significantly 
correlated with their clinical ranking (Figure B.3, Appendix B). These simulated results 
are consistent with the correlation observed in a prior study between INDIGO-MTB FIC 
scores and percentage of patients with negative culture after treatment from 57 
randomized clinical trials [8]. Based on these results, both interaction measurements 
have the potential to help predict the clinical efficacy of drug combination regimens.  
 
The FIC value is one measure of drug interactions in vitro; however, there are many 
factors that impact regimen efficacy in vivo that FIC alone does not capture. Measuring 
the iDIS can incorporate changes in concentration due to PK variability, changes to 
dosing regimens, and heterogeneous antibiotic concentrations due to granuloma 
structure and the varying environments where bacteria reside impact the degree to 
which the drug interactions impact killing rates. It also includes effects of the immune 
responses occurring with granulomas. 
 
3.4.4 Spatial variation in drug concentration influences iDIS in granulomas 
Nonuniform drug distributions within granulomas arise due to barriers to diffusion that 
the cellular structure of granulomas creates [20–22,30]. The spatial variation in antibiotic 
concentrations within a granuloma leads to variations in local effective concentrations, 
and ultimately antibiotic killing rates and iDIS. The free drug concentrations available to 
induce bactericidal activity against Mtb are also influenced by binding to extracellular 
matrix as well as partitioning into macrophages [40]. Hence, we next focused on the 
contribution of the drug spatial variation to iDIS. 
 
Figure 3.7 shows the spatial variation for effective drug concentrations normalized to the 
regimen’s non-replicating Mtb ('( parameter and iDIS for four of the regimens 
simulated: HRZE, RE, HE and RM. These regimens demonstrate a mix of synergistic 
and antagonistic combinations that also exhibit both strong and weak iDIS values. For 
the two synergistic combinations, HRZE and RE, effective concentrations are lower 
within a granuloma than just outside it, lowering the killing rate constants. Because most 
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non-replicating Mtb are found within the hypoxic caseum which is typically located 
toward the center of the granuloma, the effective concentrations in those caseated 
regions and inside the granuloma are the concentrations that are relevant to predicting 
sterilization rates. However, lower effective concentrations inside granulomas and 
caseated regions can also result in higher iDIS (Figure 3.7). Because iDIS tends to be 
higher within granulomas where Mtb reside, this may contribute to synergistic 
combinations performing better than antagonistic combinations of similar effective 
concentrations. 
 
Figure 3.7 Contribution of individual antibiotics to the in vivo drug interaction score (iDIS).  
Values of iDIS are associated with proportion of each antibiotic's contribution to the effective concentration. Four 
different regimens are shown: HRZE (first row), RE (second row), HE (third row), and RM (fourth row). Heat maps 
show the effective concentration normalized to the C50 for non-replicating Mtb of the combination (first column) and 
the fraction of each antibiotic’s contribution to the effective concentration (second and third columns). The calculated 
iDIS value for non-replicating Mtb is shown in the fourth column, with the color bar representing the iDIS value with 
blue representing a synergy, white representing additivity, and red representing antagonism. All heat maps reflect 
conditions 6 hours after dosage with each antibiotic in the relevant regimen.  
 
An additional aspect that influences the iDIS is the relative contribution of each antibiotic 
in the combinations (Figure 3.7, columns 2 and 3). Antibiotic combinations that 
contribute more equally to the effective concentration deviate more from additivity than 
combinations of antibiotic concentrations in which contributions are uneven (i.e. when 
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one antibiotic has a much higher adjusted concentration than the other antibiotics). 
Although RE has a more synergistic FIC than HRZE, the iDIS against non-replicating 
Mtb for HRZE is higher than RE, and HRZE has better efficacy than RE. This is partially 
due to R and Z contributing to the effective concentration in the granuloma evenly (R 
~50% contribution, Z ~40% contribution). The contributions from R and E in RE, 
however, are more disproportionate, with >90% of the effective concentration due to R 
and <10% of the effective concentration from E.  
 
A similar situation occurs with the two antagonistic combinations HE and RM. Although 
RM is predicted to be strongly antagonistic, its efficacy is still average compared across 
all regimens tested. HE, on the other hand, has a less antagonistic FIC, but performs 
more poorly than RM. When looking at both antibiotic contributions for these two 
regimens and the iDIS against non-replicating Mtb, we see that H accounts for ~75% of 
the effective concentration and E accounts for ~25%. Although not equal contributions, 
this still allows for an antagonistic interaction to occur. With the RM combination, R 
accounts for almost all of the contribution to the effective concentration because its 
levels are higher relative to its own ('(, resulting in almost no antagonistic interaction to 
occur with M, despite the high FIC. For antagonistic combinations, uneven contributions 
from the different antibiotics in the combination can mitigate the effect of the 
antagonistic interaction. 
 
Due to this dependence on drug concentrations, the predicted iDIS varies for different 
doses and regimens of the same drug combination (Figure B.4, Appendix B). In 
contrast, the FIC interaction score is fixed for a combination irrespective of the dosage. 
As doses vary in vivo, the strength of the synergistic or antagonistic interactions can 
either increase or decrease, depending on the specific combination of antibiotics. One 
common trend is less frequent dosing tends to decrease the interaction strength, which 
we observe for both the HRZE and RE combinations. 
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3.4.5 Plasma clearance rates correlate with in vivo drug interaction score 
Even for a given simulated granuloma and drug regimen, antibiotic concentrations can 
vary due to host-to-host PK variability [32]. This can also result in changes in iDIS. We 
picked four different regimens, ranging from synergistic to antagonistic (HRZE, RE, HE, 
RM) to exhaustively explore the impact of various PK parameters. The plasma 
clearance rate constant for many of the antibiotics in these regimens is significantly 
correlated with predicted iDIS, particularly the clearance rate constants for R, E and M 
(Table 3.1). A more detailed analysis of correlations between plasma PK parameters 
and iDIS is shown in Table B.3 (Appendix B). The R clearance rate constant is strongly 
correlated with iDIS, with coefficients between 0.8 and 0.9, depending on the regimen. 
The correlation coefficients for the clearance rate constant for R are positive for 
synergistic combinations (HRZE, RE), and negative for antagonistic combinations (RM). 
Because iDIS values that deviate further from 1 imply a stronger interaction, this means 
that faster clearance rates for R tend to increase the interaction strength. The opposite 
is true for the clearance rate constant of E. The correlation coefficient between the 
clearance rate constant for E and predicted iDIS is negative in synergistic combinations 
(HRZE, RE), and positive in the antagonistic combination (HE). While this may seem 
counterintuitive, it supports the idea that the iDIS value is dependent on relative in vivo 
drug concentrations. Faster clearance rates generally result in lower concentrations in 
plasma, and consequently lower concentrations in the granuloma. Because R tends to 
contribute more to effective concentrations than other antibiotics, increasing the 
clearance rates for R will strengthen the interaction by decreasing R concentration and 
allow for more even contributions. For E, whose contribution to effective concentration 
tends to be lower, increasing clearance rates result in lower E concentrations and 
contributions, and scenarios of even more lopsided contributions and less interaction. 
Relative drug concentrations inside the granuloma affect the strength of drug 
interactions, and these strong correlations indicate that interactions may be stronger or 
weaker for certain combinations depending on an individual’s PK [32]. 
 
Table 3.1 Significant antibiotic clearance rate constants in determining iDIS 
The relationship between clearance rate constants for different antibiotics is correlated with iDIS with non-replicating 
Mtb during the first dose of therapy. Table shows PRCC values relating the clearance rate constants to the predicted 





PRCC Values for predicted iDIS 
R clearance E clearance M clearance 
HRZE 0.89 -0.56  N/A 
RE 0.90 -0.92  N/A 
HE  N/A 0.88 N/A  
RM -0.83 N/A  0.99 
 
 Discussion 
The need for multiple drug regimens to treat TB raises a number of issues that can be 
capitalized on to advance treatment for the world’s worst killer by disease. In particular, 
understanding the role of interactions occurring in either a synergistic or antagonistic 
fashion between anti-TB antibiotics in vivo may provide a more rational approach to 
choosing novel combinations that have greater clinical efficacy. However, measuring 
drug interactions in vivo is challenging due to the limited throughput, cost, and time 
involved in testing drugs in model organisms. In this study, we introduce a 
computational pipeline that can simulate in vivo interactions by using datasets derived 
from individual drug-response transcriptomes and PK/PD, thereby greatly reducing cost 
and time. Our approach integrates interaction scores of combinations of antibiotics into 
a computational model that simulates drug delivery into the lung, spatial concentrations 
of drugs and pharmacodynamic effects within TB granulomas.   
 
To evaluate drug regimens, we introduce a new metric called the in vivo drug interaction 
score (iDIS) that is dynamic and unique for each mycobacterium based on its location 
and metabolic state (i.e. replicating/non-replicating) within a granuloma. Unlike the in 
vitro drug interaction scores derived from checkerboard assays and INDIGO-MTB, 
which are fixed for given drug combinations, the in vivo score can provide a more 
nuanced impact of drug interactions on pathogen clearance. This allowed us to 
compare various drug regimens and rank them based on their in vivo interactions. We 
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found that our ranking of regimens is highly concordant with clinically observed efficacy 
of various drug combinations [45].  
 
When simulating all regimens considered in this study, the FIC alone does correlate 
with the simulated and predicted outcomes from our model. However, there are a 
handful of regimens that do not fit the trend. Measuring the iDIS, which evaluates the 
relative increase or decrease in killing rate due to the interaction within the complex 
granuloma environment, provides a complementary measure of regimen outcome. This 
is because the effect that drug interactions have on killing rate constants is dependent 
on the balance of contributions from each single antibiotic. Combinations with highly 
synergistic or antagonistic FIC values may be closer to additive if only one antibiotic is 
present in sufficient quantities within a granuloma. 
 
Our analysis of various drug regimens revealed ways of amplifying synergy as well 
mechanisms to mitigate antagonism in vivo. We found that some combinations with in 
vitro antagonism perform well clinically due to the distinct spatial distribution of the 
underlying drugs. Antagonistic interactions can be mitigated if the drugs have uneven 
distributions and effective concentrations or through less frequent dosing. Overall, we 
find that combinations with strong in vitro synergy remain synergistic or additive in vivo. 
Hence screening for synergy in vitro can be a useful strategy for identifying regimens 
with strong in vivo activity. In a minority of cases, this synergy may not be achieved in 
vivo; nevertheless, synergistic combinations generally outperform antagonistic 
regimens.   
 
As part of this study, we wanted to determine which combinations of antibiotics are 
predicted to have strong synergy and antagonism, as well as which combinations are 
predicted to have high efficacy. We screened 64 combinations and regimens of front-
line regimens (HRZE) along with M and L. The clinically used HRZE regimen does 
outperform other screened combinations, which highlights the need for new drugs to 
achieve the aim of improving TB treatment. Based on the INDIGO-MTB model, we 
previously identified drug combinations involving new TB drugs such as bedaquiline that 
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have better synergy than HRZE. Given the concordance between INDIGO-MTB FIC 
and various clinical metrics observed in this study, the synergistic combinations 
identified by INDIGO-MTB may be promising leads for further optimization using 
GranSim for reducing treatment time [16]. 
 
A limitation to our computational model is that the same FIC value is applied to all Mtb 
within a simulation, regardless of its environment or metabolic state. It is likely that the 
strength of a given interaction, or even whether it is synergistic or antagonistic, is 
dependent on the bacterium’s microenvironment in the granuloma [50,51]. Additionally, 
these simulations represent treatment of primary granulomas in TB disease, and do not 
necessarily reflect the true and enormous complexity of granuloma lesions that occur 
during TB disease. Further, as the simulations are at the granuloma scale, relating the 
outcomes measured by the simulation to clinical outcomes is difficult. The final limitation 
is that we only considered combinations of six different antibiotics. There are many 
other antibiotics in use or in development for use to treat TB. Expanding our ability to 
accurately simulate the PK/PD of additional antibiotics will greatly increase our ability to 
answer how important drug interactions are in determining regimen efficacy.  
 
In sum, our study addresses an important gap in current methods for identifying 
promising drug combinations for TB treatment by presenting a new pipeline for 
evaluating interactions between drugs in vivo. This pipeline provides an additional 
metric with which to evaluate novel combinations of antibiotics, explain mechanisms of 
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 Abstract 
Introduction: Tuberculosis (TB), one of the most common infectious diseases, requires 
treatment with multiple antibiotics taken over at least 6 months. This long treatment 
often results in poor patient-adherence, which can lead to the emergence of multi-drug 
resistant TB. New antibiotic treatment strategies are sorely needed. New antibiotics are 
being developed or repurposed to treat TB, but as there are numerous potential 
antibiotics, dosing sizes and potential schedules, the regimen design space for new 
treatments is too large to search exhaustively. Here we propose a method that 
combines an agent-based multi-scale model capturing TB granuloma formation with 
algorithms for mathematical optimization to identify optimal TB treatment regimens.  
Methods: We define two different single-antibiotic treatments to compare the efficiency 
and accuracy in predicting optimal treatment regimens of two optimization algorithms: 
genetic algorithms (GA) and surrogate-assisted optimization through radial basis 
function (RBF) networks. We also illustrate the use of RBF networks to optimize double-
antibiotic treatments. 
Results: We found that while GAs can locate optimal treatment regimens more 
accurately, RBF networks provide a more practical strategy to TB treatment optimization 
with fewer simulations, and successfully estimated optimal double-antibiotic treatment 
regimens.  
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Conclusions: Our results indicate surrogate-assisted optimization can locate optimal TB 
treatment regimens from a larger set of antibiotics, doses and schedules, and could be 
applied to solve optimization problems in other areas of research using systems biology 
approaches. Our findings have important implications for the treatment of diseases like 
TB that have lengthy protocols or for any disease that requires multiple drugs. 
 
 Introduction 
Tuberculosis (TB) is a disease caused by infection with Mycobacterium tuberculosis, 
and an estimated one fourth of the world’s population has a latent M. tuberculosis 
infection [1]. In 2015, TB was responsible for 1.4 million deaths [2]. The typical 
treatment of drug-susceptible TB is a lengthy antibiotic regimen of at least six months 
beginning with four antibiotics for two months, namely isoniazid (INH), rifampin (RIF), 
ethambutol, and pyrazinamide. This regimen is followed by a continuation phase of two 
antibiotics (INH and RIF) for an additional four months [3]. Although largely considered 
a successful treatment for drug-susceptible TB, poor patient-adherence and the 
emergence of multi-drug-resistant TB indicate a need for better antibiotic treatments 
[3,4]. Programs such as DOT (directly observed treatment) have been put into place to 
track drug compliance, but this is costly and untenable for many TB patients world-wide 
[5,6]. Additional antibiotics are currently being developed or repurposed to treat TB 
[7,8]. Comparing treatments can involve large meta-analysis studies, and head-to-head 
comparisons of alternative protocols are often lacking [9,10]. Overall, the regimen 
design space for new antibiotic treatments, including combination treatments, is 
enormous and impossible to thoroughly examine in either an animal model or clinical 
setting (Figure 4.1). Identifying better antibiotic treatments (e.g. shorter, less toxic, 
cheaper, and/or more efficacious treatments) presents a challenging optimization 
problem of finding the best combination and regimen of antibiotics. 
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Figure 4.1 Estimating the size of the TB antibiotic regimen design space (RDS).  
The number of potential antibiotic treatment regimens can be estimated by assuming values for the following 
variables: the number of treatment segments (M), such as an initial, intensive and continuation phase; number of 
antibiotics available for use (c); maximum number of antibiotics in each treatment segment (n); and available dose 
levels (D).  Frequency (F) refers to the different possible dosing frequencies to be tested, e.g. once weekly, daily, etc.   
 
There has been some effort to optimize TB treatment and clinical pharmacology of TB 
regimens [11–13]. In this work, we seek to formalize locating better antibiotic treatment 
regimens as an optimization problem. The goal of our treatment optimization problem is 
to identify the region of the regimen design space (combinations of antibiotics and 
treatment variable ranges) that contain optimal treatment protocols, rather than identify 
a single, optimal treatment with high precision. Optimal treatment variables (such as 
dose size or dosing frequency) identified with high precision would not necessarily 
translate to a clinical treatment, because clinical doses and dosing frequencies must be 
realistic to implement (e.g. using available dosages).  
Systems biology has been used to study a wide array of topics [14] including systems 
pharmacology [15–17], vascular and muscle growth [18], or cancer development and 
therapy [19–21]. Computational modeling and systems biology approaches can help 
integrate large sets of data and provide additional biological insights, e.g. by using 
models to predict optimal conditions or to control model behavior [22–24]. As models 
that describe biological phenomena grow more complicated, there is a need for the 
proper tools to obtain the most out of these models.  
c
n
(D × F) n
M
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In this work, we ask whether computational modeling of M. tuberculosis infection and 
antibiotic treatment can be used as an efficient strategy to identify better antibiotic 
treatment regimens. We have developed a hybrid, multi-scale model of granuloma 
formation to predict antibiotic efficacy [25,26]. Granulomas, regions of infected and 
inflamed lung tissue, form in response to M. tuberculosis lung infection. We simulate the 
dynamics of granuloma formation and function in the framework of a hybrid, multi-scale 
agent-based model [27–29]. These dynamics are crucial to understanding TB antibiotic 
efficacy, as the structure of granulomas influences antibiotic exposure to bacterial 
populations [26,30,31]. Although our model can assist in screening new antibiotic 
treatments, the computational complexity and number of granuloma simulations 
required to test all potential treatment regimens (Figure 4.1) prevents us from testing 
every possibility in the regimen design space. However, combining our granuloma 
model with optimization algorithms could provide a viable way to narrow the design 
space and guide animal and clinical trials.  
A diverse set of optimization algorithms are applied in science, math and engineering 
[32,33]. Population-based algorithms, including the genetic algorithm (GA), can be used 
to solve optimization problems with objective functions that are functions of a 
computational model or simulation output [34]. GAs have been used to solve 
optimization problems in fields as varied as robotics, engineering design and pattern 
recognition, and cancer vaccination schedules in mice [32,35–38]. The GA utilizes ideas 
from natural selection to partially search a variable design space, and its framework 
allows for different ways to represent solutions as chromosomes, define objective 
functions, select parents and generate offspring [32]. The algorithm begins by 
generating a population of solutions and evaluating their objective function values. The 
best individuals from the population are selected to be parents, and a new population of 
solutions is generated through crossover operations between the parents and random 
mutations. New generations of solutions are generated until the algorithm converges on 
an optimum. 
Optimization problems can also be solved through surrogate-assisted optimization, 
which generates a model to predict the value of an objective function throughout the 
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design space based on known objective function values. The surrogate model is then 
used to search for the optimal solution, which can be useful in situations where 
evaluating the objective function through experiments or running computational models 
is expensive or inefficient [39,40]. The surrogate model can be built through 
mathematical approximation or interpolation strategies, such as radial basis function 
(RBF) networks [41,42]. With this method, RBFs are used as interpolants between 
sample data points, so that a prediction of an unknown objective function can be 
expressed as a sum of all of the basis functions in the network. These RBF networks 
can be applied to efficiently predict the function response throughout the entire variable 
design space [41–43]. 
Here, we compare the application of GAs and RBF network surrogate models to 
optimize antibiotic treatment of TB. We rely on our published computational granuloma 
model to simulate the infection and immune response and a linked 
pharmacokinetic/pharmacodynamics (PK/PD) model to simulate drug treatment [25,26]. 
We first examine treatment with a single antibiotic to determine whether GAs or RBF 
network methods are better suited for treatment optimization. We then test the method 
of choice on the more complicated antibiotic optimization problem of two antibiotics 
administered simultaneously. Finally, we discuss barriers and approaches for solving 
higher dimensional problems (e.g. greater than two antibiotics) with these methods. 
 Model and Methods 
4.3.1 Computational Granuloma Model 
When M. tuberculosis infects lung tissue, an immune response occurs that leads to the 
formation of multiple granulomas, pockets of infected and inflamed tissue that are 
composed of various immune cells, dead cell debris and bacteria. These granulomas 
help prevent bacteria from spreading both by immunologically restraining and physically 
containing bacteria, but also present a physiological barrier to antibiotic diffusion 
[26,30,31]. We previously developed a computational model (GranSim) to study the 
formation of a granuloma by tracking immune cell and bacteria populations. Briefly, this 
multi-scale, hybrid model incorporates an agent-based model, ordinary differential 
equations (ODEs) and partial differential equations (PDEs) to describe and simulate 
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granuloma formation and function, and has been developed based on experimental 
data from in vitro, mouse and non-human primate models [27–29]. The agent-based 
model operates on the molecular and cellular levels and reads out at a tissue scale; 
individual immune cells (such as T cells and macrophages) are modeled as agents that 
are recruited and interact with each other according to a set of rules (see 
http://malthus.micro.med.umich.edu/GranSim/). ODEs and PDEs are used to describe 
molecular scale events, such as receptor-ligand binding or cytokine and antibiotic 
diffusion, which are solved through the implementation of efficient numerical solvers 
[44]. 
Previously, we incorporated antibiotics into GranSim to study how treatment with two 
first-line antibiotics, isoniazid (INH) and rifampin (RIF), affects sterilization of bacteria 
from a granuloma [25,26]. In the treatment model, concentrations of antibiotics in the 
plasma are described by a compartmental pharmacokinetic (PK) model that captures 
their distribution following oral administration [30]. A tissue PK model was used to 
determine intracellular and extracellular antibiotic concentrations in both uninfected 
lungs and granulomas, and antibiotic pharmacodynamic (PD) parameters determine 
killing of M. tuberculosis within granulomas. The PK and PD models are calibrated to 
experimental data from M. tuberculosis infected rabbits and nonhuman primates. 
Through both agent-based and PK model components, GranSim captures physiological 
organization and antibiotic distributions observed in granulomas, as shown in Figure 
4.2. 
To simulate antibiotic treatment, two variables per antibiotic are defined: the dose size 
and the dosing frequency. The dose size determines the amount of drug given at each 
dose, and the dosing frequency determines the number of doses per week. Each 
GranSim simulation provides time courses for all cellular and bacterial populations at 
the single granuloma scale. There are multiple additional model outputs from GranSim 
treatment simulations, but we will focus here on tracking the number of days of 




Figure 4.2 Visual representation of simulated granuloma.  
The left side shows a snapshot of a granuloma simulation with each cell or compartment type: resting macrophages 
(green), activated macrophages (blue), infected macrophages (orange), chronically infected macrophages (red), 
caseation (white), and T-cells (purple, pink and light blue). The right shows unbound INH concentration on the 
simulation grid, with values ranging from about 0 to 1.5 mg/L (low concentration in blue, high concentration in red), 
illustrating the lack of antibiotic diffusion into granulomas. The entire snapshot represents an area of 16 mm2 of lung 
tissue. 
 
4.3.2 Defining the optimization problem 
For optimizing TB antibiotic treatment regimens, the treatment variables and objective 
function must be defined. Figure 4.3 shows how the treatment variables can be 
expressed as a vector, with each element defined as one of the variables. In this 
definition, each antibiotic could be given at a different dose size and dosing frequency 
throughout the treatment. This vector could be lengthened to include different doses 
and frequencies over time to represent different treatment phases, such as the intensive 
and continuation phases of current TB treatments [3].  
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Figure 4.3 Regimens as vectors and optimization algorithms  
(a) The antibiotic treatment regimen can be expressed as a vector of individual variables. (b) Strategy to define and 
solve the TB antibiotic optimization problem. The process begins by defining the treatment variables and their 
bounds, and an objective function to evaluate treatment efficacy. Two optimization algorithms are considered: GA 
and surrogate-assisted optimization with an RBF network. Both optimization algorithms ultimately converge to an 
optimal treatment regimen prediction. 
 
The goal of the objective function is to compare the efficacies of different antibiotic 
treatments. For a shorter treatment time, a goal could be to minimize the time to 
sterilization. However, only minimizing the time to sterilization would likely result in a 
regimen with the highest allowable dosage of antibiotic, and more adverse side effects 
in patients. With this in mind, our objective function should be one that balances finding 
a treatment with a fast time to sterilization while keeping dosages low.  The objective 
function we define here takes as input the regimen of n potential antibiotics defined by 
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the input variable vector of length 2n. This objective function defines a surface in 2n-
dimensional space where the global minimum of the surface corresponds to the “best” 
treatment regimen. The objective function value for a given antibiotic treatment is 
evaluated by simulating treatment of multiple granulomas with GranSim. The general 
form of the objective function we use is 
 8(9) = $(9)$6




 Eq. 4.1 
 
where $(9) is the average time to sterilize a granuloma for a given antibiotic treatment 9. 
Each treatment is simulated with multiple granulomas to account for host variability and 
model stochasticity. If a granuloma doesn’t sterilize for a given treatment, the time to 
sterilization for that granuloma is set as the total simulated treatment length when 
calculating $(9), as a way to inflate the average time to sterilization and increase the 
value objective function for a treatment that fails to sterilize multiple granulomas. </ and 
4/ are the components of the input vector that correspond to the dose size and dose 
frequency, respectively, of antibiotic i (where i is the index for INH, RIF, or any other 
antibiotic). Both objective function terms are scaled to be of similar magnitude. The first 
term is divided by a characteristic time to sterilization, $6, which is defined based on a 
typical average time to sterilization for a given treatment optimization problem. The 
second term is divided by the maximum amount of antibiotic based on the upper bounds 
of the treatment variables, </,!"# and 4/,!"#. We seek to locate an antibiotic regimen 
that minimizes this objective function, implying that an optimal regimen is one that 
simulates a fast average time to sterilization, but also gives a relatively low dose of 
antibiotic. The dose-weight parameter, :, can be adjusted to place varying emphasis on 
the amount of antibiotic given. To our knowledge, this is the first time an objective 
function has been defined for optimizing TB antibiotic regimens. In the future, there may 
be other important terms to consider including in the objective function. For example, it 
may be important to consider the percent of granulomas sterilized, whether there is 
excessive recruitment of immune cells, emergence of drug-resistance, and/or drug cost.  
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4.3.3 Genetic algorithm implementation 
We used MATLAB’s genetic algorithm (ga) function, and varied the settings for 
population size, generation stall limit, and a tolerance condition to test accuracy and 
convergence speed (MathWorks®, MATLAB 2015a). Figure 4.3 shows how GA can be 
implemented to solve treatment regimen optimization. Population size defines the 
number of individuals that are evaluated in each generation. The tolerance and 
generation stall limit are both stopping criteria. The generation stall limit defines the 
number of generations over which the average relative change in the best individual’s 
fitness is calculated. If this average relative change is less than the tolerance, the 
algorithm stops searching. Two different settings are discussed here: default and 
relaxed settings. Default settings are MATLAB’s built-in settings based on the type of 
problem and here define a population size and generation stall limit of 50, and a 
tolerance of 10-6. The relaxed settings we determined through trial and error to increase 
convergence efficiency, resulting in a decrease in the accuracy of the solution. The 
relaxed settings have a population size of 12 individuals, generation stall limit of 5 
individuals and a tolerance of 10-5. 
4.3.4 Surrogate-assisted optimization using radial basis function networks 
For simplicity, we used an RBF network trained from a set of data points without 
resampling.  Resampling can further improve the predictive and optimization power of 
the surrogate model [33,40,45,46]. We use the RBF networks here to predict the 





 Eq. 4.2 
where x is the variable input vector (here x is the vector in Figure 4.3), and =- are the 
weights on the radial basis functions >-. We use Gaussian RBFs centered at one of the 
sample points, with k representing the number of basis functions in the network. To find 
the optimal weights, the sum of the squared error is minimized between the predicted 
values and true value at each of the known sample points. To predict the value of the 
objective function for a given treatment, we evaluate Eq. 4.1 with the RBF network 
prediction of the time to sterilization for that treatment. 
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With a basis function centered at each sample point, the largest set of basis functions 
that could be used in the RBF network is equal to the number of sample points. 
However, using the full set can lead to over fitting. To avoid this, the RBF networks used 
in this study are built through forward selection, following the work of Orr [41]. The 
network begins with an empty set of basis functions and introduces whichever basis 
function minimizes the standard error the most. Basis functions are added one at a time 
until the standard error is lowered by < 0.01% over the last three basis function 
additions. 
4.3.5 Single-antibiotic test problems 
We crafted two test problems based on our published simulations of treatment to find 
optimal dose size and dosing frequency for a single antibiotic [25]. Thus we can 
propose two-dimensional optimization problems with known solutions, and use the 
optimization algorithms to solve the problem and test their performance. The data were 
generated by simulating antibiotic treatment with INH or RIF at five different dose sizes 
and seven dose frequencies to give 35 different treatments for each antibiotic. To do 
this, granuloma formation following infection was simulated for 100 days (no antibiotic 
treatment), with host variability included by simulating 82 granulomas with parameter 
values chosen from a uniform distribution.  Antibiotic treatment for 180 days was then 
simulated, and the average time to sterilization all bacteria from all granulomas for each 
treatment regimen was calculated. Based on this average time to sterilization and the 
antibiotic regimen, the objective function value (Eq. 4.1) for each treatment can be 
evaluated, with $6 defined as the longest average time to sterilization from the set of 35 
treatments. With the 35 objective function values, we generated an objective function 
response surface through linear interpolation between the known points. From this 
surface, we know the global minimum for each test problem, indicated by the circles in 
Figure 4.4a and Figure 4.4b corresponding to the treatment variables in Figure 4.4c. 
Because the recommended regimens for TB treatment consist of a combination of 
antibiotics, these single-antibiotic optimal treatments do not correspond to a practical 
treatment. Rather, these objective function response surfaces constitute the test 
problems we will use to determine the performance of different optimization algorithms.  
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Figure 4.4 Contour plots for optimization test problems 
Contour plots for INH (a) and RIF (b) single antibiotic treatment optimization test problems used to evaluate the 
performance of the genetic algorithms and RBF networks. Different treatments (35 for each antibiotic) were simulated 
by varying the dose size at five different levels (5, 15, 25, 35, and 45 mg/kg for INH; 10, 20, 30, 40, and 60 mg/kg for 
RIF) and seven dosing frequencies (1, 3, 5, 7, 9, 11, 14 doses per week) of the antibiotic, encompassing a realistic 
range for TB treatment. This range was chosen to encompass human equivalent doses in non-human primates (note, 
however, that treatment of humans with a single antibiotic is not standard-of-care). The objective function value (Eqn. 
1) was determined for each treatment, and contour plots were generated to represent the objective function response 
surface defined by the 35 treatments and linear interpolation between them. The circle on each contour plot shows 
the location of the global minimum for that test problem, which corresponds to the antibiotic treatments given in the 
table (c). 
 
4.3.6 Double-antibiotic treatment optimization implementation 
Optimizing the dose size and dosing frequency when treating with two antibiotics (INH 
and RIF) is a four-dimensional optimization problem with variables INH dose size, INH 
dosing interval, RIF dose size and RIF dosing interval. We optimized double-antibiotic 
treatments using two RBF network surrogate models trained from two sets of data. The 
first, referred to as the training set, contains 45 treatments generated through Latin 
Hypercube Sampling (LHS) [47,48]. The second set of data is our edge-supplemented 
training set. Because RBF networks interpolate between the training points, we sampled 
81 treatments to define the edges of the regimen design space to improve the RBF 
network accuracy near the design space edges. We generated all possible 
combinations of the four treatment variables at three discrete values for each variable: 
the variable’s lower bound, an intermediate value, and its upper bound. The edge-
supplemented set consists of the same 45 treatments of the training set plus the 81 
INH Dose (mg/kg)










































































edge treatments (i.e., 126 different treatments). The number of treatments in the training 
set was chosen based on a general rule of using about 10 points for every dimension of 
the optimization problem [49,50]. In addition to the two training sets just defined, we 
simulated a test set of 45 treatments chosen using LHS to validate the RBF network. 
We set variable ranges so that INH dose size could range from 0 to 45 mg/kg, RIF dose 
size from 0 to 60 mg/kg, and INH and RIF dosing frequencies from 1 to 14 doses per 
week. Because the plasma PK model is calibrated to non-human primate data, we 
chose these treatment boundaries as a range of non-human primate doses that yield 
human-equivalent exposure similar to clinical doses [3,25,51]. 
We treated a set of 73 granulomas, each with a different granuloma parameter set, with 
each of the 126 treatments and calculated the average time to sterilization for each 
treatment. With both the training set and edge-supplemented training set, we generated 
RBF networks to predict the average time to sterilization for any possible treatment 
variable combination. We used these RBF networks to search for local optima at 
discretely evaluated predictions of the objective function given by Eq 4.1, with a 
characteristic time to sterilization $6 defined as 120 days. Unlike the single-antibiotic test 
problems where we defined the longest average time to sterilization as $6, we do not 
know the shape of the objective function with double-antibiotic treatments, so the 
maximum average time to sterilization in the regimen design space is unknown. We 
chose 120 days as the characteristic time to sterilization based on our experience that 
most granuloma treatment simulations would sterilize within this time frame. We varied 
the dose-weight parameter   to investigate how the balance between quickly sterilizing 
the granuloma and antibiotic dose effects the predicted optimal treatment. 
 Results and Discussion 
4.4.1 Using RBF networks is more efficient but GA is more accurate when solving 
single-antibiotic treatment optimization 
For antibiotic treatment optimization, it is our goal to locate the region of the regimen 
design space representing treatments that quickly kill all bacteria (a fast time to 
sterilization) while minimizing the amount of antibiotic given. To test whether GA or RBF 
networks are more appropriate for TB treatment optimization, we generated two test 
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problems to optimize single-antibiotic treatments. These two-dimensional test problems 
have known solutions, shown in Figure 4.4 and are based on our previous published 
simulations with GranSim [25]. We optimized dose size and dosing frequency for INH or 
RIF using either a GA or an RBF network prediction (Figure 4.3). To optimize using an 
RBF network prediction, we train the RBF networks using 21 treatments chosen using 
LHS and their associated objective function values sampled from the test-problem 
objective function response surface. We performed 30 independent optimizations on 
both test problems with both optimization algorithms to capture the variation in solutions 
of each algorithm. The optimal treatments obtained for each method are shown in 
Figure 4.5.  
Optimization using an RBF network lacks the accuracy to precisely find the known 
solution to the test problems, although most of the solutions are found in the same 
region as the known solution (Figure 4.5a and Figure 4.5d). In contrast, using GA, with 
default stopping criteria (Figure 4.5b and Figure 4.5e), we accurately identified the 
global minimum of the test problem. All 30 runs yielded the known solution for the INH 
test problem, and almost all known solutions for the RIF test problem. Relaxing the 
stopping criteria for the GA can decrease the number of function evaluations, but at the 
expense of accuracy in finding the global minimum, as shown by the variation in 
solutions shown in Figure 4.5c and Figure 4.5f. 
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Figure 4.5 Comparing solutions using RBF network predictions and GA  
Each test problem was solved using RBF network predictions (a and d) and GA with the default (b and e) and relaxed 
settings (c and f) with 30 independent optimizations. The location of the global minimum found with each optimization 
is represented by an “x” on the contour plots. Larger “x’s” indicate that multiple runs found a global minimum at that 
location. 
 
Based on accuracy, the GA has an advantage over the RBF networks. However, one of 
the defining characteristics of our TB treatment optimization problem is that each 
simulation is computationally expensive. Evaluating the efficacy of a single antibiotic 
treatment regimen requires multiple granuloma simulations and based on the time per 
granuloma simulation, uses between 300 and 400 CPU-hours (based on run times on 
XSEDE Comet). Because of this, the number of function evaluations (number of 
different treatments simulated) associated with each method is important in determining 
performance of the optimization algorithms. The RBF networks generate their solution 
with far fewer function evaluations, especially when compared to the default GA 
stopping criteria (Table 4.1). Even with relaxed stopping criteria, the GA solutions 
require orders of magnitude more function evaluations on average than the RBF 
networks. 
If the overall goal is to identify the region of the design space that provides the best 
solutions rather than a unique location, which is the case with our treatment optimization 
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problem, then RBF network predictions can be effective. Although the RBF networks 
provide less accuracy, one benefit is that they provide a predicted response surface at 
any point in the regimen design space. With this information, the user can identify the 
region of the design space where the global minimum might occur, even if the predicted 
global minimum is not exactly accurate.  
The objective function for the single-antibiotic test problems was chosen with the goal to 
locate a treatment that can quickly sterilize a granuloma while keeping antibiotic doses 
relatively low. However, different optimal treatment regimens could be defined based on 
different goals with different objective functions. For example, if toxicity or drug cost is a 
higher concern, then higher weights could be placed on the amount of antibiotics given. 
Adding a penalty based on the percentage of granulomas that did not sterilize would 
emphasize searching for treatments that have higher probabilities of sterilizing every 
granuloma in a host. Using RBF networks to locate optimal treatments allows for easy 
comparison of additional objective functions. With a set of treatments simulated with 
GranSim, different outputs or statistics from the model can be combined in different 
ways to generate different objective function response surfaces, without having to 
repeat treatment simulations. 
4.4.2 RBF networks can be used to predict optimum double-antibiotic treatments  
We next predicted optimal treatment regions when administering both INH and RIF 
simultaneously to study whether utilizing optimization would extend to a higher 
dimensional problem (more antibiotics). Based on our single-antibiotic treatment 
optimization results, we chose RBF networks rather than GA for this problem. We 
generated two different RBF networks from our training set and edge-supplemented 
training set to predict the average time to sterilization for a treatment. Using these two 
RBF networks, we evaluated their accuracy by comparing the predicted average time to 
sterilization and the simulated average time to sterilization at the test set treatments. 
Varying the dose-weight parameter, we located multiple, local optimal treatments based 
on the objective function in Eq. 4.1 and the average time to sterilization predictions from 
both RBF networks. The training set RBF network identified 8 optimal treatments, and 
the edge-supplemented RBF network identified 7 optimal treatments.  
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The edge-supplemented training set RBF network is more accurate and has a higher 
correlation coefficient when predicting average time to sterilization than the training set 
RBF network (Figure 4.6). This is not surprising as the edge-supplemented training set 
has more training points. We next compared prediction accuracy by simulating each of 
the optimal treatments identified by the RBF networks. We found that the RBF network 
generated with the edge-supplemented training set provides a more accurate prediction 
of the 7 optimal treatments it identified when compared to the accuracy of the training 
set RBF network at predicting its 8 optimal treatments (Figure 4.6c). The presence of 
training points along the edge of the regimen design space reduces the amount of error 
and thus yields more accurate optimal treatment identification. 
 
Figure 4.6 Testing the accuracy of RBF network generated solutions 
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(a,b) The simulated average time to sterilization vs. the RBF-predicted average time to sterilization is shown for each 
of the 45 test set treatments using the training set RBF network (a) and the edge-supplemented training set RBF 
network (b). The edge-supplemented training set RBF network is a more accurate predictor of average time to 
sterilization, indicated by the higher coefficient of determination. (c) The average prediction error and standard 
deviation (mean ± SD) are shown for the test set treatments (as in parts a and b) and at the estimated optimal 
treatments for the training set RBF network (n=8) and the edge-supplemented RBF network (n=7, optimal treatments 
with predicted and simulated times to sterilization listed in Table 4.2). The edge-supplemented training set RBF 
network has a lower average error at its estimated optimal treatments than the training set RBF network. 
 
The optimal treatments from the edge-supplemented training set RBF network are listed 
in Table 4.2. Optimal treatments were located with dose-size weights of 0.75, 1, 2, and 
3. As the dose-weight parameter is varied from 0.75 to 3, there are two general regions 
where optimal treatments are located. The first optimal region is a dose of INH between 
~20-25 mg/kg given once a day with a low dose of RIF given about twice a week. The 
second optimum treatment is a similar dose size of INH given only once a week with an 
intermediate dose of RIF given every 1-2 days (Table 4.2), which shows similar dose 
sizes to non-human primate human-equivalent doses for recommended CDC regimens 
[3,51]. With this information, the two optimum treatments can be compared, and the 
best treatment can be chosen based on other criteria, such as the predicted time to 
sterilization or clinical practicality. For each toxicity weight, the daily INH doses with 
twice weekly RIF doses gives a faster time to sterilization than the other optimum 
treatment (Table 4.2). 
RBF networks interpolate between known data points, so training the network with only 
the 45 points chosen using LHS can lead to inaccurate predictions along the edge of the 
design space. Adding training points along the edges can fix this but presents a barrier 
when scaling to optimization problems in higher dimensions. With optimization of more 
than two antibiotics or greater than four dimensions, evaluating every possible point 
along the edge of the design space becomes inefficient. To solve higher dimensional 
problems, resampling the objective function after an initial surrogate model is built can 
provide an efficient way of minimizing the objective function with the fewest number of 
sample points [33,39,40,45,46]. We plan to use these more complex sampling and 
resampling methods to improve the predictive and optimization power of the surrogate 
model in future studies of optimization treatments adding in additional antibiotics. 
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The surrogate models we build here are based solely on simulated data, using a model 
we developed based on a variety of animal data.  However, surrogate modeling can be 
applied to data obtained through physical experiments as well. As with simulated data, 
the most frequent limiting factor to developing an accurate surrogate model is the 
density of data points within the design space. A low estimate for the number of data 
points required to build an accurate surrogate model is 10 for each design variable in 
the optimization problem, although 2 or 3 times as many points may be required 
depending on the specific problem and the desired accuracy of the surrogate model 
[49,50]. For many experimental studies, achieving this resolution of data may be 
infeasible. In these cases, there are a few possible solutions. One solution is to reduce 
the number of design variables to the most important and hold all others constant. 
Estimating optima of objective functions with one or two variables requires significantly 
fewer points than objective functions using three or more variables. Another solution is 
to use multi-fidelity surrogate modeling and combine the sparsely collected 
experimental data with larger sets of simulated data [52,53]. 
There are other antibiotics that are being considered for new TB therapy, including 
fluoroquinolones and oxazolidinones. We plan to investigate these as candidates for 
optimizing TB treatment with the optimization framework presented here. As we 
consider additional antibiotics, optimizing treatments with GranSim can provide 
predictions on whether antibiotic treatments will be successful in human clinical trials. 
While the simulations presented here represent treatment of a single granuloma, 
simulations with additional antibiotics will need to consider treatment of multiple 
granulomas in a single host. Providing this information could help prevent wasted 
resources arising from failed clinical trials and could help drugs reach the clinic more 
rapidly. Some antibiotics, such as moxifloxacin, showed promise in shortening TB 
treatment in animal trials, but failed to do so in human trials [54–56]. Using the 
optimization framework outlined here, we could identify treatments that have a higher 
probability of succeeding in human trials.  
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 Conclusions 
Current TB treatment is long and has many complications that indicate the need for 
better therapies. Based on the number of combination regimens of all potential 
antibiotics for TB, finding the best treatment regimen presents a challenging 
optimization problem. We presented a framework of combining our multi-scale, hybrid 
model of granuloma formation and treatment with optimization algorithms to predict 
optimal treatment regimens. Because each treatment simulation is computationally 
expensive, using an efficient algorithm is necessary for treatment optimization. We 
show that using a RBF network surrogate model is more suitable for predicting optimal 




Table 4.1 Average number of function evaluations required to solve each of the test problems with each 
optimization method.  
The RBF network predictions were always generated with 21 sample points. For GA optimizations, the number of 
function evaluations was averaged over the 30 independent optimizations. The average number of granuloma 
simulations required to find the optimum treatment is equal to the average number of function evaluations times the 
number of granulomas (in this problem, 82) simulated per treatment. 
 Average Number of Function Evaluations Required 
Optimization Method INH Test Problem RIF Test Problem 
RBF Network 21 21 
Default Genetic Algorithm 3,855 4,085 




Table 4.2 The local optima located for the objective function to evaluate INH/RIF antibiotic treatments for the 
different weight parameters.  
Because we identified local optimal treatments, multiple optima can be identified for a single dose-size weight. As the 
weight parameter increases, the local optima tend towards treatments that have lower total weekly doses and a 
higher predicted time to sterilization.  Predictions were tested by running simulations at those points, giving the 






































0.75 28.9 7.3 8.6 1.9 210.7 16.1 226.8 10.2 16.3 
1 
22.5 1.1 25.7 4.9 25.9 125.8 151.8 17.3 21.9 
25.7 7.3 8.6 1.9 187.4 16.1 203.4 11.8 16.8 
2 
22.5 1.1 17.1 3.7 24.1 63.3 87.4 25.9 31.0 
22.5 7.3 4.3 1.9 171.2 8.0 179.2 15.5 21.9 
3 
19.3 1.1 12.9 3.7 20.7 47.8 68.4 30.2 42.4 
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Chapter 5 Optimizing Doses of First-line Tuberculosis 
Antibiotics Identifies Alternative Regimens with High Efficacy 
in Virtual Clinical Trials 
 
 Introduction 
Even though tuberculosis (TB) has been around for thousands of years, we have 
treated TB disease with primarily the same drugs for close to 50 years [1]. Caused by 
the pathogen Mycobacterium tuberculosis (Mtb), the preferred, standard antibiotic 
regimen is estimated to have a success rate of ~95% [2,3]. With ~5% treatment failure 
rate, the standard regimen alone has not provided a significant decrease in the global 
TB burden. TB is one of the world’s deadliest infectious diseases, evaluated by number 
of annual deaths, and the World Health Organization aims to decrease the number of 
TB-related deaths by 90% by 2030 [4]. While vaccination efforts can also reduce the 
number of new TB cases, a highly efficacious drug regimen will continue to be needed 
to treat TB until its eradication, and changes to the existing regimen for drug-sensitive 
TB may help achieve this goal. 
 
When Mtb infects lung tissue, the immune response results in the formation of a 
granuloma. The granuloma is a collection of immune cells recruited to the site of 
infection to control the pathogen [5]. The granuloma contains Mtb and is therefore the 
target for antibiotic treatment. Different subpopulations of Mtb, such as extracellular or 
intracellular (inside macrophages or neutrophils) and replicating or non-replicating, exist 
in the granuloma depending on the microenvironment. The structure of the granuloma 
can act as a mechanism to control infection, but it also presents a physiological barrier 
to antibiotic diffusion [6–8].  
 
The current standard regimen for drug-susceptible TB involves up to 6 months or more 
of therapy with the antibiotics isoniazid (H), rifampin (R), ethambutol (E), and 
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pyrazinamide (Z). New regimens attempting to shorten TB treatment have been 
clinically tested, but with limited success. Efforts to introduce fluoroquinolones, such as 
gatifloxacin and moxifloxacin (M), into regimens for drug-susceptible TB to shorten 
treatment from 6 months to 4 months failed to show noninferiority to control regimens 
[2,3,9].  
 
Multiple factors limit the ability to shorten the standard regimen for drug-susceptible TB. 
First, the structure of the granuloma influences both antibiotic distribution and can result 
in lower concentrations inside the granuloma [7,8]. Second, microenvironments can 
promote Mtb to shift towards phenotypic states that are tolerant towards antibiotics [10] 
For example, Mtb collected from granuloma caseum, material consisting of dead cell 
debris, show high levels of tolerance to antibiotics [11]. Third, host-to-host variability in 
drug absorption and metabolism kinetics leads to PK variability that has been clinically 
linked to worse outcomes in TB treatment [12]. 
 
A goal for identifying better regimens for TB treatment involves finding a regimen that 
can manage and overcome all three of these complications: the heterogeneity in 
granulomas and antibiotic distribution, antibiotic-tolerant Mtb, and host-to-host PK 
variability. By addressing these complications, a better regimen is one that would 
successfully treat more individuals with a shorter treatment duration. Efforts to utilize 
experimental PK data to determine optimal doses can consider some factors that 
complicate treatment but rely on the existence of good experimental data and are 
resource-limited in the number of regimens that can be experimentally or clinically 
tested [13]. 
 
Using computational modeling to predict regimen efficacy provides a more efficient way 
of predicting regimen efficacy and determining optimal doses. We have previously 
shown how our computational simulation of granuloma formation, function and 
treatment can simulate efficacies of different TB regimens (Chapters 2 and 3) [7,14,15]. 
This computational simulation, called GranSim, can simulate granuloma heterogeneous 
environments that impact antibiotic distribution, and shows that different granuloma 
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types sterilize at varying rates even with the same drug regimen [7,14,15]. By 
accounting for the mechanisms that complicate TB treatment, we can accurately predict 
granuloma sterilization with different regimens. Formalizing the goal of optimizing 
antibiotic regimens as finding the optimal dosing schedule that minimizes both the time 
to sterilize a granuloma and total antibiotic dose, we have shown that we can utilize 
surrogate-assisted optimization algorithms to accurately and efficiently predict optimal 
regimens (Chapter 4) [16]. Using GranSim, we can predict granuloma-level sterilization 
when simulating TB treatment, but we are ultimately interested in predicting how a 
regimen treats an individual, and how the regimen performs in an entire population.  
 
I have two goals in this chapter. First, I examine the standard HRZE regimen and 
whether more optimal doses of these drugs can be identified.  To do this I optimize the 
doses for HRZE at the granuloma scale using a surrogate-assisted optimization 
algorithm (Chapter 4) and compare the efficacies of optimal regimens identified. I also 
present a process of generating a virtual population to simulate a virtual clinical trial 
(VCT) that captures the heterogeneity and variability in both granulomas and plasma PK 
and examine predicted optimal HRZE regimens in this population. 
 
Second, I ask whether improvements to the standard HRZE regimen could be obtained 
by substituting moxifloxacin for isoniazid or rifampin. Fluoroquinolones are frequently 
prescribed for treating multi-drug resistant TB [17]. A study comparing three 
fluoroquinolones predicted that moxifloxacin has better and more robust sterilizing 
activity compared to levofloxacin and gatifloxacin [8]. Substituting isoniazid or rifampin 
with moxifloxacin has been investigated as a way to potentially shorten treatment, or as 
an alternative for TB cases with resistance to isoniazid or rifampin. Clinical trials have 
been conducted to test whether the inclusion of moxifloxacin in place of isoniazid or 
rifampin could shorten treatment regimens [3,18]. However, many of these clinical trials 
failed to show an advantage over the HRZE regimen. To investigate the performance of 
these alternative regimens, here, I simulate the HRZE regimen and regimens where 
moxifloxacin (M) replaces H or R (HMZE and RMZE) in non-human primates (NHPs). 
Although these simulations are at the granuloma scale, they are useful for predicting 
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outcomes of NHP experiments currently being performed in the lab of our collaborator, 
Professor Joanne Flynn at the University of Pittsburgh. In addition to predicting 
outcomes for these regimens, we can predict which alternative regimens are interesting 
candidates for future experimental studies. 
 
 Methods 
5.2.1 GranSim and pharmacokinetic/pharmacodynamic modeling 
As a basis for the granuloma treatment optimization and hosts for the virtual clinical trial, 
I utilize our computational model of granuloma formation and function, GranSim. This 
model is described briefly below and in previous chapters (Chapters 2, 3 and 4). 
GranSim is an agent-based model that simulates the immune response in TB disease 
with granuloma formation as an emergent behavior [7,19–22]. Agents in this agent-
based model include immune cells, such as macrophages and T-cells, and individual 
Mtb that interact with each other according to a set of rules (for more complete 
description of rules, see http://malthus.micro.med.umich.edu/GranSim/). For the 
purpose of this work, GranSim provides a simulation that can recreate the heterogeneity 
and PK variability associated with TB treatment in a granuloma and can simulate the 
spatial distribution of antibiotics and sterilizing ability of different antibiotic regimens 
(Chapter 2) [7,8,14,15].  
 
The PK/PD model within GranSim simulates the plasma concentration over time 
following oral doses of antibiotics, the subsequent spatial concentration in the simulated 
granuloma, and the bactericidal activity based on the local concentration. The plasma 
PK model uses a compartmental, ordinary differential equation model to simulate 
absorption through transit compartments into the plasma, exchange with peripheral 
tissue, and first-order elimination from the plasma [7,23]. Plasma PK parameters for H, 
R, E and Z were calibrated based on human plasma measurements [14,24]. The tissue 
PK model references the concentration in the plasma to calculate flux through vascular 
sources in the computational grid, diffusion through tissue, binding to caseum, and 
partitioning into macrophages [7,15,25]. The PD model uses a Hill curve to determine 
the concentration dependent antibiotic killing rate constant [26], to determine the rate of 
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death per time step. The concentration used in the Hill curve is an effective 
concentration, calculated as the sum of all antibiotic concentrations converted to the 
equipotent concentration of the antibiotic of the highest maximal killing rate constant. 
Based on the predicted fractional inhibitory concentration, the effective concentration is 
adjusted to account for synergistic or antagonistic concentrations (Chapter 3) [27,28]. 
 
5.2.2 HRZE dose multi-objective optimization problem 
Defining an optimization requires defining the objective function (or multiple objective 
functions, see next section) whose values are to be minimized, and the design variables 
that define the domain of those objective functions. For the purpose of optimizing the 
doses for HRZE, the variables include the individual doses for each antibiotic. The 
sampling ranges for each dose variable were set to range from 0 mg/kg to double the 
standard CDC dose [1]. Maximum doses for each antibiotic were set to 10, 20, 40 and 
50 mg/kg for H, R, E, and Z, respectively. Because the ranges for these doses are 
different, the design variables used to define the objective function domains are 
normalized to range from 0 to 1. The objective functions include minimizing the total 
antibiotic dose and the sterilization time for that combination of doses. The total 
antibiotic dose is evaluated as the sum of the normalized antibiotic doses. The 
sterilization time is evaluated as the time to completely sterilize a granuloma, averaged 
over a set of granulomas. Granulomas that fail to sterilize are assigned a sterilization 
time of 180 days (length of treatment) to ensure they have the highest objective function 
value. 
 
5.2.3 Multi-objective Surrogate-assisted Optimization Algorithm 
The goal of multi-objective optimization is to find the optimal trade-off between two or 
more objectives by identifying the variable combinations that make up that optimal 
trade-off [29]. Using a surrogate-assisted framework involves predicting each objective 
based on the outcomes of the already sampled regimens. The surrogate predictions of 
each objective can then be used as a computationally-inexpensive alternative to predict 
the objective functions throughout the whole design space. Here, I use a kriging-based 
surrogate model to generate the objective function predictions. This kriging-based 
prediction and optimization algorithm is based on a set of open source MATLAB 
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functions developed by Forrester and Sóbester [30,31]. Using a surrogate-assisted 
framework provides an efficient and accurate way to thoroughly investigate the regimen 
design space and predict optimal doses (Chapter 4) [16]. 
 
First, the algorithm samples the antibiotic doses to generate a set of initial regimens for 
simulating treatment (Figure 5.1). A Latin hypercube sampling (LHS) design samples 
the doses to evenly distribute throughout the regimen design space [31,32]. Then, 
GranSim simulates treatment with each of these regimens on a set of 30 granulomas, 
and records the day when all Mtb are dead evaluate the sterilization time, reported as 
the average time when all Mtb are dead over the 30 granulomas (see section below for 
description of the 30 granulomas).  
 
Second, based on the sampled regimens and the calculated values of the 
corresponding objective functions, the algorithm builds a kriging-based surrogate model 
to predict the values of the objective functions at any point in the variable design space. 
The kriging model operates by assuming that the value of a function f of n variables at 
any n-dimensional vector x can be stated as the sum of some unknown mean (μ) and 
an error term that is a function of position (Eq. 5.1) [33].  
 
 8(9) = ? + @(9) Eq. 5.1 
 
To provide an estimate for the error at any given x, we assume the errors at two points 
are correlated based on the distance between those two points. The correlation in error 
between points i and j, equal to component Rij in the correlation matrix R, exponentially 
decays with respect to the weighted distance between them (Eq. 5.2). 
 
 






9			(7+ ≥ 0) 
Eq. 5.2 
 
Given k sample data points of f throughout the design space, the model maximizes the 
likelihood function (Eq. 5.3, Eq. 5.4, Eq. 5.5) by varying the weight parameters θh and ph to 
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obtain the best fit. The vector y of length k has entries with the values of the observed 
function at each of the sample points.	With the optimized parameters θh and ph, the 
value of f at any point x* is predicted with Eq. 5.6, where the vector r of length k is given 
such that its entry i is given as the correlation in error between sample point x(i) and x*. 
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 QR($∗) = K̂ + T′D1'(I − JK̂) Eq. 5.6 
 
Once the kriging model for each objective is tuned, the algorithm resamples the design 
space to select the regimen that maximizes the likelihood of expected improvement of 
the objective functions. The expected improvement criterion seeks the set of design 
variables that maximizes the expected distance from the points currently in the Pareto 
front [31,34]. At this point, GranSim simulates the sampled regimen that maximizes the 
likelihood of improving the values. An iterative process continues, where the algorithm 
adds new regimen results to the set of sampled regimens and objective functions and 
updates the kriging model until the algorithm samples the number of specified regimens. 
 
To visualize the results of the optimization algorithm, we can plot both objective function 
outcomes for each regimen against each other. If the regimen design space is well-
sampled, and the algorithm successfully identifies regimens that provide the trade-off 
between the two objectives, sterilization time and total dose, this plot provides a 
visualization of the Pareto front. The Pareto front is the set of regimens contained in the 
Pareto set, which is defined as regimens that have non-dominated objective function 
values [35]. In other words, the set of non-dominated solutions represent the 
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compromise between the two objective functions, where no regimen in the set has a 




Figure 5.1 Surrogate-assisted optimization algorithm  
The surrogate-assisted optimization algorithm begins by sampling the variable domain defined by the dose range for 
each antibiotic using LHS. Based on the initial set of regimens, treatment is simulated on a set of granulomas using 
GranSim. The outputs of GranSim are then used to calculate the objective function values for each regimen. The 
multi-objective scheme here uses the average granuloma sterilization time and the total antibiotic dose as the two 
objectives to minimize. Based on the sampled regimens and their objective function values, the surrogate models are 
tuned. Until the specified number of regimens is sampled, an iterative process occurs where new regimens are 
sampled from the variable domain. New regimens are selected by maximizing the predicted improvement to the 
existing Pareto front. Once all regimens are sampled, the full Pareto front, and all objective function values for the 
sampled regimens can be plotted to evaluate the performance of each regimen and identify optimal trade-offs. 
 
5.2.4 Set of granulomas for dose optimization 
To evaluate the average sterilization time objective function, we need a set of 
granulomas to simulate each regimen. Because the optimization algorithm involves an 
iterative process, and samples numerous regimens, computational expense and 
efficiency is a concern. We simulate a set of 500 granulomas, with immune parameter 
ranges listed for granulomas with low colony forming unit (CFU, number of bacteria) 
measures in Table 2.1. Because we simulate these granulomas on a 200x200 grid 
instead of the 300x300 grid required of the high-CFU granulomas, the low-CFU 
granulomas are much less computationally expensive. To find an optimal regimen, we 
want to find a regimen that is able to sterilize the worst granulomas. To do this, we 
selected the 30 granulomas with the highest CFU from the set of 500 simulated 
granulomas to represent the hardest to treat granulomas that are still able to be run on 
Initial regimen sample 
with LHS





















H + R + Z + E
U($∗) = K + /($∗) 
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the 200x200 grid. We treated these granulomas with the sampled set of regimens, 
varying doses of the four first-line antibiotics. For optimization with the four-first line 
antibiotics, we simulate these 30 granulomas with both low plasma PK exposure (low 
PK) and average PK exposure by setting the plasma PK parameters according to the 
low and average levels listed in Table 2.2. 
 
5.2.5 Host formation and virtual clinical trial population 
To explore how these regimens perform in a whole infected host, we need to create a 
simulation that represents a group of granulomas as a whole infected lung. TB disease 
in primates results in the formation of multiple granulomas, and successful treatments 
must sterilize the entire lung [36]. Here, we define a host as a collection of granulomas 
with the same plasma PK parameters. This definition assumes a granuloma develops 
independently of the status of the other granulomas in the host but captures the primary 
host-level characteristic by allowing for the same PK within a host and variable PK 
throughout the population. To build the population of hosts, we first created an in silico 
repository of granulomas, ranging from low to high CFU, using two sets of immune 
parameter ranges to generate the low and high CFU granulomas, based on the 
parameter ranges for these two groups in Table 2.1. These granulomas are a different 
set than the set of 30 granulomas used for optimization and include a greater diversity 
of granulomas. Because the number of overall granuloma simulations in the host 
simulations is smaller than the number required for dose optimization, we can afford to 
include the higher CFU granulomas on the 300x300 which provides a greater diversity 
of granuloma types into the hosts. We simulate the low-CFU granulomas on a 200x200 
grid with 500 different parameter sets for 500 different granulomas. We simulate the 
high-CFU granulomas on a 300x300 grid, due to their tendency to have larger 
diameters, with 200 different parameter sets [14]. A total of 514 granulomas were 
unsterilized after simulating 300 days (354 low-CFU and 160 high-CFU). 
 
To generate the list of granulomas that comprise a host, we use measurements of CFU 
per granuloma from 623 granulomas from 38 non-human primates (NHP) to determine 
the relative probability a granuloma has a certain level of bacteria burden. These 
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granulomas are compiled from numerous studies [37–41], and the complete set has 
been used for model calibration in a previous study [42]. Animals were infected with a 
low dose Mtb and necropsy was performed according to previously described protocols 
[36, 38]. The age of the granulomas excised during necropsy for bacterial burden 
measurement varies, depending on the study, but ranges from 4-17 weeks after initial 
Mtb infection. Figure 5.2 shows the CFU/granuloma distributions for both simulated 
granulomas and NHP granulomas.  
 
We next binned the NHP granulomas into 4 different levels: less than 103 CFU (36% of 
granulomas), between 103 and 104 CFU (33% of granulomas), between 104 and 105 
CFU (26% of granulomas), and greater than 105 CFU (5% of granulomas). We similarly 
binned the in silico granulomas sampled from those bins with the relative probabilities 
based on the NHP granulomas to generate a collection of 10 granulomas for each host. 
We generated a total of 400 hosts and randomly placed them into four treatment groups 
(Figure 5.3). To introduce plasma PK variability, we sampled 400 parameter sets using 
LHS from the plasma PK ranges that capture the range of human plasma concentration 
(Table 2.2), and assigned each parameter set to a host. We simulate the hosts in each 
treatment group with one of four regimens. The four regimens include one control group 
that is the regimen with the standard, recommended doses, and the other three are 
regimens identified as potential optimal regimens using the surrogate-assisted 
optimization algorithm. We statistically compare the differences in host sterilization 
times between each treatment group and the control group using a t-test with a 
significance level of A < 0.01. 
 
5.2.6 Non-human primate granulomas for moxifloxacin treatment simulation 
To predict regimen efficacy in non-human primates (NHPs), we simulate a set of 500 
granulomas, with immune parameter ranges for the low-CFU granulomas (Table 2.1). 
To match the timeline of infection and treatment based on NHP experiments, we 
simulate these granulomas for 100 days in the absence of antibiotics to allow for 
granuloma formation. After day 100, we treat granulomas with different regimens for an 
additional 100 days, or until granuloma sterilization. The simulated regimens include the 
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standard combination of antibiotics (HRZE), and regimens where moxifloxacin (M) is 
used to replace R in the regimen (HMZE) or H in the regimen (RMZE). We calibrate 
plasma PK parameters for M to NHP plasma concentrations following a dose of 50 
mg/kg (see Appendix D for parameters and calibration). Tissue PK parameters for M 
were calibrated and established in a previously published study [8]. We use doses for 
each antibiotic with daily administration at the NHP equivalent dose to the human 
recommended doses: H, 15 mg/kg; R, 20 mg/kg; M, 35 mg/kg; Z, 50 mg/kg; E 55 mg/kg 
[43]. 
 
5.2.7 Surrogate-model prediction behavior 
To check that the kriging-model produces realistic predictions of the objective functions, 
we evaluate the objective function predictions for both the average granuloma 
sterilization time and total daily dose. Holding the three other variable doses constant at 
their standard dose, the kriging-model predicts the average sterilization time and total 
daily dose for the full range of the fourth antibiotic dose. The surrogate models for 
average sterilization and total antibiotic dose were built based on a sample of 40 initial 
regimens, and 20 infill sampled regimens.  
 
Figure 5.4 shows the surrogate model predictions of average granuloma sterilization 
time and total daily antibiotic dose while varying each antibiotic. As expected, the 
relationship between antibiotic dose and total daily dose is linear, and the range of 
responses corresponds to the expected linear prediction for each antibiotic. The 
prediction for the average granuloma sterilization time also shows the expected trend. In 
general, as antibiotic dose increases the sterilization time decreases. However, some of 
the predictions show that as antibiotic dose is increased, there is no additional gain in 
sterilization time, and the sterilization time levels. This provides some indication that 
there may be an optimal trade-off between antibiotic dose and sterilization time, and 





Figure 5.2 Granuloma CFU Distributions 
The CFU/granuloma distributions for experimentally measured non-human primate granulomas (red, NHP), and 
simulated granulomas (blue). The distributions represent CFU/granuloma measurements from 623 granulomas from 
38 NHP and 514 simulated granulomas. The NHP granulomas are compiled from numerous studies [37–41], and 
represent granulomas that came from NHPs at timepoints ranging from 4-17 weeks after infection. 
 
 
Figure 5.3 Virtual population from in silico granulomas  
In silico granulomas are generated by simulating GranSim by sampling 500 low-CFU granulomas and 200 high-CFU 
granulomas based on immune parameter ranges defined in Chapter 2. Granulomas are simulated for 300 days, and 
then any non-sterilized granulomas are included the granuloma repository. Then, 10 granulomas are sampled with 
relative probabilities to match CFU/granuloma distributions from non-human primate granulomas. These individual in 
silico granulomas are then grouped into virtual hosts. Each host is assigned plasma PK parameters to generate PK 
variability in the virtual population., Finally, hosts are sorted into treatment groups for a virtual clinical trial.   
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Figure 5.4 Surrogate model predictions 
The kriging-based surrogate model predicts the total antibiotic dose and average sterilization time for different 
regimens as doses vary. While holding every other antibiotic dose constant, the objective function prediction while 
varying a single antibiotic’s dose shows the general relationship between antibiotic dose and objective output. 
Surrogate model predictions were made based on 60 regimens simulated in 30 granulomas with average PK 
exposure (A) and low PK exposure (B). 
 
 Results 
5.3.1 Pareto-fronts predict potential optimal regimens for average and low plasma 
concentrations 
To identify optimal regimens to test in our virtual clinical trial, there are a number of 
goals in mind, and they correspond closely with the objective functions used for 
optimization. The first is to try and find a regimen that decreases the sterilization time, 
while simultaneously attempting to decrease total antibiotic dose. The other goal is to try 
and identify a regimen that will perform well with low plasma antibiotic concentrations 
individuals (referred to as low PK), while not significantly increasing sterilization time or 




multi-objective optimization problem uses objectives of minimizing both the average 
granuloma sterilization time and total daily antibiotic dose. To find the optimal doses for 
the HRZE regimen, we trained the kriging-based surrogate model by initially sampling 
40 regimens and adding 20 regimens iteratively resampled. The variables used to 
define the regimens are the dosages for each antibiotic (total of 4 variables). The 
optimization algorithm resamples points by maximizing the expected improvement of 
both objectives and improving the Pareto front (Methods). We performed optimization 
on 30 granulomas and evaluate the average sterilization time for these 30 granulomas 
as the first objective function. The second objective function is the sum of the dosage 
parameters for each antibiotic. HRZE doses are optimized under two different sets of 
simulations. The first involved optimizing doses on the 30 granulomas with average 
plasma PK exposure and concentrations. The second was on the same 30 granulomas 
with plasma low PK concentrations. 
 
Based on the sampled regimens identified through the optimization algorithm, we 
identify a number of non-dominated solutions on the Pareto front. Figure 5.5 shows the 
simulated objective function outcome for each sampled regimen, with the non-
dominated solutions in red. Additionally, the standard dose simulation is shown for 
comparison.  
 
For the average PK optimization, the standard regimen is identified as near the 
predicted Pareto front. This implies that the standard doses are already near optimal for 
individuals with average PK exposure. At the same time, there are some regimens that 
appear to provide similar average sterilization times while simultaneously decreasing 
the overall antibiotic dose. For low PK optimization, the predicted Pareto front pushes 
further towards lower antibiotic doses and sterilization times than the current regimen 
with standard doses. This indicates that individuals with low PK exposure may have 
regimens available that provide shorter average sterilization times while simultaneously 
allowing for a lower total dose, and that the current regimen may not necessarily be 





Figure 5.5 Pareto fronts for HRZE dose optimization 
Each of the objective function outcomes for the 60 regimens simulated in 30 average PK (A) and low PK (B) 
granulomas plotted against each other represent the trade-off between the two objectives. Each point represents a 
given regimen with a unique combination of doses for the four antibiotics: H, R, E and Z. Points in red indicate non-
dominated regimens on the predicted Pareto front. The green point is the regimen based on the doses currently used, 
standardized doses. Potential alternative regimens listed in Table 5.1 are indicated by arrows in the plots. 
 
Based on the Pareto front predictions in Figure 5.5, there are a few regimens that 
satisfy some of the goals of regimen optimization. These regimens are indicated by 
arrows on the Pareto front plots, and their doses are listed in Table 5.1. Treatment 1 
appears as a regimen in both the average and low PK Pareto fronts. For average PK 
individuals, Treatment 1 is predicted to slightly decrease the total antibiotic dose while 
barely affecting the average time to sterilization. For low PK individuals, Treatment 1 is 
predicted to both decrease the total antibiotic dose and shorten the average time to 
sterilization.  In other words, although the current antibiotic regimen doses are predicted 
to be suboptimal for low PK individuals, it is possible there is a regimen that is optimal 
for both average and low PK individuals. 
 
Treatment 2 was selected as another potential regimen of interest. Although it is 
predicted to sterilize granulomas approximately 10 days slower than the control or 
Treatment 1, it has a much lower overall antibiotic dose. Treatment 3 was selected 
because it has low antibiotic doses for all four drugs and is predicted to have roughly 
equivalent sterilization times compared to Treatment 1 in low PK individuals. 
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Table 5.1 Doses for each regimen identified for the treatment groups, and pointed in the Pareto fronts in 









Control 5 10 20 25 
Treatment 1 7 15 3 20 
Treatment 2 7 9 6 5 
Treatment 3 6 18 10 3 
 
5.3.2 Testing optimal regimens at the granuloma scale shows slightly faster sterilization 
times as compared to the standard HRZE regimen 
Using the optimal regimens selected from the Pareto fronts in Figure 5.5 and listed in 
Table 5.1, we tested the efficacy of each against the control at the granuloma scale. 
The set of granulomas consisted of the 160 high-CFU granulomas generated for the 
host library (Methods). To compare efficacy at the granuloma scale, we focused on 
simulating treatment in these granulomas that would be hardest to treat. We simulated 
this set of 160 granulomas under three different PK conditions. The first is simulating 
each granuloma with average PK exposure for every antibiotic. The second is repeating 
the simulations, but with every antibiotic set to have low PK exposure. The third 
scenario is simulating the granulomas with each granuloma assigned a variable PK 
exposure, sampled from the full ranges of plasma PK parameters (Appendix C, Table 
C.1) to determine whether differences in regimens only exist at certain levels of PK 
exposure, or if they are detectable within the whole range of PK exposure.  
 
Treatment outcomes, measured as the sterilization time for each granuloma, for each 
treatment group and PK pairing, are shown in Figure 5.6. We first examined granulomas 
when average PK parameters were used. None of the identified optimal regimens 
outperform the control treatment. Treatments 2 and 3 are predicted to have slower 
sterilization times on average when compared to the control. Treatment 1 and the 
control treatment generate statistically identical sterilization time distributions. When the 
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same set of granulomas is simulated with low PK exposure parameters, Treatment 1 
shows statistically significant improvement in sterilization time when compared to the 
control treatment. However, when PK variability is introduced back into the simulations, 
the results converge on the same distributions as constant average PK, and there is no 
statistical difference between Treatment 1 and the control. This is unsurprising, since 
we saw little or no differences in the average and low PK scenarios, but also indicates 
that differences will likely be small in a virtual population.  
 
 
Figure 5.6 Granuloma level outcomes for the optimal treatment regimens 
The sterilization time distribution for the set of large, caseous granulomas treated when given average PK (A), low PK 
(B) and variable PK (C) exposures for all four antibiotics. The treatment groups and numbers refer the treatment 
regimens defined by the doses listed Table 5.1. Statistical significance between mean sterilization time in each 
treatment group and the control is determined with a t-test with significance levels labeled above each treatment 
group (NS p > 0.01; * p < 0.01; ** p < 0.001; *** p < 0.0001). 
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5.3.3 Variability of virtual clinical trials weakens ability to differentiate between regimen 
efficacies 
We observe that the regimens compared at the granuloma scale may show small 
improvements when compared to the control regimen under low plasma antibiotic 
concentrations, but that difference is obscured when variability in PK exposure is 
introduced. Next, we seek to find if any differences in the regimens is detectable in a 
virtual population when evaluating host sterilization times. Comparing the regimens of 
Table 5.1 in a virtual clinical trial setting introduces additional sources of variability that 
exist in a real population, including the heterogeneity of granulomas that exist within and 
across hosts and the variability in PK exposure for different antibiotics. We generate the 
virtual hosts and sort them into treatment groups according to Figure 5.3. Because 
granulomas are grouped into hosts, we use the overall host sterilization time used as 
the primary outcome for the virtual clinical trial.  
 
Figure 5.7 shows the distribution of host sterilization times for each treatment group 
regimen. Like the average and variable PK granuloma outcomes in Figure 5.6, 
Treatment group 1 shows no statistically significant difference when comparing the 
average sterilization time to the control group. The regimens for VCT treatment groups 
2 and 3 show small but statistically significant increases of about 2 days in average host 
sterilization times as compared to control. Thus, unless hosts with low PK can be 
identified pre-treatment, the HRZE regimens identified in Table 5.1 do not offer a 
significant advantage over the standard HRZE regimen.  
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Figure 5.7 Host sterilization time in virtual clinical trial 
The host sterilization times in days following treatment start for the control group and each of the three treatment 
group regimens defined by the doses listed Table 5.1. Treatment groups are given different regimens with varying 
doses of HRZE, and each group represents the sterilization times from 100 hosts. Statistical significance between 
mean sterilization time in each treatment group and the control is determined with a t-test with significance levels 
labeled above each treatment group (NS p > 0.01; * p < 0.01; ** p < 0.001). 
 
5.3.4 Moxifloxacin-containing regimens present an additional alternative to successful 
treatment of drug-sensitive TB 
We next turned to designing better regimens for drug-susceptible TB by using different 
antibiotics. Fluoroquinolones are frequently prescribed for treating multi-drug resistant 
TB [17]. A study comparing three fluoroquinolones predicted that moxifloxacin has 
better and more robust sterilizing activity compared to levofloxacin and gatifloxacin [8]. 
Substituting isoniazid or rifampin with moxifloxacin has been investigated as a way to 
potentially shorten treatment, or as an alternative for TB cases with resistance to 
isoniazid or rifampin. Clinical trials have been conducted to test whether the inclusion of 
moxifloxacin in place of isoniazid or rifampin could shorten treatment regimens [3,18]. 
However, many of these clinical trials failed to show an advantage over the HRZE 
regimen.  
 
We can better understand the results from these clinical trials, and perhaps suggest 
more fruitful directions for treatment optimization, by simulating these same antibiotic 
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regimens, and predict outcomes to help inform non-human primate (NHP) experiments. 
To simulate the conditions of NHP treatment, we simulated a set of 334 granulomas for 
100 days following infection and treated with three different regimens: HMZE, RMZE, 
and HRZE. We use doses for each antibiotic with daily administration at the NHP 
equivalent dose to the human recommended doses: H, 15 mg/kg; R, 20 mg/kg; M, 35 
mg/kg; Z, 50 mg/kg; E 55 mg/kg [43]. We calibrated the plasma PK parameters for each 
antibiotic non-human primate plasma concentrations and doses (see Appendix C for 
parameters and calibration for M) [7,42]. Figure 5.8 shows the percentage of 
granulomas sterilized over the course of treatment for each regimen. During the first 
week, the number of granulomas sterilized is similar for each regimen. After a week of 
treatment, however, HMZE is only able to sterilize a few more granulomas, and only 
sterilizes 46% of granulomas after 100 days. In contrast, RMZE and HRZE sterilize all 
granulomas before 50 days of treatment. Comparing the percentage of granulomas 
sterilized over time, RMZE and HRZE perform similarly, and RMZE may be a useful 
alternative in patients with adverse reactions to H or with mono-H resistant TB. We 
predict HMZE is an inferior regimen on the basis of percentage of sterilized granulomas 
after 100 days. However, its ability to rapidly sterilize some granulomas early in 
treatment means that early measurements in clinical trials (such as early bactericidal 
activity), or short term in vitro measurements, could be misleading in predicting its 
overall efficacy in vivo. 
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Figure 5.8 NHP treatment moxifloxacin-containing regimens 
The percentage of granulomas (n = 334) sterilized over 100 days of treatment for NHP granulomas treated with 
HMZE, RMZE and HRZE regimens. Panel B shows the boxplot of sterilization times for granulomas that sterilized 
with 100 days (unsterilized granulomas are excluded) for each regimen. 
 
 Discussion 
New drug regimens are desperately needed for TB to combat the long length and side 
effects of current treatments and to improve efficacy. Successful clinical trials are a 
requirement for new regimens and treatments to be approved. Generally, the population 
of interest in clinical trials of new TB regimens is all individuals with TB. However, 
populations of individuals have varying disease severity, types of granulomas, and PK 
exposure through varying drug absorption and metabolism/elimination kinetics. The 
corresponding groups of individuals sampled to represent a population in clinical trials 
also includes this same heterogeneity. In general, this is useful, because it allows us to 
ensure the regimen tested is successful in a general population.  
 
In this chapter, we first sought to optimize the doses for HRZE to identify the optimal 
trade-off between sterilization time and total antibiotic dose. Because GranSim is a 
simulation at the scale of an individual TB granuloma, the optimization algorithm finds 
optimal doses for granuloma level treatment. But ultimately these regimens need to be 
successful at the host scale, and then in an entire population. The results presented 
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address how optimization at the granuloma scale compares to one measure of efficacy 
(sterilization time) of regimens tested in heterogenous and non-heterogenous 
populations of both granulomas and hosts. 
 
Looking at the Pareto front predictions, generated from sampled regimens simulated to 
treat granulomas with average and low PK antibiotic parameters, we see that the 
standard HRZE regimen is already near optimal and close to the predicted Pareto front 
for individuals with average PK concentrations (Figure 5.5). However, for individuals 
with low PK concentrations, the control regimen is further from the Pareto front, and 
there are a number of potential regimens that could simultaneously decrease overall 
antibiotic dose and decrease average sterilization time. Selecting three different 
regimens as potential alternatives to the control regimen and comparing efficacies at the 
granuloma level, we confirm the predictions from the Pareto front. The control regimen 
is not outperformed by any treatment, unless it is compared while treating granulomas 
that have both high CFU and parameters causing low PK exposure. Under average or 
variable PK conditions, the control regimen is as good or better than the potential 
alternatives. This trend observed for the average and variable PK granulomas extends 
to the virtual population. This is unsurprising, because the virtual population has the 
same amount of PK variability as the granuloma-level comparisons of Figure 5.6. 
 
Although these regimens fail to significantly outperform the standard (control) HRZE 
regimen regarding average sterilization time, we predicted they both have acceptable 
levels of efficacy. In particular, Treatment 1 is never statistically worse than the control 
treatment, whether comparing at the granuloma or host level. While these results do not 
suggest replacing the standard regimen, they do provide a way of identifying potential 
regimens that could be used as alternatives. For some of the treatment groups, doses 
for E and Z are low, and indicate that these could be useful regimens in situations 
where administration of either of those drugs to a given patient is not advised or not 
possible. This could be due to existing allergies to the antibiotic, the onset of adverse-
drug reactions, or unavailability of the antibiotic. 
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Another important observation from these results is that the current regimen is already 
near-optimal. This is not surprising, as although optimization schemes were not 
performed to determine the regimen, this regimen has undergone extensive research 
within patients over decades to ensure doses corresponding to appropriate levels of 
antibiotic to achieve their intended therapeutic effect. Using the Pareto front predictions, 
we see that the average individual does not have many alternative doses to improve the 
sterilization time without significantly increasing antibiotic doses. And when comparing 
efficacies in a heterogenous virtual clinical trial, the control does not get outperformed. If 
we are to shorten drug-susceptible TB treatment, it will likely require the use of novel 
antibiotics.  
 
As a potential alternative combination of antibiotics, replacing either isoniazid of rifampin 
with moxifloxacin has been tested clinically. When comparing the HMZE and RMZE 
regimens to the preferred HRZE into our simulated non-human primate granulomas, we 
also confirm that introducing moxifloxacin does not outperform the standard regimen. 
However, a third regimen, RMZE, sterilizes granulomas at a similar rate as HRZE, and 
could be a suitable alternative when isoniazid is ineffective, due to resistance or 
adverse drug reactions. 
 
Although these results do not necessarily identify a regimen that will outperform the 
currently used regimen, we were able to quickly identify promising alternatives, and 
potentially a new regimen (Treatment 1) that could improve treatment for individuals 
with whose own PK parameters lead to lower plasma concentrations. Importantly, using 
simulations to evaluate optimal doses and combinations of antibiotics provides a rapid 
and inexpensive way to identify regimens for further testing, and could reduce the 
resources and number of clinical trials required to develop and approve new antibiotic 
regimens for TB treatment. 
 
These results also highlight the idea that identifying differences in regimens in a clinical 
trial setting is difficult when looking at the full heterogeneity of a population. Yet, even if 
two regimens appear the same on average at the population level, that doesn’t mean 
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they are the same for an individual. That Treatment 1 outperforms the standard regimen 
in granulomas with low antibiotic exposure indicates that applying personalized 
medicine to TB treatment could be beneficial. While designing a regimen for every TB 
patient is not yet feasible, treating different groups of TB patients with different regimens 
could improve efficacy, reduce side effects, and decrease the TB global burden. In 
order to do this, we need to identify ways to measure which patients have more severe, 
complicated TB lesions, and whether they are at risk for low plasma antibiotic 
concentrations. PET/CT scans can provide a way towards this goal, but the equipment 
is expensive, so other routes should be tried [39]. Using measurements that evaluate 
disease severity and pharmacokinetics as requirements for inclusion into a given clinical 
trial could help to reduce the heterogeneity of the population, allowing a better chance 
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Chapter 6 Conclusions 
 
 Summary of research findings 
Improving antibiotic treatment for tuberculosis (TB) could help to significantly decrease 
global TB deaths and disease burden. Caused by the pathogen Mycobacterium 
tuberculosis (Mtb), lesions in the lungs called granulomas form in response to infection 
with Mtb. Because variability in plasma pharmacokinetics (PK) and granuloma 
heterogeneity impact antibiotic distribution in granulomas and overall regimen efficacy, 
considering these aspects in new antibiotic regimen design is critical. This thesis 
presents methodologies for modeling antibiotic treatment and predicting regimen 
efficacy and optimal regimens. This work presents a method of incorporating and 
modeling the variability observed in antibiotic concentrations into PK models, the 
heterogeneity of granulomas, and drug-drug interactions to predict antibiotic regimen 
efficacy. Using GranSim, our computational model of granuloma formation and function, 
we can apply optimization algorithms to predict optimal antibiotic doses and compare 
different regimens from the granuloma to population scales. 
 
6.1.1 Integrating plasma pharmacokinetic variability into granuloma-level 
pharmacokinetics 
Natural variability in the population in how individuals absorb, distribute and eliminate 
antibiotics from the body impacts antibiotic concentrations in the granuloma. 
Incorporating this PK variability into computational models of TB treatment is necessary 
for accurate predictions of antibiotic distributions in granulomas and regimen efficacies. 
Because the source of PK variability occurs at the host scale, when calibrating tissue 
specific PK parameters to experimentally measured granuloma concentrations, this 
variability must be accounted for. In Chapter 2, we present a process of utilizing 
GranSim to calibrate antibiotic tissue PK parameters based on average granuloma 
concentrations. By appropriately accounting for this variability, and accurately 
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calibrating the tissue PK parameters, we can recreate the qualitative distributions of 
antibiotics in granulomas. 
 
6.1.2 Modeling the effect of drug-drug interactions on antibiotic killing rates 
Drug-drug interactions can play an important role in selecting the best combination of 
drugs for treatment. With TB antibiotics, the fractional inhibitory concentration (FIC), is a 
commonly used measurement to evaluate the strength of the synergistic or antagonistic 
interaction [1]. In Chapter 3, we develop a model for integrating the FIC for a 
combination of antibiotics into our PD model by defining an effective concentration that 
incorporates the contribution of each antibiotic and adjusts the effective concentration 
according to the strength of the interaction. This adjustment in the effective 
concentration results in a consequent increase or decrease in the antibiotic killing rate 
constant. Using this model, we can efficiently simulate a large number of antibiotic 
combinations and measure the effect that drug-drug interactions have on antibiotic 
killing rates and overall granuloma sterilization. This model has the important 
characteristic that the strength of the interaction weakens when antibiotic concentrations 
are uneven (e.g. when one antibiotic has a much higher concentration than the others). 
Because of this, we can predict the actual in vivo effect of the drug-drug interaction on 
the antibiotic killing rate. 
 
6.1.3 Defining improving antibiotic regimens as an optimization problem 
With the incorporation of PK variability, granuloma heterogeneity, and drug-drug 
interactions into a computational model, we can predict the efficacy of a given regimen 
at the granuloma scale. But with this model, how do we find optimal regimens, when 
defining a regimen by its antibiotic dose and dosing frequency, in the high dimensional 
regimen design space? Evolutionary algorithms are powerful in finding global optima in 
high dimensional spaces, even in multi-modal functions with numerous local optima. 
However, they sample the design space inefficiently, and require the iterative evolution 
of populations of samples that make their limit their use when optimizing 
computationally expensive functions. Surrogate-assisted optimization is a class of 
alternative algorithms that allows for efficient exploration of the design space and 
accurate prediction of objective function values and optima. Surrogate-assisted 
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optimization algorithms may not be as useful at predicting and optimizing over multi-
modal, rapidly changing surfaces, but they can be useful in predicting optimal regimens. 
The relationship between the variables describing regimens and their objective 
functions are frequently simple surfaces, often monotonically increasing or decreasing.  
 
In Chapter 4, we show that we can use surrogate-assisted optimization to predict 
regimens that still maintain clinical relevance [2]. We can improve the accuracy of 
predicting objective functions using surrogate models by adding resampling schemes 
and resampling the design space in regions that either have high levels of uncertainty, 
or by sampling areas with higher probabilities of containing global optima [3]. 
Additionally, by using a multi-objective optimization scheme, we can compare two 
competing objectives without imposing a weight on those objectives. In this way, we can 
identify the optimal trade-off between the objectives. In other words, we can identify the 
point when increasing antibiotic dose no longer results in a decrease in sterilization 
time. 
 
6.1.4 Variability in pharmacokinetics and granuloma heterogeneity impact granuloma 
sterilization 
With an antibiotic regimen such as the standard therapy for drug-susceptible TB that 
has a relatively high level of success when treating disease, understanding the 
mechanisms and conditions of failure is important to understanding how to improve 
efficacy. Based on the results presented in Chapter 2, it is clear that natural variability in 
the population regarding how antibiotics are absorbed, distributed, and eliminated from 
the body can create conditions of treatment failure. Currently used regimens are 
successful for the average individual, but still fail to cure TB in some individuals. When 
parameters causing low antibiotic concentrations in plasma are paired with high 
bacterial burden, and lesions that inhibit antibiotic diffusion and accumulation, we show 
that these create conditions where granulomas fail to sterilize. The results of Chapter 2 
reinforce another important concept in TB treatment. Antibiotics can distribute differently 
in a granuloma, and will complement each when given in combination, by accumulating 
in different regions of the granuloma and having different levels of bactericidal activity 
against different subpopulations of Mtb [4]. 
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6.1.5 Antibiotic concentrations in granulomas impact the strength of synergistic and 
antagonistic antibiotic combinations 
Specialization in the spatial distributions of antibiotics is not the only way that antibiotics 
given in combination can complement each other. Drug-drug interactions between 
antibiotics can also generate synergistic and antagonistic interactions that produce 
higher or lower levels of bactericidal activity, especially when observed in vitro. 
However, are these same interactions observed in a granuloma, and do they impact 
sterilizing ability? A relationship exists between the fractional inhibitory concentration of 
a combination of antibiotics and its observed clinical efficacy [5], but does not 
completely explain the efficacy of all antibiotic combinations. In Chapter 3, we show that 
by using computational modeling to measure the real impact these drug interactions 
have on the antibiotic killing rate constant, based on predicted in vivo concentrations of 
the antibiotics, we generate a much stronger predictor of in vivo efficacy. This is an 
important finding because some combinations that are strongly antagonistic interactions 
in vitro could still be efficacious regimens. And similarly, a strong synergistic interaction 
is not enough to result in highly efficacious regimen. 
 
6.1.6 Predicting optimal regimens in a virtual population 
In Chapter 5, we use a multi-objective, surrogate-assisted optimization scheme to 
optimize the doses for the four first-line TB antibiotics: isoniazid, rifampin, pyrazinamide 
and ethambutol. We optimize these doses for granulomas with different levels of 
antibiotic concentrations in plasma. We find that the currently used doses are near-
optimal for the four first-line antibiotics when they are able to achieve average levels of 
concentration in plasma and the granuloma. However, we predict that granulomas 
simulated with low plasma antibiotic concentrations have alternative regimens with 
higher levels of efficacy, while also allowing for lower overall doses of antibiotics. This 
indicates that there may be alternative regimens that improve treatment in individuals 
with pharmacokinetics that result in low plasma antibiotic concentrations. This result is 
connected to our findings in Chapter 2, where we observe that PK variability can create 
conditions that result in granulomas that fail to sterilize with antibiotic treatment. Using 
computational modeling, coupled with surrogate-assisted optimization algorithms, we 
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predict there may be alternative doses that can improve treatment under these 
conditions. However, performing clinical trials to detect the differences between 
alternative regimens in a diverse population may be difficult. We show that when these 
regimens are tested in a virtual clinical trial accounting for the range of PK variability 
and granuloma heterogeneity, alternative regimens only show equal sterilization rates 
when compared to the control regimen consisting of the currently recommended doses. 
 
 Future directions 
Computational modeling of in-host dynamics of Mtb infection and immune response in 
TB disease has made numerous contributions to the field from studying immunological 
mechanisms, analyzing disease progression, and simulating antibiotic treatment [6]. 
Certainly, computational modeling is a long way from completely replacing these 
experimental alternatives, but computational modeling can provide a vital role in 
accelerating experimental research by predicting promising routes and helping to avoid 
investing in failed therapies. The continual advancement of these models to include 
additional features can improve their ability to recapitulate the behavior in the biological 
system. In terms of modeling work presented in this thesis, this could include simulating 
more complex lesion types, improving pharmacodynamic models, and modeling new 
antibiotics and therapies. Adding new objectives when optimizing antibiotic regimens 
can diversify the types of optimal regimens identified and improve treatment in a diverse 
population. 
 
6.2.1 Improvements to GranSim 
There are three improvements to GranSim that could further improve its ability to 
describe and predict antibiotic efficacy. First, the simulations we present in this work do 
not explicitly include fibrosis, the depositing of connective tissue such as collagen during 
pathological would healing, although GranSim has been used to simulate fibrosis [7]. 
Fibrotic granulomas are often associated with healing granulomas and fibrosis 
frequently arises with antibiotic treatment [8–10]. This could present an even more 
impermeable barrier to diffusion than the cells within a granuloma alone. Fibrosis is 
potentially an important part of why drug treatment takes so long and can fail to sterilize 
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granulomas. As the granuloma starts to heal, it may wall off remaining Mtb, limiting 
antibiotic diffusion to those regions. Second, cavitation is another pathological 
manifestation of TB disease that is related to more severe disease and higher rates of 
treatment failure and formation of resistance, and occurs when the granuloma structure 
begins to degrade and liquify, forming cavities in the lungs [11–14]. Modeling how Mtb 
persist in cavity walls, and the pharmacokinetics of cavities, would provide another 
potentially critical understanding of how treatments fail. Third, while we have addressed 
TB mostly as a pulmonary disease, existing in granulomas in the lungs, extrapulmonary 
involvement is not uncommon [15]. In particular, granuloma formation and involvement 
in lymph nodes in macaques is associated with more severe disease and dissemination 
events [16,17]. Extending plasma PK models to include a lymph node compartment that 
receives antibiotic from peripheral tissue and adds antibiotic back into a plasma 
compartment would provide an organ-level prediction of antibiotic concentration in 
lymph nodes. Within the lymph, the same tissue PK phenomena that govern antibiotic 
distribution in lungs and granulomas could be used to describe the distribution of 
antibiotics in lymph node granulomas. Because granulomas in lymph nodes tend to 
have limited ability to kill Mtb and often associated with higher Mtb burden in non-
human primate models [16,18], modeling lymph node treatment could increase our 
understanding of TB treatment failure and inform better regimen design. 
 
6.2.2 Improvements to the pharmacodynamic model 
The relationship between antibiotic concentration and pharmacodynamic effect is critical 
to determining antibiotic treatment efficacy. In this thesis, we utilize a Hill curve to 
describe this effect, which is a widely used model to describe the pharmacodynamics of 
therapeutic agents, and in this research describes the relationship between antibiotic 
concentration and the killing rate constant [19–21]. However, there are often distinct 
concentration levels that exhibit bacteriostatic and bactericidal effect of TB antibiotics 
[22]. Capturing the pharmacodynamic effect of both growth inhibition and bactericidal 
effects could enhance the ability to predict an antibiotic regimen’s efficacy. Because 
GranSim already includes the bactericidal effect with the Hill curve, a potential option for 
modeling growth inhibition would involve utilizing another Hill curve that evaluates the 
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reduction in Mtb growth rate. This bacteriostatic function could evaluate how much the 
growth rate decreases as a function of the concentration, with parameters influenced by 
minimum inhibitory concentration measurements [22]. Because non-replicating Mtb are 
typically more tolerant to a variety of antibiotics [23], a potential consequence of 
introducing this bacteriostatic effect would result in lower overall killing activity when one 
antibiotic is exhibiting a bacteriostatic effect. The ability to simulate the conditions when 
this phenomenon occurs could improve our ability to predict regimens that have higher 
risks of treatment failure. 
 
The drug-drug interactions modeled in Chapter 3 use fractional inhibitory concentrations 
that are constant for the given combination of antibiotics. However, the conditions within 
a granuloma, and the microenvironments that impact bacterial metabolism and 
phenotypic state can also impact the synergistic or antagonistic interactions [24]. 
GranSim is well suited to accommodate these changes in interactions due to 
microenvironments, through either course-grained representation based on variable 
growth rate of Mtb in the model, or fine-grained calculation of the metabolites and 
nutrients in a granuloma [25]. Introducing these environment dependent interactions 
would improve GranSim’s ability to predict how drug interactions impact sterilization rate 
and regimen efficacy. 
 
6.2.3 Host-directed therapies 
Many pathological characteristics of TB disease are caused by the body’s own immune 
response. Host-directed therapies that modulate immune responses could limit harmful 
inflammation or improve the efficacy of antibiotic therapy. The formation of the 
granuloma, and consequent tissue damage, are mostly dictated by the level and control 
of the inflammatory responses, and a proper balance between pro- and anti-
inflammatory responses is necessary for granuloma maintenance [26–28]. Modulating 
the immune response can alter the progression of TB disease. For example, anti-TNF 
therapies (such as those given for the treatment of rheumatoid arthritis) can result in 
reactivation of latent infections [29–31]. Studies in non-human primates suggest there 
may be some host-directed therapies that could be beneficial in improving responses to 
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drug treatment. Neutralization of IL-10 in non-human primates during Mtb infection does 
not change overall disease outcomes compared to untreated non-human primates, but 
results in immunologically different granulomas that could potentially impact antibiotic 
activity [32]. The use of IL-1 receptor antagonists together with linezolid treatment in 
non-human primates is a potential host-directed therapy to reduce linezolid toxicity and 
reduce TB-associated inflammation in the lungs [33]. If the granuloma is the product of 
an immune response, can we discover additional ways to modulate the immune 
response to adjust the structure of the granuloma, and improve antibiotic accumulation 
in granulomas? Or is it possible that relieving some of the immune pressure can shift 
Mtb out of a phenotypic state that is more tolerant to antibiotics to a state where that is 
more susceptible? Potential host-directed therapies could prove useful in conjunction 
with antibiotics, but the inflammatory balance that is required to maintain a granuloma 
and control Mtb infection is delicate, and there is potential for these therapies to do 
more harm than good. 
 
6.2.4 Additional antibiotics to simulate new regimens 
The antibiotics studied in this work included the four-first line antibiotics (isoniazid, 
rifampin, ethambutol, and pyrazinamide), and the fluoroquinolones moxifloxacin and 
levofloxacin. However, there are numerous other antibiotics in the TB drug pipeline that 
would be useful introductions into the model. Perhaps the most exciting antibiotics are 
included in the Nix-TB, or BPaL regimen, consisting of bedaquiline, pretomanid, and 
linezolid. Each of these are newer antibiotics that have shown success in clinical trials 
at reducing the treatment duration of extensively drug resistant TB (XDR-TB) from 24 
months to 6 months [34]. Bedaquiline is a diarylquinoline that is highly active against 
replicating and non-replicating bacterial population [35], and has promise in being a 
useful antibiotic in treating TB despite its high caseum binding fraction and limited 
transport into caseous lesions [36]. Linezolid is a potent antibiotic, but has many 
associated toxicities, particularly bone marrow suppression. A recent study showed that 
co-administration of IL-1 receptor antagonistic could reduce inflammation and linezolid 
associated toxicity [33]. While these are some of the most exciting drugs that have 
made it through the gauntlet of studies to clinical testing clinically, there are many other 
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candidates in the pipeline [37,38]. Modeling new antibiotics as they are being developed 
gives another tool in identifying the best regimens and identify the best experiments and 
trails to conduct when investigating new regimens. 
 
6.2.5 New objectives for optimization and regimen evaluation 
Using alternative objectives to evaluate and optimize antibiotic regimens would provide 
additional treatment options that can achieve different goals. Considering other events 
during TB treatment, such as antibiotic toxicity and the formation of resistant Mtb could 
be additional objectives to consider in regimen optimization. Evaluating regimens based 
on the time required to sterilize a granuloma or host, as implemented here, is a logical 
choice. Not only does faster sterilization mean that one is less likely to fail to completely 
sterilize and relapse, but it also means that treatment durations could potentially 
shorten. Balancing sterilization time with total antibiotic dose is necessary, because 
minimizing sterilization time would only result in an optimization algorithm finding the 
highest allowable dose of antibiotic. Minimizing toxicity is an important objective and 
related to antibiotic dose. As toxicity and adverse drug reactions occur in TB treatment, 
patient adherence and regimen efficacy decrease [39]. Designing a regimen that 
minimizes the frequency or probability of adverse-drug reactions could be beneficial at 
increasing overall treatment success rates. Measuring and modeling toxicity, either 
through the explicit modeling of toxic antibiotic metabolites, or by relating long-term drug 
exposure to risk of adverse-drug events, would be a useful objective [40,41].  
 
An additional objective could be minimizing the risk of resistance development. 
Antibiotic resistance is a very concerning aspect of TB treatment [42,43]. Although the 
simulations presented in this thesis did not involve any resistant Mtb, it is a functionality 
built into our model for isoniazid and rifampin, and has been used to study the 
emergence and treatment of resistant Mtb [44]. The ability to simulate the spatial 
distribution of antibiotics in granulomas is so important in evaluating resistance risk. 
Even if average granuloma concentrations are above concentrations that could reduce 
development of resistant Mtb [45], the distribution of certain antibiotics may create 
microenvironments that meet the criteria for resistance selection. Sub-therapeutic 
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concentrations have the potential to promote resistance [46]. Measuring the amount of 
time Mtb spend at concentrations that pose higher risks of resistance formation could be 
an additional objective to minimize. Minimizing the risk of resistance would allow for the 
selection of optimal regimens that are good at sterilizing granulomas, but also mitigate 
the growing threat of rising antibiotic resistance in TB disease.  
 
6.2.6 Improving therapy in a heterogeneous population 
Modern research in medicine and health sciences has promoted the idea of 
personalized medicine [47]. Understanding the specifics of an individual’s disease, 
whether it is a specific type of mutation in cancerous tissue or the severity of the 
disease, could allow physicians to design a treatment course specific to that individual. 
Many findings in this thesis would support the role of personalized medicine for TB 
treatment. If PK variability is important in determining treatment success and changing 
doses could create regimens that are more optimal for people with low levels of plasma 
antibiotic concentrations, tailoring a regimen to that individual has the potential for being 
the best option.  
 
However, applying personalized medicine in practice has a couple of major limitations. 
The first is that each individual requires attention from medical professionals, and those 
medical professionals need to spend the time and resources to evaluate the 
personalized regimen for that patient. Given the global scale, and prevalence in low-
resource regions of our world, this type of personalized attention is not feasible. The 
second limitation is that personalized medicine requires some type of biomarker that is 
easily measured, so we would need biomarkers predictive of disease progression, 
reactivation, and treatment success [48]. 
 
A more realistic approach to applying personalized medicine in TB treatment would be 
using a stratified approach. Stratified medicine involves treating subgroups of patients 
similarly, depending on some characteristic of their disease [49]. Based on the findings 
of this work, those groups could stratify based on average PK exposure versus low PK 
exposure, or complex TB lesions versus smaller granulomas. Again, a barrier to 
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implementing stratified medicine in the clinic is determining the metrics with which to 
stratify the patients. Advancing our ability to determine the prognosis of TB patients and 
monitor antibiotic concentrations through already used diagnostics and tests, such as 
chest X-rays, sputum cultures, time to positivity measurements, and drug sensitivity 
tests could all be pieces of information with which to stratify individuals [50]. The 
required research pipeline to realize the clinical application of stratified medicine 
techniques involves identifying easily measurable metrics through which to stratify 
patients, followed by clinical testing and monitoring of programs that utilize these 
methods.  
 
Designing better antibiotic regimens for TB treatment should involve ensuring that the 
antibiotic regimen is efficacious for all individuals. Whether its designing one regimen 
that works for an entire heterogenous population, or finding regimens that work best in 
stratified groups, using computational modeling can help to design these regimens. 
Representing the complexity in the immune response, disease progression, and 
treatment with a computational model can help us to understand the underlying 
mechanisms that determine regimen efficacy. Through the use of optimization 
algorithms to screen new antibiotic combinations and doses, we can identify the trade-
off between different objectives when designing antibiotic regimens and use this 
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Figure A.1 Calibrated dose response curves 
Calibrated dose-response curves (lines) to in vitro data (dots) of dose response assays from individual experiments 
from the literature for each antibiotic under various culture conditions. References for the data sets are listed in Table 
2.3. Calibrated curves for antibiotics are presented in rows in the order INH, RIF, EMB and PZA from top to bottom. 
Gray shaded regions indicate concentration values reached in granulomas. 
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Figure A.2 Simulated spatial RIF distribution 
The simulated spatial distribution of RIF in a granuloma with larger amounts of caseum. Concentrations shown are 
based on those observed after six hours following a fifth daily dose of 10 mg/kg RIF. The granuloma is simulated on a 
200x200 simulation grid representing 4 mm x 4 mm of lung tissue. Compared to the single-dose RIF concentration in 
a smaller granuloma, accumulation of RIF is observed in caseated regions of the granuloma (lighter pockets 





Figure A.3 Non-replicating Mtb are correlated with treatment outcomes 
The number of non-replicating Mtb at the beginning of therapy (300 days post infection) is positively correlated with 
sterilization time or number of remaining Mtb at the end of treatment (180 days of treatment).  (INH, A; RIF, B; EMB, 
C; PZA, D). INH and EMB show strong positive relationships with correlation coefficients 0.78 and 0.95 respectively. 
The correlations are for RIF and PZA, with coefficients of 0.69 and 0.45 respectively. RIF has the best ability to kill 
non-replicating Mtb, so the sterilization time is less dependent on that subpopulation’s size. PZA shows little 
sterilizing activity in granulomas, so the number left at the end of treatment is more correlated with the initial number 
of Mtb.  
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Figure A.4 The type of bacterial death during each treatment with average PK for low-CFU  
The type of bacterial death during each treatment with average PK for low-CFU (A, B and C) and high-CFU (D, E, 
and F) granulomas. Figure shows the distribution of the percentrage of bacteria that die due to various causes over 
all granulomas. The types of death displayed are bacteria that died due to antibiotics (A and D), bacteria that died 
due to an immune response (B and E), and bacteria that died due to natural death through either starvation or death 




Figure A.5 Risk of granuloma treatment failure.  
Simulated granulomas were classified into four risk of treatment failure categories based on sterilization time when 
treated with HRZE with average (A, C, E, G) and low (B, D, F, H) PK exposure. The four categories were unsterile 
(failed to sterilize), high (sterilized after 150 days), medium (sterilized between 90 and 150 days), and low (sterilized 
before 90 days). The plots show the distribution of pretreatment CFU/granuloma, diameter, amount of caseation 
(measured in number of caseated compartments in the simulation), and percentage of intracellular Mtb, for each risk 
category, with the median value indicated by the red line. Each dot is a single granuloma. Red dots indicate 





Appendix B Supplementary Information for Chapter 3 
 
Table B.1 List of regimens simulated and their corresponding fractional inhibitory concentrations (FIC).  
The antibiotics included and their abbreviations and standard doses are isoniazid (H, 5 mg/kg), rifampin (R, 10 
mg/kg), ethambutol (E, 20 mg/kg), pyrazinamide (Z, 25 mg/kg), moxifloxacin (M, 7 mg/kg), and levofloxacin (L, 17 
mg/kg). The regimen names give the single letter abbreviation, followed by the dose in mg/kg for that antibiotic. If no 
number is listed, the standard dose was used. The doses per week (dpw) are listed at the end of the regimen. If no 
doses per week is listed, doses were simulated as administered daily. The regimens used for validation of the model 



































































*Used for validation 
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Table B.2 Host immune parameters used with GranSim to generate the granuloma bio-repository.  
Timestep units represent 10-minute time steps in the agent-based simulation. The minimum and maximum values for 
parameter ranges used in sampling are listed. Parameters are based on previous GranSim studies [2,3]. 
Parameter Definition Units Min Max 
# immune cell deaths 
causing compartment 
caseation 
 6 10 
Time to heal caseated 
compartment 
Timesteps 909 1365 
TNF threshold for 
causing immune cell 
apoptosis 
Molecules 690 1035 
Rate constant for TNF-
induced apoptosis 
1/s 1.36e-6 2.04e-6 
Minimum chemokine 
concentration to induce 
chemotaxis 
Molecules 0.27 0.41 
Maximum chemokine 
concentration to induce 
chemotaxis 
Molecules 392 588 







Time between resting 
macrophage movements 
Timesteps 4 6 
Time between active 
macrophage movements 
Timesteps 15 23 
 
Time between infected 
macrophage movements 
Timesteps 169 255 
TNF threshold to induce 
NFkB activation 
Molecules 42.8 64.1 
Rate constant for NFkB 
activation 




 0.0738 0.111 
Killing probability 
adjustment for resting 
macrophages with NFkB 
activation 
 0.129 0.194 
# bacteria to cause NFkB 
activation 
 236 354 
 166 
# bacteria for 
macrophage to become 
chronically infected 
 12 18 
# bacteria to cause 
macrophage to burst 
 19 29 
# bacteria activated 
macrophage can 
phagocytose 
 3 5 
Probability activated 
macrophage will will heal 
a caseated compartment 
 0.00459 0.00687 
Probability a T-cell will 
move to same 
compartment as a 
macrophage 
 0.0367 0.0550 
Probability IFNγ 
producing T-cell induces 
Fas/FasL apoptosis 
 0.0293 0.0439 
Probability IFNγ 
producing T-cell also 
produces TNF 
 0.0514 0.0770 
Probability cytotoxic T-
cell kills macrophage 
 0.00505 0.0121 
Probability cytotoxic T-
cell kills a macrophage 
and all its intracellular 
bacteria 




 0.00584 0.00876 
Time when T-cell 
recruitment begins 
Timesteps 3225 4722 
Time delay after T-cell 
recruitment begins until 
maximal recruitment rate 
Timesteps 650 976 
Macrophage maximal 
recruitment probability 
 0.0241 0.0361 
Macrophage threshold for 
recruitment by 
chemokines 
Molecules 0.641 0.960 
Macrophage threshold for 
recruitment by TNF 
Molecules 0.00859 0.0129 
Macrophage half 
saturation for recruitment 
by TNF 
Molecules 1.22 1.82 
 167 
Macrophage half 
saturation for recruitment 
by chemokine 
Molecules 1.68 2.52 
IFNγ producing T-cell 
maximal recruitment 
probability 
 0.0484 0.0726 
IFNγ producing T-cell 
threshold for recruitment by 
chemokine 
Molecules 0.0535 0.0802 
IFNγ producing T-cell 
threshold for recruitment 
by TNF 
Molecules 1.01 1.51 
IFNγ producing T-cell half 
saturation for recruitment 
by TNF 
Molecules 1.22 1.82 
IFNγ producing T-cell half 
saturation for recruitment 
by chemokine 
Molecules 1.64 2.46 
Probability a IFNγ 
producing T-cell is 
cognate 
 0.0437 0.0655 
Cytotoxic T-cell maximal 
recruitment probability 
 0.0370 0.0554 
Cytotoxic T-cell threshold 
for recruitment by 
chemokine 
Molecules 3.55 5.32 
Cytotoxic T-cell threshold 
for recruitment by TNF 
Molecules 0.920 1.38 
Cytotoxic T-cell half 
saturation for recruitment 
by TNF 
Molecules 0.715 1.07 
Cytotoxic T-cell half 
saturation for recruitment 
by chemokine 
Molecules 5.24 7.86 
Probability a cytotoxic T-
cell is cognate 




 0.0246 0.0369 
Regulatory T-cell 
threshold for recruitment 
by chemokine 
Molecules 2.03 3.04 
Regulatory T-cell 
threshold for recruitment 
by TNF 
Molecules 1.65 2.47 
 168 
Regulatory T-cell half 
saturation for recruitment 
by TNF 
Molecules 2.00 3.00 
Regulatory T-cell half 
saturation for recruitment 
by chemokine 
Molecules 1.23 1.84 
Probability a regulatory 
T-cell is cognate 
 0.0400 0.0600 
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Table B.3 Plasma PK PRCC Values 
For four regimens (HRZE, RE, HE and RM), the table shows the PRCC values relating the plasma PK parameters to the predicted iDIS for non-replicating Mtb 
during the first dose of treatment. All PRCC values reported are significant with p<0.01 and NS designates that the parameter was not significant. The parameters 
for each antibiotic listed include the absorption rate constant (kAbs), the intercompartmental clearance (Q), the volume of distribution for the plasma (central) 
compartment (Vol. Dist. Cent.), the volume of distribution for the peripheral compartment (Vol. Dist. Periph.), and the clearance rate constant (CL). 
  INH RIF EMB PZA MXF 































HRZE NS -0.66 0.34 -0.18 -0.20 0.28 NS NS NS 0.89 0.43 NS 
-
0.26 NS -0.56 NS NS 0.54 NS 0.21       
RE      NS NS NS NS 0.90 0.74 -0.27 
-
0.23 -0.20 -0.92            
HE -0.31 -0.87 0.67 -0.33 -0.39      -0.68 0.26 0.30 0.20 0.88            
RM           NS NS NS -0.26 -0.83                     NS 
-




Figure B.1 Measures of regimen efficacy are correlated with interaction strength associated with intracellular 
replicating Mtb killing rate for 64 regimens.  
The mean decrease in log CFU (0-14) averaged over each 100 granulomas simulated for each regimen (A) and 
percentage of sterilized (negative) granulomas after eight weeks of treatment (B) are weakly positively correlated with 
the average interaction strength experienced by non-replicating Mtb during the first 24 hours of treatment with 
correlation coefficients of 0.28 and 0.35 respectively. Mean sterilization time for each regimen over 100 granulomas 
(C) is negatively correlated with the average interaction strength with a correlation coefficient of -0.38. Each point 
represents the regimen outcome measurement for a given regimen and error bars indicate +/- standard deviation 
from the sample of 100 granulomas simulated. The colored points correspond to the regimens HRZE (light blue), RE 




Figure B.2 Measures of regimen efficacy are correlated with interaction strength associated with extracellular 
replicating Mtb killing rate for 64 regimens.  
The mean decrease in log CFU (0-14) averaged over each 100 granulomas simulated for each regimen (A) and 
percentage of sterilized (negative) granulomas after eight weeks of treatment (B) are weakly positively correlated with 
the average interaction strength experienced by non-replicating Mtb during the first 24 hours of treatment with 
correlation coefficients of 0.28 and 0.35 respectively. Mean sterilization time for each regimen over 100 granulomas 
(C) is negatively correlated with the average interaction strength with a correlation coefficient of -0.38. Each point 
represents the regimen outcome measurement for a given regimen and error bars indicate +/- standard deviation 
from the sample of 100 granulomas simulated. The colored points correspond to the regimens HRZE (light blue), RE 





Figure B.3 Comparison of treatment simulations with clinical trial results  
Comparison of treatment simulations with clinical trial results for 26 different regimens compiled in Bonnet et al. 
(2017)[1]. The clinical regimen efficacy metric used is solid culture conversion following 8 weeks of therapy. We 
compare the confidence intervals (black) to the percent of simulated granulomas that sterilized (lower red bar) or had 
fewer than 10 CFU after 8 weeks of therapy (upper red bar, red dot average of error bars) for all 26 regimens (A). 
Regimens are abbreviated by the single antibiotic abbreviation, followed by the dose in mg/kg for that antibiotic, with 
the doses per week (dpw) listed at the end of the regimen abbreviation. FIC is negatively correlated with clinical rank 
with a weighted correlation of -0.74 (B), and iDIS is positively correlated with clinical rank with a weighted correlation 





Figure B.4 Heat map of predicted iDIS value for different regimens of the same antibiotic combination.  
The list of regimens is ordered by decreasing predicted in vivo DIS for regimens involving the antibiotic combination 
RE (A), HE (B), HR (C), HRE (D), HRZ (E) and HRZE (F). For predicated IDIS blue represents synergy, white 
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Appendix C Supplementary Information for Chapter 5 
 
Table C.1 NHP plasma PK parameters. 
The ranges for the plasma PK parameters calibrated to NHP plasma data. Parameters calibrated in previously 
published studies [1,2], except for moxifloxacin, whose data and calibrated curves are shown in Figure C.1. 
Parameter Units INH RIF MXF EMB PZA 
Absorption rate 
constant 






























































Figure C.1 NHP plasma PK calibration for MXF 
The calibrated ranges for the plasma PK parameters calibrated to NHP plasma data (black dots) and the range of 
simulation outcomes (blue shaded area) with median concentration (blue line). Median plasma PK parameter 
calibrated to minimize the sum of the squared error between data and simulation outcome, and the ranges for 
parameters were set to capture full range of observed data. Data from NHP were obtained by administering a single 




1.  Pienaar E, Cilfone NA, Lin PL, Dartois V, Mattila JT, Butler JR, et al. A 
computational tool integrating host immunity with antibiotic dynamics to study 
tuberculosis treatment. J Theor Biol. 2015;367: 166–179. 
doi:10.1016/j.jtbi.2014.11.021 
2.  Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, et al. 
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection 
in macaques. Proc Natl Acad Sci. 2012;109: 14188–14193. 
doi:10.1073/pnas.1121497109 
 
